

Caribbean Region

Country Operational Plan

FY 2016



Budget Summary Reports

Summary of Planned Funding by Agency and Funding Source

| Agency | GAP | Funding Source GHP-State | GHP-USAID | Funding Source Total | Applied Pipeline | Total All Funding Sources and Applied Pipeline Amount |
|-----------|-----------|-----------------------------|-----------|-------------------------|---------------------|--|
| State | | 399,544 | | 399,544 | 94,962 | 494,506 |
| USAID | | 4,845,010 | 6,536,628 | 11,381,638 | 3,121,254 | 14,502,892 |
| DOD | | 0 | | 0 | 798,000 | 798,000 |
| РС | | 0 | | 0 | 119,587 | 119,587 |
| HHS/CDC | 1,593,750 | 6,798,711 | | 8,392,461 | 2,766,696 | 11,159,157 |
| HHS/HRSA | | 2,008,000 | | 2,008,000 | 0 | 2,008,000 |
| State/WHA | | 200,000 | | 200,000 | 0 | 200,000 |
| Total | 1,593,750 | 14,251,265 | 6,536,628 | 22,381,643 | 6,900,499 | 29,282,142 |

Summary of Planned Funding by Budget Code and Agency

| | Agency | | | | | | | | |
|-------------|---------|-----------|-----|-----------|--------------|----|-----------|-------------------|-----------|
| Budget Code | State | State/WHA | DOD | HHS/CDC | HHS/HRS A | PC | USAID | On Hold Amount | Total |
| НВНС | | | 0 | 231,319 | 288,000 | | 4,256,678 | 0 | 4,775,997 |
| НКІД | | | | | | | 105,688 | 0 | 105,688 |
| HLAB | | | 0 | 1,663,465 | | | | 0 | 1,663,465 |
| HTXS | | | | 616,480 | 1,669,935 | | 906,707 | 0 | 3,193,122 |
| НУСТ | | | 0 | 187,745 | | | 782,506 | 0 | 970,251 |
| HVMS | 399,544 | | 0 | 2,758,257 | | 0 | 1,170,462 | 0 | 4,328,263 |
| HVOP | | 200,000 | 0 | 89,329 | | 0 | 1,439,708 | 0 | 1,729,037 |
| HVSI | 0 | | 0 | 2,595,350 | | | 217,572 | 0 | 2,812,922 |
| HVTB | | | | | | | 0 | 0 | 0 |
| мтст | | | | 0 | | | | 0 | 0 |

Custom 2017-04-11 10:08 EDT



Approved

| OHSS | | | | 172,898 | 50,065 | 0 | 2,502,317 | 0 | 2,725,280 |
|------|---------|---------|---|-----------|-----------|---|------------|---|------------|
| PDCS | | | | 13,364 | | | | 0 | 13,364 |
| PDTX | | | | 64,254 | | | | 0 | 64,254 |
| | 399,544 | 200,000 | 0 | 8,392,461 | 2,008,000 | 0 | 11,381,638 | 0 | 22,381,643 |



Technical Areas

Technical Area Summary

Technical Area: Care

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| НВНС | 4,588,904 | 0 |
| НКІД | 97,193 | 0 |
| PDCS | 13,364 | 0 |
| Total Technical Area Planned Funding: | 4,699,461 | 0 |

Technical Area: Governance and Systems

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HLAB | 1,368,681 | 0 |
| HVSI | 2,074,417 | 0 |
| OHSS | 2,556,456 | 0 |
| Total Technical Area Planned Funding: | 5,999,554 | 0 |

Technical Area: Prevention

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|--|----------------------------|----------------|
| HVCT | 827,335 | 0 |
| HVOP | 1,565,368 | 0 |
| МТСТ | 0 | |
| Total Technical Area Planned Funding: | 2,392,703 | 0 |

Technical Area: Treatment

| Budget Code | Budget Code Planned Amount | On Hold Amount |
|-------------|----------------------------|----------------|
| HTXS | 3,093,638 | 0 |



| PDTX | 64,254 | 0 |
|--|-----------|---|
| Total Technical Area Planned Funding: | 3,157,892 | 0 |



Antigua and Barbuda



Bahamas

| Indicator Number | Label | 2017 |
|------------------|-------------------------------------|-------|
| | KP_PREV_DSD Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV | - |
| | preventive interventions that are | n/a |
| | based on evidence and/or meet the | |
| | minimum standards required (DSD) | |
| | Number of key populations reached | |
| | with individual and/or small group | |
| | level HIV preventive interventions | 1,102 |
| | that are based on evidence and/or | 1,102 |
| | meet the minimum standards | |
| | required | |
| | Total estimated number of key | |
| | population in the catchment area | 4,409 |
| KP_PREV_DSD | By key population type: Men who | |
| | have sex with men who are sex | |
| | workers (Numerator: Number of | |
| | key populations reached with | |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men who are NOT | |
| | sex workers (Numerator: Number | |
| | of key populations reached with | 372 |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |



| the minimum standards required) | |
|-------------------------------------|-----|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | |
| level HIV preventive interventions | 730 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| ,· , , | |



| populations reached with individual | |
|-------------------------------------|-------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 1,489 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | 2,920 |
| Total estimated number of key | 2,020 |
| rotal ostimated number of key | |



| | population in the catchment area) | |
|------------|---------------------------------------|-----|
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | Number of individuals who received | |
| | T&C services for HIV and received | 882 |
| | their test results during the past 12 | 002 |
| | months | |
| HTC_TST_TA | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | 1.90,00A. 20 10 Maio | |



| Age/sex: 50+ Male |
|-----------------------------|
| Age/sex: 5-9 Female |
| Age/sex: 10-14 Female |
| Age/sex: 15-19 Female |
| Age/sex: 20-24 Female |
| Age/sex: 25-49 Female |
| Age/sex: 50+ Female |
| Test Result by Age and Sex: |
| Positive: 10-14 Male |
| Test Result by Age and Sex: |
| Positive: 15-19 Male |
| Test Result by Age and Sex: |
| Positive: 20-24 Male |
| Test Result by Age and Sex: |
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |



| Negative: 25-49 Male | |
|---|-----|
| Test Result by Age and Sex: | |
| Negative: 50+ Male | |
| Test Result by Age and Sex: | |
| Negative: <1 Female | |
| Test Result by Age and Sex: | |
| Negative: 10-14 Female | |
| Test Result by Age and Sex: | |
| Negative: 15-19 Female | |
| Test Result by Age and Sex: | |
| Negative: 20-24 Female | |
| Test Result by Age and Sex: | |
| Negative: 25-49 Female | |
| Test Result by Age and Sex: | |
| Negative: 50+ Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 Male | |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 294 |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 | |
| Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: 15+ | 588 |
| Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Female | |
| Test Result by Aggregated Age | |



| and Sex: Positive <15 Male | |
|------------------------------------|----|
| Test Result by Aggregated Age | 10 |
| and Sex: Positive 15+ Male | 18 |
| Test Result by Aggregated Age | |
| and Sex: Positive <15 Female | |
| Test Result by Aggregated Age | 20 |
| and Sex: Positive 15+ Female | 30 |
| Test Result by Age: Positive: <1 | |
| Test Result by Age: Positive: 1-9 | |
| Age/sex: <1 | |
| Age/sex: 1-9 | |
| Service Delivery Point | |
| (Community): Index testing | |
| Service Delivery Point | |
| (Community): Homebased testing | |
| Service Delivery Point | |
| (Community): Mobile testing | |
| Service Delivery Point | |
| (Community): Other | |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |



| by Age: <15 other |
|---|
| Service Delivery Point (Facility): Inpatient |
| Service Delivery Point (Facility): Outpatient |
| Service Delivery Point (Facility): Pediatric |
| Service Delivery Point (Facility): Malnutrition facilities |
| Service Delivery Point (Facility): Other PITC |
| Service Delivery Point (Facility): VCT |
| Service Delivery Point (Facility): VMMC |
| Service Delivery Point (Facility): PMTCT |
| Service Delivery Point (Facility): TB Clinics |
| Service Delivery Point (Facility): Index testing |
| Service Delivery Point (Facility) by Age: <15 Inpatient |
| Service Delivery Point (Facility) by Age: >15 Inpatient |
| Service Delivery Point (Facility) by Age: <15 Outpatient |
| Service Delivery Point (Facility) by Age: >15 Outpatient |
| Service Delivery Point (Facility) by Age: <15 Pediatroc |
| Service Delivery Point (Facility) by Age: >15 Pediatroc |
| Service Delivery Point (Facility) by |



| | Age: <15 Malnutrition facilities | |
|-----------|--------------------------------------|-----|
| | Service Delivery Point (Facility) by | |
| | Age: >15 Malnutrition facilities | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Index testing | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Index testing | |
| | Number of adults and children | |
| | newly enrolled on antiretroviral | 240 |
| | therapy (ART) | |
| TX_NEW_TA | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: <1 Male | |
| | By Age/Sex: 1-4 Male | |
| L | · · · | |



| | By Age/Sex: 5-9 Male | |
|---|--|-----|
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |
| E | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: <1 Female | |
| | By Age/Sex: 1-4 Female | |
| | By Age/Sex: 5-9 Female | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <15 Male | |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 114 |
| | Aggregated Grouping by Age: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | |
| l | Aggregated Grouping by Age/Sex: 1-14 Female | |
| L | Aggregated Grouping by Age/Sex: 15+ Female | 126 |
| S | Sum of Aggregated Age/Sex | 240 |
| 1 | | |



| | disaggregates | |
|-----------|--|---|
| | Pregnancy status | |
| | Breastfeeding status | |
| | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program | |
| | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| | CD4: Number of laboratories that participate in this PT program | 1 |
| | CD4: Number of laboratories that perform this testing | 1 |
| LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 4 |
| | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 4 |
| | HIV serologic/diagnostic testing: Number of laboratories that | 4 |



| | perform this testing | |
|--|---------------------------------------|---|
| | HIV viral load: Number of | |
| | laboratories that achieve | 1 |
| | acceptable successful passing | I |
| | criteria in this PT program | |
| | HIV viral load: Number of | |
| | laboratories that participate in this | 1 |
| | PT program | |
| | HIV viral load: Number of | |
| | laboratories that perform this | 1 |
| | testing | |
| | TB diagnostics (AFB microscopy): | |
| | Number of laboratories that | 4 |
| | achieve acceptable successful | 1 |
| | passing criteria in this PT program | |
| | TB diagnostics (AFB microscopy): | |
| | Number of laboratories that | 1 |
| | participate in this PT program | |
| | TB diagnostics (AFB microscopy): | |
| | Number of laboratories that | 1 |
| | perform this testing | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | processing enteria in ano i i program | |



| | TB diagnostics (Culture/DST): | |
|-----------|------------------------------------|--------|
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | PEPFAR resources used for | |
| | HIV-program related commodities: | 1,333 |
| | planned & purchased in the last 12 | 1,000 |
| | months by Implementing Partner | |
| | Number of HIV Test Kits purchased | |
| | Number of HIV CD4 Reagents | |
| | purchased | |
| | Number of Condoms purchased | |
| | Number of HIV Viral Load | 4 000 |
| | Reagents purchased | 1,333 |
| | Number of HIV ARVs purchased | |
| INVS_COMD | Number of Second Line HIV ARVs | |
| | purchased | |
| | HIV Test Kits: Dollars planned | |
| | (COP)/ spent (Actual) | |
| | HIV CD4 Tests: Dollars planned | |
| | (COP)/ spent (Actual) | |
| | HIV Viral Load: Dollars planned | |
| | (COP)/ spent (Actual) | 40,000 |
| | Condoms: Dollars planned (COP)/ | |
| | spent (Actual) | |
| | HIV ARVs: Dollars planned (COP)/ | |
| | spent (Actual) | |



Barbados

| Indicator Number | Label | 2017 |
|------------------|----------------------------------|-------|
| | Number of adults and children | |
| | receiving antiretroviral therapy | 1,578 |
| | (ART) | |
| | Age/Sex: <1 Male | |
| | Age/Sex: 1-4 Male | |
| | Age/Sex: 5-14 Male | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 20+ Male | |
| | Age/Sex: <1 Female | |
| | Age/Sex: 1-4 Female | |
| | Age/Sex: 5-14 Female | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| TX_CURR_TA | Sum of Age/Sex disaggregations | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | |
| | Aggregated Age/Sex: 1-14 Male | |
| | Aggregated Age/Sex: 15+ Male | 899 |
| | Aggregated Age/Sex: <15 Female | |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 679 |
| | Sum of Aggregated Age/Sex <15 | |
| | Sum of Aggregated Age/Sex 15+ | 1,578 |
| | Sum of Aggregated Age/Sex | |
| | disaggregates | 1,578 |



| | Age/Sex: <1 | |
|------------|----------------------------------|-----|
| | Age/Sex: 1-9 | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 10-14 Female | |
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children | |
| | newly enrolled on antiretroviral | 164 |
| | therapy (ART) | |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| TX_NEW_DSD | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 | |
| | Male | |
| | Aggregated Grouping by Age/Sex: | |



| | <15 Male | |
|-----------|--|-----|
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 82 |
| | Aggregated Grouping by Age/Sex: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 82 |
| | Sum of Aggregated Age/Sex disaggregates | 164 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 6 |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: <1 Male | |
| | By Age/Sex: 1-4 Male | |
| | By Age/Sex: 5-9 Male | |
| TX_NEW_TA | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: <1 Female | |
| | By Age/Sex: 1-4 Female | |
| | By Age/Sex: 5-9 Female | |



| | By Age/Sex: 10-14 Female | |
|------------|---|-----|
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <a><15 Male | |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 0 |
| | Aggregated Grouping by Age: <1 Female | |
| | Aggregated Grouping by Age/Sex: <a><15 Female | |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 6 |
| | Sum of Aggregated Age/Sex disaggregates | 6 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | TX_PVLS_TA Percentage of ART patients with a viral load result | |
| TX_PVLS_TA | documented in the medical record and/or laboratory information systems (LIS) within the past 12 | n/a |
| | months with a suppressed viral load (<1000 copies/ml) | |



| Number of adults and pediatric patients on ART with suppress viral load results (<1,000 copie documented in the medical rec and /or supporting laboratory results within the past 12 mont | ed s/ml) ords |
|--|---------------------|
| Number of adult and pediatric / patients with a viral load result documented in the patient med record and /or laboratory rec in the past 12 months. | ART lical 1,578 |
| Numerator: Age/Sex by Indicat <1 Routine | |
| Numerator: Age/Sex by Indicat <1 Targeted | |
| Numerator: Age/Sex by Indicat 1-9 Routine | ion: |
| Numerator: Age/Sex by Indicat 1-9 Targeted | ion: |
| Numerator: Age/Sex by Indicat 10-14 Female Routine | ion: |
| Numerator: Age/Sex by Indicat 10-14 Female Targeted | ion: |
| Numerator: Age/Sex by Indicat 10-14 Male Routine | ion: |
| Numerator: Age/Sex by Indicat 10-14 Male Targeted | ion: |
| Numerator: Age/Sex by Indicat 15-19 Female Routine | ion: |
| Numerator: Age/Sex by Indicat 15-19 Female Targeted | ion: |
| Numerator: Age/Sex by Indicat 15-19 Male Routine | ion: |
| Numerator: Age/Sex by Indicat 15-19 Male Targeted | ion: |



| Numerator: Age/Sex by Indication: 20-24 Female Routine |
|--|
| Numerator: Age/Sex by Indication: 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: 20-24 Male Routine |
| Numerator: Age/Sex by Indication: 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| Numerator: Age/Sex by Indication: 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: 25-49 Male Routine |
| Numerator: Age/Sex by Indication: 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: 50+ Female Routine |
| Numerator: Age/Sex by Indication: 50+ Female Targeted |
| Numerator: Age/Sex by Indication: 50+ Male Routine |
| Numerator: Age/Sex by Indication: 50+ Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine |



| Numerator: Aggregate Age/Sex by |
|-----------------------------------|
| Indication: 15+ Female Targeted |
| Numerator: Aggregate Age/Sex by |
| Indication: 15+ Male Routine |
| Numerator: Aggregate Age/Sex by |
| Indication: 15+ Male Targeted |
| Numerator: Indication: Routine |
| Numerator: Indication: Targeted |
| Numerator: Preg/BF by Indication: |
| Breastfeeding Routine |
| Numerator: Preg/BF by Indication: |
| Breastfeeding Targeted |
| Numerator: Preg/BF by Indication: |
| Pregnant Routine |
| Numerator: Preg/BF by Indication: |
| Pregnant Targeted |
| Denominator: Indication: Routine |
| Denominator: Indication: Targeted |
| Denominator: Age/Sex by |
| Indication: <1 Routine |
| Denominator: Age/Sex by |
| Indication: <1 Targeted |
| Denominator: Age/Sex by |
| Indication: 1-9 Routine |
| Denominator: Age/Sex by |
| Indication: 1-9 Targeted |
| Denominator: Age/Sex by |
| Indication: 10-14 Female Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Targeted |
| |



| | 1 |
|-----------------------------------|---|
| Denominator: Age/Sex by | |
| Indication: 15-19 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 25-49 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 25-49 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 25-49 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 25-49 Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 50+ Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 50+ Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Routine | |



| 1 | |
|------------------------------------|-----|
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Targeted | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Routine | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Targeted | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Routine | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Targeted | |
| Numerator Aggregated Age/Sex: | |
| <15 Male | |
| Numerator Aggregated Age/Sex: | 719 |
| 15+ Male | 719 |
| Numerator Aggregated Age/Sex: | |
| <15 Female | |
| Numerator Aggregated Age/Sex: | 543 |
| 15+ Female | 040 |
| Denominator Aggregated Age/Sex: | |
| <15 Male | |
| Denominator Aggregated Age/Sex: | 899 |
| 15+ Male | 033 |
| | |



| | Denominator Aggregated Age/Sex: | |
|-----------|--|-----|
| | <15 Female | |
| | Denominator Aggregated Age/Sex: 15+ Female | 679 |
| | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program | |
| | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| | CD4: Number of laboratories that participate in this PT program | 1 |
| | CD4: Number of laboratories that perform this testing | 1 |
| LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 5 |
| | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 5 |
| | HIV serologic/diagnostic testing: | 5 |



| Number of laboratories that | |
|---------------------------------------|---|
| perform this testing | |
| HIV viral load: Number of | |
| laboratories that achieve | 1 |
| acceptable successful passing | I |
| criteria in this PT program | |
| HIV viral load: Number of | |
| laboratories that participate in this | 1 |
| PT program | |
| HIV viral load: Number of | |
| laboratories that perform this | 1 |
| testing | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | |
| achieve acceptable successful | 1 |
| passing criteria in this PT program | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | 1 |
| participate in this PT program | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | 1 |
| perform this testing | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | |
| achieve acceptable successful | 0 |
| passing criteria in this PT program | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | 0 |
| participate in this PT program | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | 0 |
| perform this testing | |
| TB diagnostics (Culture/DST): | |
| Number of laboratories that | 0 |
| achieve acceptable successful | Ŭ |
| | |



| ſ | | |
|-----------|---|--------|
| | passing criteria in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | PEPFAR resources used for | |
| | HIV-program related commodities: | 500 |
| | planned & purchased in the last 12 | 500 |
| | months by Implementing Partner | |
| | Number of HIV Test Kits purchased | |
| | Number of HIV CD4 Reagents | |
| | purchased | |
| | Number of Condoms purchased | |
| | Number of HIV Viral Load | |
| | Reagents purchased | 500 |
| | Number of HIV ARVs purchased | |
| INVS_COMD | Number of Second Line HIV ARVs | |
| | purchased | |
| | HIV Test Kits: Dollars planned (COP)/ spent (Actual) | |
| | HIV CD4 Tests: Dollars planned | |
| | (COP)/ spent (Actual) | |
| | HIV Viral Load: Dollars planned | 25,000 |
| | (COP)/ spent (Actual) | |
| | Condoms: Dollars planned (COP)/ | |
| | spent (Actual) | |
| | HIV ARVs: Dollars planned (COP)/ | |
| | spent (Actual) | |



Belize - Caribbean

Approved



Technical Area Summary Indicators and Targets

Dominica

Approved



Technical Area Summary Indicators and Targets

Grenada



Guyana

| Indicator Number | Label | 2017 |
|------------------|---|-------|
| | KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required (DSD) | n/a |
| | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 2,652 |
| | Total estimated number of key population in the catchment area | 3,658 |
| KP_PREV_DSD | By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | |
| | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet | 1,286 |



| the minimum standards required) | |
|---|-------|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | 1 000 |
| level HIV preventive interventions | 1,366 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| n i i i i i i i i i i i i i i i i i i i | |



| populations reached with individual | |
|--------------------------------------|-------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 1,837 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| ` number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| | |
| By key population type: Female | 1 004 |
| sex workers (FSW) (Denominator: | 1,821 |
| Total estimated number of key | |



| | population in the catchment area) | |
|--|---------------------------------------|-------|
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | Number of individuals who received | |
| | T&C services for HIV and received | 4,607 |
| | their test results during the past 12 | 4,007 |
| | months | |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | v | |



| Age/sex: 50+ Male |
|---|
| Age/sex: 5-9 Female |
| Age/sex: 10-14 Female |
| Age/sex: 15-19 Female |
| Age/sex: 20-24 Female |
| Age/sex: 25-49 Female |
| Age/sex: 50+ Female |
| Test Result by Age and Sex: |
| Positive: 10-14 Male |
| Test Result by Age and Sex: |
| Positive: 15-19 Male |
| Test Result by Age and Sex: |
| Positive: 20-24 Male |
| Test Result by Age and Sex: |
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: Positive: 50+ Female |
| |
| Test Result by Age and Sex: Negative: 10-14 Male |
| |
| Test Result by Age and Sex: Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |
| , |



| Negative: 25-49 Male | |
|-------------------------------|-------|
| Test Result by Age and Sex: | |
| Negative: 50+ Male | |
| Test Result by Age and Sex: | |
| Negative: 10-14 Female | |
| Test Result by Age and Sex: | |
| Negative: 15-19 Female | |
| Test Result by Age and Sex: | |
| Negative: 20-24 Female | |
| Test Result by Age and Sex: | |
| Negative: 25-49 Female | |
| Test Result by Age and Sex: | |
| Negative: 50+ Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 Male | 83 |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: 15+ Male | 2,019 |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 | 73 |
| Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: 15+ | 2,432 |
| Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Female | |
| Test Result by Aggregated Age | _ |
| and Sex: Positive <15 Male | 6 |
| Test Result by Aggregated Age | 99 |
| | |



| d Sex: Positive | 15+ Male | |
|------------------|-------------------|-------|
| st Result by Age | gregated Age | 4 |
| d Sex: Positive | <15 Female | 4 |
| st Result by Age | gregated Age | 101 |
| d Sex: Positive | 15+ Female | 101 |
| st Result by Age | e: Positive: <1 | |
| st Result by Age | e: Positive: 1-9 | |
| e/sex: <1 | | |
| e/sex: 1-9 | | |
| rvice Delivery P | Point | |
| ommunity): Inde | ex testing | 150 |
| rvice Delivery P | | |
| - | nebased testing | |
| rvice Delivery P | Point | |
| ommunity): Mob | | 1,739 |
| rvice Delivery P | Point | |
| ommunity): Othe | er | 763 |
| rvice Delivery P | Point (Community) | |
| Age: <15 index | | |
| rvice Delivery P | Point (Community) | |
| Age: 15+ index | testing | |
| rvice Delivery P | Point (Community) | |
| Age: <15 home | | |
| rvice Delivery P | Point (Community) | |
| Age: 15+ home | ebased testing | |
| rvice Delivery P | Point (Community) | |
| Age: <15 mobil | le testing | |
| rvice Delivery P | Point (Community) | |
| Age: 15+ mobil | le testing | |
| rvice Delivery P | Point (Community) | |
| Age: <15 other | | |
| rvice Delivery P | Point (Community) | |
| Age: <15 other | | |
| rvice Delivery P | Point (Facility): | |



| Inpatient | |
|---|-------|
| Service Delivery Point (Facility): | |
| Outpatient | |
| Service Delivery Point (Facility): | |
| Pediatric | |
| Service Delivery Point (Facility): | |
| Malnutrition facilities | |
| Service Delivery Point (Facility): Other PITC | 1,655 |
| Service Delivery Point (Facility): VCT | |
| Service Delivery Point (Facility): VMMC | |
| Service Delivery Point (Facility): PMTCT | |
| Service Delivery Point (Facility): TB Clinics | |
| Service Delivery Point (Facility): Index testing | 300 |
| Service Delivery Point (Facility) by Age: <15 Inpatient | |
| Service Delivery Point (Facility) by Age: >15 Inpatient | |
| Service Delivery Point (Facility) by Age: <15 Outpatient | |
| Service Delivery Point (Facility) by Age: >15 Outpatient | |
| Service Delivery Point (Facility) by Age: <15 Pediatroc | |
| Service Delivery Point (Facility) by | |
| Age: >15 Pediatroc | |
| Service Delivery Point (Facility) by | |
| Age: <15 Malnutrition facilities | |
| Service Delivery Point (Facility) by | |



| | ۰ ۲ | |
|--------------|---------------------------------------|-----|
| | Age: >15 Malnutrition facilities | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Index testing | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Index testing | |
| | Number of active beneficiaries | |
| | served by PEPFAR OVC programs | 162 |
| OVC_SERV_DSD | for children and families affected by | |
| | HIV/AIDS | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 15-17 Male | |
| | By: Age/sex: Male 18-24 | |
| | By: Age/sex: Male 25+ | |
| | Age/Sex: 18+ Male | 52 |



| Age/Sex: 10-14 Female | |
|---------------------------------------|-----|
| Age/Sex: 15-17 Female | |
| By: Age/sex: 18-24 Female | |
| By: Age/sex: 25+ Female | |
| Age/Sex: 18+ Female | 83 |
| Sum of Age/Sex disaggregates | 135 |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 15-17 | |
| | |



| Required only for DREAMS | |
|-----------------------------------|--|
| countries - By service, age and | |
| sex: Education Support Male 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Male <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Male 10-14 | |
| Required only for DREAMS | |
| | |



| | es - By service, age and arenting/Caregiver Programs 5-17 |
|-------------------------------|---|
| Require countri sex: Pa | ed only for DREAMS es - By service, age and arenting/Caregiver Programs |
| | ed only for DREAMS |
| | es - By service, age and arenting/Caregiver Programs 5+ |
| countri | ed only for DREAMS es - By service, age and |
| Requir | ed only for DREAMS es - By service, age and |
| sex: So 10-14 | ocial Protection Female |
| countri | ed only for DREAMS es - By service, age and ocial Protection Female |
| countri | ed only for DREAMS es - By service, age and ocial Protection Female |
| countri | ed only for DREAMS es - By service, age and ocial Protection Female 25+ |
| countri | ed only for DREAMS es - By service, age and ocial Protection Male <1 |
| Require countri | ed only for DREAMS es - By service, age and ocial Protection Male 10-14 |



| Required only for DREAMS | |
|-----------------------------------|--|
| countries - By service, age and | |
| sex: Social Protection Male 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| | |



| sex: Economic Strengthening Male 10-14 |
|--|
| Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male |
| 15-17 |
| Required only for DREAMS countries - By service, age and sex: Economic Strengthening Male 18-24 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Economic Strengthening Male |
| 25+ |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Female <1 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Female 10-14 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Female 15-17 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Female 18-24 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Female 25+ |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Male <1 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Male 10-14 |



| Required only for DREAMS |
|-----------------------------------|
| countries - By service, age and |
| sex: Other Services Male 15-17 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Male 18-24 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Male 25+ |
| Age/Sex: <1 |
| Age/Sex: 1-9 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Education Support 1-9 Male |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Parenting/Caregiver Programs |
| Male 1-9 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Social Protection Programs |
| Male 1-9 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Economic Strengthening Male |
| 1-9 |
| Required only for DREAMS |
| countries - By service, age and |
| sex: Other Services Male 1-9 |
| Program Completion: Active |
| Program Completion: Graduation |
| Program Completion: Transferred |
| Program Completion: Exited |
| without graduation |
| |



| | By Aggregated Age/Sex: <18 Male | 12 |
|-----------------|---------------------------------------|-------|
| | By Aggregated Age/Sex: 18+ Male | |
| | By Aggregated Age/Sex: <18 | 15 |
| | Female | 15 |
| | By Aggregated Age/Sex: 18+ | |
| | Female | |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Education Support Female 1-9 | |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Parenting/Caregiver Programs | |
| | Female 1-9 | |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Social Protection Programs | |
| | Female 1-9 | |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Economic Strengthening | |
| | Female 1-9 | |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Other Services Female 1-9 | |
| | The number of PLHIV who were | |
| | screened for TB symptoms at the | 1 740 |
| | last clinical visit at a HIV facility | 1,718 |
| | during the reporting period. | |
| TB_SCREENDX_DSD | Screened for TB by Age/Sex:<15 | 0 |
| | Male | 9 |
| | Screened for TB by Age/Sex: 15+ | |
| | Male | 644 |
| | Screened for TB by Age/Sex:<15 | |
| | Female | 35 |
| | Screened for TB by Age/Sex: 15+ | 1,030 |
| 4 | , , | |



| | Female | |
|----------------|--|-------|
| | Screen Result: Screened Positive for TB | 35 |
| | TB Positive by Age/Sex: <15 Male | |
| | TB Positive by Age/Sex: 15+ Male | |
| | TB Positive by Age/Sex: <15 Female | |
| | TB Positive by Age/Sex: 15+ Female | |
| | [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB | 35 |
| | [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only | 27 |
| | [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay | 8 |
| | [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) | |
| TB_SCREENDX_TA | The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period. | 1,861 |
| | Screened for TB by Age/Sex: <15 Male | 100 |
| | Screened for TB by Age/Sex: 15+ Male | 837 |
| | Screened for TB by Age/Sex: <15 Female | 94 |
| | Screened for TB by Age/Sex: 15+ Female | 830 |
| | Screen Results: Screened Positive for TB | 38 |
| | TB Positive by Age/Sex: <15 Male | |



| | TB Positive by Age/Sex: 15+ Male | |
|--------------|--|-----|
| | TB Positive by Age/Sex: <15 | |
| | Female | |
| | TB Positive by Age/Sex: 15+ | |
| | Female | |
| | [Sub-Disagg of Screen Results] | |
| | Specimen Sent: Specimen sent for | 38 |
| | bacteriologic diagnosis of active TB | |
| | [Sub-disagg of Specimen Sent] | |
| | Diagnostic Test: Smear Only | 29 |
| | [Sub-disagg of Specimen Sent] | |
| | Diagnostic Test: Xpert MTB/RIF | 9 |
| | assay | - |
| | [Sub-disagg of Specimen Sent] | |
| | Diagnostic Test: Other (Not Xpert) | |
| | PMTCT_EID_TA Percent of infants | |
| | born to HIV-positive women that | |
| | receive a virological HIV test within | n/a |
| | 12 months of birth (TA) | |
| | Number of infants who had a | |
| | virologic HIV test within 12 months | |
| | of birth during the reporting period | |
| | Number of HIV- positive pregnant | |
| | women identified during the | |
| | reporting period (include known | |
| PMTCT_EID_TA | HIV-positive women at entry into | |
| | PMTCT) | |
| | By infants who received a virologic | |
| | test within 2 months of birth | 38 |
| | By infants who received their first | |
| | virologic HIV test between 2 and 12 | 2 |
| | months of age | - |
| | Sum of Infant Age disaggregates | 40 |
| | | |
| | By infants with a positive virologic test result within 12 months of birth | |
| | | |



| | | 1 |
|-------------|-----------------------------------|-------|
| | Number of infants with a positive | |
| | virological test result within 2 | 0 |
| | months of birth | |
| | Number of infants with a negative | |
| | virological test result within 2 | |
| | months of birth | |
| | Number of infants with a positive | |
| | virological test result between 2 | |
| | and 12 months of birth | |
| | Number of infants with a negative | |
| | virological test result between 2 | |
| | and 12 months of birth | |
| | Number of infants with a positive | |
| | virological test result within 12 | 0 |
| | months of birth | |
| | Number of adults and children | |
| | receiving antiretroviral therapy | 1,718 |
| | (ART) | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | 9 |
| TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 644 |
| | Aggregated Age/Sex: <15 Female | 35 |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 1,030 |
| | Sum of Aggregated Age/Sex <15 | 44 |
| | Sum of Aggregated Age/Sex 15+ | 1,674 |
| | Sum of Aggregated Age/Sex | · |
| | disaggregates | 1,718 |
| | Age/Sex: <1 | |
| | Age/Sex: <1-9 | |
| | nye/0er. <1-3 | |



| | Age/Sex: 10-14 Male | |
|------------|----------------------------------|-------|
| | Age/Sex: 10-14 Female | |
| | Aggregated Age/Sex: 1-14 Male | |
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children | |
| | receiving antiretroviral therapy | 1,861 |
| | (ART) | |
| | Age/Sex: <1 Male | |
| | Age/Sex: 1-4 Male | |
| | Age/Sex: 5-14 Male | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 20+ Male | |
| | Age/Sex: <1 Female | |
| | Age/Sex: 1-4 Female | |
| TX_CURR_TA | Age/Sex: 5-14 Female | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Sum of Age/Sex disaggregations | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | 94 |
| | Aggregated Age/Sex: 1-14 Male | |
| | Aggregated Age/Sex: 15+ Male | 830 |
| | Aggregated Age/Sex: <15 Female | 100 |
| | Aggregated Age/Sex: 1-14 Female | |
| | | |



| | Aggregated Age/Sex: 15+ Female | 837 |
|------------|--|-------|
| | Sum of Aggregated Age/Sex <15 | 194 |
| | Sum of Aggregated Age/Sex 15+ | 1,667 |
| | Sum of Aggregated Age/Sex disaggregates | 1,861 |
| | Age/Sex: <1 | |
| | Age/Sex: 1-9 | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 10-14 Female | |
| | Sum of Aggregated Age/Sex (<1 and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 322 |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| TX_NEW_DSD | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |



| | Sum of Age/Sex disaggregates | |
|-----------|--|-----|
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <15 Male | 2 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 147 |
| | Aggregated Grouping by Age/Sex: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | 2 |
| | Aggregated Grouping by Age/Sex: 15+ Female | 171 |
| | Sum of Aggregated Age/Sex disaggregates | 322 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 349 |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| TX_NEW_TA | By Age/Sex: <1 Male | |
| | By Age/Sex: 1-4 Male | |
| | By Age/Sex: 5-9 Male | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |



| | By Age/Sex: 25-49 Male | |
|-------------|--|-----|
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: <1 Female | |
| | By Age/Sex: 1-4 Female | |
| | By Age/Sex: 5-9 Female | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <15 Male | 2 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 163 |
| | Aggregated Grouping by Age: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | 2 |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 182 |
| | Sum of Aggregated Age/Sex disaggregates | 349 |
| | Pregnancy status | |
| | Breastfeeding status | |
| TX_PVLS_DSD | TX_PVLS_DSD Percentage of | n/a |



| i I | |
|---------------------------------------|-------|
| ART patients with a viral load result | |
| documented in the medical record | |
| and/or laboratory information | |
| systems (LIS) within the past 12 | |
| months with a suppressed viral | |
| load (<1000 copies/ml) | |
| Number of adults and pediatric | |
| patients on ART with suppressed | |
| viral load results (<1,000 copies/ml) | |
| documented in the medical records | 1,160 |
| and /or supporting laboratory | |
| results within the past 12 months. | |
| Number of adult and pediatric ART | |
| patients with a viral load result | |
| documented in the patient medical | 1,546 |
| record and /or laboratory records | , |
| in the past 12 months. | |
| Numerator: Indication: Routine | 1,160 |
| Numerator: Indication: Targeted | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Routine | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Routine | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Targeted | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Targeted | |
| Numerator: Age/Sex by Indication: | |
| <1 Routine | |
| Numerator: Age/Sex by Indication: | |
| 1-9 Routine | |
| | |
| Numerator: Age/Sex by Indication: | |
| 10-14 Male Routine | |
| Numerator: Age/Sex by Indication: | |
| 15-19 Male Routine | |



| Numerator: Age/Sex by Indication: 20-24 Male Routine |
|--|
| Numerator: Age/Sex by Indication: 25-49 Male Routine |
| Numerator: Age/Sex by Indication: 50+ Male Routine |
| Numerator: Age/Sex by Indication: 10-14 Female Routine |
| Numerator: Age/Sex by Indication: 15-19 Female Routine |
| Numerator: Age/Sex by Indication: 20-24 Female Routine |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| Numerator: Age/Sex by Indication: 50+ Female Routine |
| Numerator: Age/Sex by Indication: <1 Targeted |
| Numerator: Age/Sex by Indication: 1-9 Targeted |
| Numerator: Age/Sex by Indication: 10-14 Male Targeted |
| Numerator: Age/Sex by Indication: 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: 50+ Male Targeted |
| Numerator: Age/Sex by Indication: 10-14 Female Targeted |
| Numerator: Age/Sex by Indication: 15-19 Female Targeted |



| Numerator: Age/Sex by Indication: 20-24 Female Targeted | |
|--|-------|
| Numerator: Age/Sex by Indication: 25-49 Female Targeted | |
| | |
| Numerator: Age/Sex by Indication: | |
| 50+ Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Targeted | |
| | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Routine | |
| | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Female Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Routine | |
| Denominator: Indication: Routine | 1,546 |
| Denominator: Indication: Targeted | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Routine | |
| | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Routine | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Targeted | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Targeted | |
| Denominator: Age/Sex by | |
| Indication: <1 Routine | |
| | |



| Denominator: Age/Sex by |
|----------------------------------|
| Indication: 1-9 Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Male Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Female Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Female Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Female Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Female Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Female Routine |
| Denominator: Age/Sex by |
| Indication: <1 Targeted |
| Denominator: Age/Sex by |
| Indication: 1-9 Targeted |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| |



| Denominator: Age/Sex by | |
|------------------------------------|-----|
| Indication: 50+ Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 10-14 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 25-49 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 50+ Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Routine | |
| Numerator Aggregated Age/Sex: | 20 |
| <15 Male | 29 |
| Numerator Aggregated Age/Sex: | 540 |
| 15+ Male | 543 |
| Numerator Aggregated Age/Sex: | 20 |
| <15 Female | 29 |
| | |



| | Numerator Aggregated Age/Sex: 15+ Female | 559 |
|------------|--|-------|
| | Denominator Aggregated Age/Sex: <15 Male | 38 |
| | Denominator Aggregated Age/Sex: 15+ Male | 715 |
| | Denominator Aggregated Age/Sex: <15 Female | 40 |
| | Denominator Aggregated Age/Sex: 15+ Female | 753 |
| | TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml) | n/a |
| TX PVLS TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 1,256 |
| | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,675 |
| | Numerator: Age/Sex by Indication: <1 Routine | |
| | Numerator: Age/Sex by Indication: <1 Targeted | |
| | Numerator: Age/Sex by Indication: 1-9 Routine | |
| | Numerator: Age/Sex by Indication: | |



| 1-9 Targeted |
|--|
| Numerator: Age/Sex by Indication: |
| 10-14 Female Routine |
| |
| Numerator: Age/Sex by Indication: 10-14 Female Targeted |
| |
| Numerator: Age/Sex by Indication: 10-14 Male Routine |
| |
| Numerator: Age/Sex by Indication: 10-14 Male Targeted |
| |
| Numerator: Age/Sex by Indication: 15-19 Female Routine |
| Numerator: Age/Sex by Indication: |
| 15-19 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 15-19 Male Routine |
| Numerator: Age/Sex by Indication: |
| 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 20-24 Female Routine |
| Numerator: Age/Sex by Indication: |
| 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 20-24 Male Routine |
| Numerator: Age/Sex by Indication: |
| 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 25-49 Female Routine |
| Numerator: Age/Sex by Indication: |
| 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 25-49 Male Routine |
| Numerator: Age/Sex by Indication: |
| 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: |



| 50+ Female Routine Numerator: Age/Sex by Indication: 50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Indication: Routine Numerator: Indication: Routine Numerator: Preg/BF by Indication: | Numerator: Age/Sex by Indication:50+ Female TargetedNumerator: Age/Sex by Indication:50+ Male RoutineNumerator: Age/Sex by Indication:50+ Male TargetedNumerator: Aggregate Age/Sex byIndication: <15 Female Routine | |
|--|---|--|
| 50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | 50+ Female Targeted Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | Numerator: Age/Sex by Indication: 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| 50+ Male Routine Numerator: Age/Sex by Indication: S0+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | 50+ Male Routine Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| Numerator: Age/Sex by Indication:50+ Male TargetedNumerator: Aggregate Age/Sex byIndication: <15 Female Routine | Numerator: Age/Sex by Indication: 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | 50+ Male Targeted Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | Numerator: Aggregate Age/Sex by Indication: <15 Female Routine | |
| Indication: <15 Female Routine Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Indication: <15 Female Routine | |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted | | |
| Indication: <15 Female Targeted Numerator: Aggregate Age/Sex by Indication: <15 Male Routine Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | | |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Routine | Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Routine | Indication: <15 Female Targeted | |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted | Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Indication: <15 Male Routine | |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Indication: Routine 1,256 Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Routine Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Indication: <15 Male Targeted | |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female TargetedNumerator: Aggregate Age/Sex byIndication: 15+ Male RoutineNumerator: Aggregate Age/Sex byIndication: 15+ Male TargetedNumerator: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication:Breastfeeding RoutineNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Pregnant RoutineNumerator: Preg/BF by Indication: | Indication: 15+ Female Routine | |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male RoutineNumerator: Aggregate Age/Sex by Indication: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication: Breastfeeding RoutineNumerator: Preg/BF by Indication: Breastfeeding TargetedNumerator: Preg/BF by Indication: Pregnant RoutineNumerator: Preg/BF by Indication: Pregnant RoutineNumerator: Preg/BF by Indication: | Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male RoutineNumerator: Aggregate Age/Sex byIndication: 15+ Male TargetedNumerator: Indication: Routine1,256Numerator: Indication: TargetedNumerator: Preg/BF by Indication:Breastfeeding RoutineNumerator: Preg/BF by Indication:Breastfeeding TargetedNumerator: Preg/BF by Indication:Pregnant RoutineNumerator: Preg/BF by Indication: | Indication: 15+ Female Targeted | |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male TargetedNumerator: 1ndication: Routine1,256Numerator: Indication: Targeted1Numerator: Preg/BF by Indication: Breastfeeding Routine1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Breastfeeding Targeted1Numerator: Preg/BF by Indication: Pregnant Routine1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1Pregnant Routine1Numerator: Preg/BF by Indication:1Numerator: Preg/BF by Indication:1 | Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Targeted Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Indication: 15+ Male Routine | |
| Numerator: Indication: Routine 1,256 Numerator: Indication: Targeted 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Breastfeeding Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Pregnant Routine 1,256 Numerator: Preg/BF by Indication: 1,256 Pregnant Routine 1,256 Numerator: Preg/BF by Indication: 1,256 | Numerator: Aggregate Age/Sex by | |
| Numerator: Indication: Targeted Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Indication: 15+ Male Targeted | |
| Numerator: Preg/BF by Indication: Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Indication: Routine 1,256 | |
| Breastfeeding Routine Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Indication: Targeted | |
| Numerator: Preg/BF by Indication: Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Preg/BF by Indication: | |
| Breastfeeding Targeted Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Breastfeeding Routine | |
| Numerator: Preg/BF by Indication: Pregnant Routine Numerator: Preg/BF by Indication: | Numerator: Preg/BF by Indication: | |
| Pregnant Routine Numerator: Preg/BF by Indication: | Breastfeeding Targeted | |
| Numerator: Preg/BF by Indication: | Numerator: Preg/BF by Indication: | |
| | Pregnant Routine | |
| Pregnant Targeted | Numerator: Preg/BF by Indication: | |
| | Pregnant Targeted | |
| Denominator: Indication: Routine 1,675 | | |



| Denominator: Indication: Targeted | |
|-----------------------------------|--|
| Denominator: Age/Sex by | |
| Indication: <1 Routine | |
| Denominator: Age/Sex by | |
| Indication: <1 Targeted | |
| Denominator: Age/Sex by | |
| Indication: 1-9 Routine | |
| Denominator: Age/Sex by | |
| Indication: 1-9 Targeted | |
| Denominator: Age/Sex by | |
| Indication: 10-14 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 10-14 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 10-14 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 10-14 Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 15-19 Male Targeted | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Female Routine | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 20-24 Male Targeted | |
| Denominator: Age/Sex by | |
| | |



| Indication: 25-49 Female Routine |
|------------------------------------|
| Denominator: Age/Sex by |
| Indication: 25-49 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Female Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Female Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Male Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Targeted |
| Denominator: Preg/BF by |
| Indication: Breastfeeding Routine |
| Denominator: Preg/BF by |
| |



| | Indication: Breastfeeding Targeted | |
|------------|--|-----|
| | Denominator: Preg/BF by | |
| | Indication: Pregnant Routine | |
| | Denominator: Preg/BF by | |
| | Indication: Pregnant Targeted | |
| | Numerator Aggregated Age/Sex: <15 Male | 51 |
| | Numerator Aggregated Age/Sex: 15+ Male | 549 |
| | Numerator Aggregated Age/Sex: <15 Female | 73 |
| | Numerator Aggregated Age/Sex: 15+ Female | 583 |
| | Denominator Aggregated Age/Sex: <15 Male | 77 |
| | Denominator Aggregated Age/Sex: 15+ Male | 745 |
| | Denominator Aggregated Age/Sex: <15 Female | 91 |
| | Denominator Aggregated Age/Sex: 15+ Female | 762 |
| | TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy | n/a |
| TX_RET_DSD | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 151 |
| | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the | |
| | reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 178 |



| 1 | |
|--------------------------------------|--|
| Age/Sex: <1 (Numerator: Number | |
| of adults and children who are still | |
| alive and on treatment at 12 | |
| months after initiating ART | |
| Age/Sex: 1-9 (Numerator: Number | |
| of adults and children who are still | |
| alive and on treatment at 12 | |
| months after initiating ART | |
| Age/Sex: 10-14 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 15-19 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sed: 20-24 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 25-49 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 50+ Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 10-14 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART | |
| Age/Sex: 15-19 Female | |
| (Numerator: Number of adults and | |
| 13 | |



| children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 51 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART, in the 12 months prior to the beginning of the reporting period, | |
|---|--------------------------------------|
| initiating ART Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >10 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | children who are still alive and on |
| Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the adults and children who initiated ART in the 12 months prior | treatment at 12 months after |
| (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | initiating ART |
| children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those bots to stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Age/Sex: 20-24 Female |
| treatment at 12 months after initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | (Numerator: Number of adults and |
| initiating ART Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior | children who are still alive and on |
| Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >0+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the begin have begin be available and children who initiated ART in the 12 months prior | treatment at 12 months after |
| Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >0 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior | initiating ART |
| children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Age/Sex: 25-49 Female |
| treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | (Numerator: Number of adults and |
| initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | children who are still alive and on |
| Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | treatment at 12 months after |
| Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | initiating ART |
| are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Age/Sex: 50+ Female (Numerator: |
| 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Number of adults and children who |
| Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | are still alive and on treatment at |
| number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | 12 months after initiating ART |
| initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Age/Sex: >1 (Denominator: Total |
| to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | number of adults and children who |
| period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | initiated ART in the 12 months prior |
| died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | to the beginning of the reporting |
| ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | period, including those who have |
| Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | died, those who have stopped |
| number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | ART, and those lost to follow-up) |
| initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | Age/Sex: 1-9 (Denominator: Total |
| to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | number of adults and children who |
| period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | initiated ART in the 12 months prior |
| died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | to the beginning of the reporting |
| ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | period, including those who have |
| Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | died, those who have stopped |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | ART, and those lost to follow-up) |
| adults and children who initiated ART in the 12 months prior to the | Age/Sex: 10-14 Male |
| ART in the 12 months prior to the | (Denominator: Total number of |
| | adults and children who initiated |
| beginning of the reporting period, | ART in the 12 months prior to the |
| | beginning of the reporting period, |



| including those who have died, | |
|-------------------------------------|--|
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 15-19 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 20-24 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 25-49 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 50+ Male (Denominator: | |
| Total number of adults and children | |
| who initiated ART in the 12 months | |
| prior to the beginning of the | |
| reporting period, including those | |
| who have died, those who have | |
| stopped ART, and those lost to | |
| follow-up) | |
| Age/Sex: 10-14 Female | |
| | |



| (Denominator: Total number of |
|------------------------------------|
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 15-19 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 20-24 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 25-49 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 50+ Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| |



| including those who have died, | |
|-------------------------------------|---|
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age: <15 (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Aggregated Age: 15+ (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Aggregated Age: <15 | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age: 15+ | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Numerator by Status: Pregnant | |
| Numerator by Status: | |
| Breastfeeding | |
| Denominator by Status: Pregnant | |
| Denominator by Status: | |
| Breastfeeding | |
| Aggregated Age/Sex: <15 Male | |
| (Numerator: Number of adults and | 7 |
| | |



| |] |
|--|----|
| children who are still alive and on treatment at 12 months after initiating ART) | |
| Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 64 |
| Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 8 |
| Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 72 |
| Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 8 |
| Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 76 |
| Aggregated Age/Sex: <15 Female (Denominator: Total number of | 10 |



| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, | |
|--|--|
| beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| those who have stopped ART, and those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| those lost to follow-up) Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, 84 | |
| Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | |
| ART in the 12 months prior to the 84 beginning of the reporting period, | |
| beginning of the reporting period, | |
| beginning of the reporting period, | |
| including those who have died | |
| | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| TX_RET_TA Percent of adults and | |
| children known to be alive and on | |
| treatment 12 months after initiation | |
| of antiretroviral therapy | |
| Number of adults and children who | |
| are still alive and on treatment at 200 | |
| 12 months after initiating ART | |
| Total number of adults and children | |
| who initiated ART in the 12 months | |
| prior to the beginning of the | |
| reporting period, including those 227 | |
| TX_RET_TA who have died, those who have | |
| stopped ART, and those lost to | |
| follow-up | |
| Age/Sex: <1 (Numerator: Number | |
| of adults and children who are still | |
| alive and on treatment at 12 | |
| months after initiating ART) | |
| | |
| Age/Sex: 1-9 (Numerator: Number | |
| | |
| Age/Sex: 1-9 (Numerator: Number | |



| Age/Sex: 10-14 Male (Numerator: | |
|-------------------------------------|--|
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 15-19 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 20-24 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 25-49 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 50+ Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 10-14 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 15-19 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 20-24 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| | |



| 1 | |
|--------------------------------------|--|
| Age/Sex: 25-49 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 50+ Female (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: <1 (Denominator: Total | |
| number of adults and children who | |
| initiated ART in the 12 months prior | |
| to the beginning of the reporting | |
| period, including those who have | |
| died, those who have stopped | |
| ART, and those lost to follow-up) | |
| Age/Sex: 1-9 (Denominator: Total | |
| number of adults and children who | |
| initiated ART in the 12 months prior | |
| to the beginning of the reporting | |
| period, including those who have | |
| died, those who have stopped | |
| ART, and those lost to follow-up) | |
| Age/Sex: 10-14 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 15-19 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| | |



| L | |
|-------------------------------------|--|
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 20-24 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 25-49 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 50+ Male (Denominator: | |
| Total number of adults and children | |
| who initiated ART in the 12 months | |
| prior to the beginning of the | |
| reporting period, including those | |
| who have died, those who have | |
| stopped ART, and those lost to | |
| follow-up) | |
| Age/Sex: 10-14 Female | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| | |
| those lost to follow-up) | |
| Age/Sex: 15-19 Female | |



| (Denominator: Total number of |
|-------------------------------------|
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 20-24 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 25-49 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 50+ Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Aggregated Age: <15 (Numerator: |
| Number of adults and children who |
| are still alive and on treatment at |
| 12 months after initiating ART) |
| Aggregated Age: 15+ (Numerator: |
| |



| Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age: <15 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on 10 treatment at 12 months after< | | |
|--|-------------------------------------|----|
| 12 months after initiating ART) Aggregated Age: <15 | Number of adults and children who | |
| Aggregated Age: <15 | are still alive and on treatment at | |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | 12 months after initiating ART) | |
| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Aggregated Age: <15 | |
| ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: BreastfeedingDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | (Denominator: Total number of | |
| beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | adults and children who initiated | |
| including those who have died, those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | ART in the 12 months prior to the | |
| those who have stopped ART, and those lost to follow-up) Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Pregnant Denominator by Status: Breastfeeding Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | beginning of the reporting period, | |
| those lost to follow-up)Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | including those who have died, | |
| Aggregated Age: 15+ (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | those who have stopped ART, and | |
| Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantDenominator by Status: PregnantDenominator by Status: BreastfeedingDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | those lost to follow-up) | |
| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Aggregated Age: 15+ | |
| ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: BreastfeedingDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after | (Denominator: Total number of | |
| beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status: PregnantNumerator by Status: BreastfeedingDenominator by Status: PregnantDenominator by Status: BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on status: Aggregated Age/Sex: 15+ Male status: Aggregated Age/Sex: 15+ Male st | adults and children who initiated | |
| including those who have died, those who have stopped ART, and those lost to follow-up) Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | ART in the 12 months prior to the | |
| those who have stopped ART, and those lost to follow-up)Numerator by Status: PregnantNumerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterInitiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | beginning of the reporting period, | |
| those lost to follow-up)Numerator by Status: PregnantNumerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male | including those who have died, | |
| Numerator by Status: Pregnant Numerator by Status: Breastfeeding Denominator by Status: Pregnant Denominator by Status: Breastfeeding Aggregated Age/Sex: <15 Male | those who have stopped ART, and | |
| Numerator by Status:BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | those lost to follow-up) | |
| BreastfeedingDenominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Numerator by Status: Pregnant | |
| Denominator by Status: PregnantDenominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months afterAggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Numerator by Status: | |
| Denominator by Status:BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Breastfeeding | |
| BreastfeedingAggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | Denominator by Status: Pregnant | |
| Aggregated Age/Sex: <15 Male(Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86 | Denominator by Status: | |
| (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86 | Breastfeeding | |
| (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86 | Aggregated Age/Sex: <15 Male | |
| children who are still alive and on treatment at 12 months after initiating ART)10Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after86 | | |
| initiating ART) Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after | | 10 |
| Aggregated Age/Sex: 15+ Male(Numerator: Number of adults and children who are still alive and on86treatment at 12 months after86 | treatment at 12 months after | |
| (Numerator: Number of adults and children who are still alive and on 86 treatment at 12 months after | initiating ART) | |
| children who are still alive and on 86 treatment at 12 months after | Aggregated Age/Sex: 15+ Male | |
| treatment at 12 months after | (Numerator: Number of adults and | |
| | children who are still alive and on | 86 |
| initiating ART) | treatment at 12 months after | |
| | initiating ART) | |



| Aggregated Age/Sex: <15 Female | |
|-------------------------------------|-----|
| (Numerator: Number of adults and | |
| children who are still alive and on | 10 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: 15+ Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 94 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: <15 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | 9 |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| | |
| Aggregated Age/Sex: 15+ Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | 95 |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age/Sex: <15 Female | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | 14 |
| beginning of the reporting period, | 14 |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age/Sex: 15+ Female | |
| (Denominator: Total number of | 109 |
| | |



| adults and children who initiated | |
|------------------------------------|--|
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |



Technical Area Summary Indicators and Targets

Jamaica

| Indicator Number | Label | 2017 |
|------------------|---|--------|
| | KP_PREV_DSD Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV preventive interventions that are | n/a |
| | based on evidence and/or meet the | |
| | minimum standards required (DSD) | |
| | Number of key populations reached | |
| | with individual and/or small group | |
| | level HIV preventive interventions | 2.095 |
| | that are based on evidence and/or | 2,085 |
| | meet the minimum standards | |
| | required | |
| | Total estimated number of key | 32,371 |
| | population in the catchment area | 52,571 |
| KP_PREV_DSD | By key population type: Men who | |
| | have sex with men who are sex | |
| | workers (Numerator: Number of | |
| | key populations reached with | |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men who are NOT | |
| | sex workers (Numerator: Number | |
| | of key populations reached with | 1,268 |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |



| the minimum standards required) | |
|-------------------------------------|-------|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | o / = |
| level HIV preventive interventions | 817 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| | |



| populations reached with individual | |
|-------------------------------------|--------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 18,754 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | 13,617 |
| Total estimated number of key | - , |
| / | |



| | | I |
|------------|---------------------------------------|-----|
| | population in the catchment area) | |
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | KP_PREV_TA Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | n/a |
| KP_PREV_TA | based on evidence and/or meet the | |
| | minimum standards required | |
| | (TA-only) | |
| | Number of key populations reached | |
| | with individual and/or small group | 118 |
| J. | | |



| level HIV preventive interventions | |
|-------------------------------------|--|
| that are based on evidence and/or | |
| meet the minimum standards | |
| required | |
| Total estimated number of key | |
| population in the catchment area | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | |
| level HIV preventive interventions | |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | |
| Total estimated number of key | |
| population in the catchment area) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |



| (Denominator: Total estimated | |
|-------------------------------------|-----|
| number of key population in the | |
| catchment area) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Denominator: Total estimated | |
| number of key population in the | |
| catchment area) | |
| By key population type: Men who | |
| have sex with men and are sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Men who | |
| have sex with men and are NOT | |
| sex workers (Numerator: Number | |
| of key populations reached with | |
| individual and/or small group level | 118 |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| rey populations reached with | |



| individual and/or small group level | |
|-------------------------------------|-----|
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Men who | |
| have sex with men and are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Men who | |
| have sex with men and are NOT | |
| sex workers (Denominator: Total | 376 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Denominator: Total estimated | |
| number of key population in the | |
| | |



| | catchment area) | |
|-------------|--|-------|
| | By Service: KP known positive | |
| | By Service: KP was tested as part of the program and/or KP was | |
| | referred for testing as part of the program | |
| | By New Client Status: New beneficiary | |
| | By New Client Status: Returning beneficiary within the current report period | |
| | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,859 |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | Age/sex: 50+ Male | |
| | Age/sex: 5-9 Female | |
| HTC_TST_DSD | Age/sex: 10-14 Female | |
| | Age/sex: 15-19 Female | |
| | Age/sex: 20-24 Female | |
| | Age/sex: 25-49 Female | |
| | Age/sex: 50+ Female | |
| | Test Result by Age and Sex: Positive: 10-14 Male | |
| | Test Result by Age and Sex: Positive: 15-19 Male | |
| | Test Result by Age and Sex: Positive: 20-24 Male | |



| Test Result by Age and Sex: |
|-----------------------------|
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |
| Negative: 25-49 Male |
| Test Result by Age and Sex: |
| Negative: 50+ Male |
| Test Result by Age and Sex: |
| Negative: 10-14 Female |
| Test Result by Age and Sex: |
| Negative: 15-19 Female |
| Test Result by Age and Sex: |
| Negative: 20-24 Female |
| Test Result by Age and Sex: |
| Negative: 25-49 Female |
| Test Result by Age and Sex: |
| Negative: 50+ Female |



| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male |
|--|
| |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ 735 Female |
| Test Result by Aggregated Age and Sex: Negative <15 Male |
| Test Result by Aggregated Age and Sex: Negative 15+ Male |
| Test Result by Aggregated Age and Sex: Negative <15 Female |
| Test Result by Aggregated Age and Sex: Negative 15+ Female |
| Test Result by Aggregated Age and Sex: Positive <15 Male |
| Test Result by Aggregated Age 120 and Sex: Positive 15+ Male 120 |
| Test Result by Aggregated Age and Sex: Positive <15 Female |
| Test Result by Aggregated Age 22 and Sex: Positive 15+ Female 22 |
| Test Result by Age: Positive: <1 |
| Test Result by Age: Positive: 1-9 |
| Age/sex: <1 |
| Age/sex: 1-9 |
| Service Delivery Point (Community): Index testing |
| Service Delivery Point (Community): Homebased testing |



| Service Delivery Point | |
|---|-------|
| (Community): Mobile testing | |
| Service Delivery Point (Community): Other | 1,799 |
| Service Delivery Point (Community) by Age: <15 index testing | |
| Service Delivery Point (Community) by Age: 15+ index testing | |
| Service Delivery Point (Community) by Age: <15 homebased testing | |
| Service Delivery Point (Community) by Age: 15+ homebased testing | |
| Service Delivery Point (Community) by Age: <15 mobile testing | |
| Service Delivery Point (Community) by Age: 15+ mobile testing | |
| Service Delivery Point (Community) by Age: <15 other | |
| Service Delivery Point (Community) by Age: <15 other | |
| Service Delivery Point (Facility): Inpatient | |
| Service Delivery Point (Facility): Outpatient | |
| Service Delivery Point (Facility): Pediatric | |
| Service Delivery Point (Facility): Malnutrition facilities | |
| Service Delivery Point (Facility): Other PITC | |
| Service Delivery Point (Facility): VCT | |
| Service Delivery Point (Facility): VMMC | |



| Service Delivery Point (Facility): PMTCT |
|--|
| Service Delivery Point (Facility): TB Clinics |
| Service Delivery Point (Facility): Index testing |
| Service Delivery Point (Facility) by Age: <15 Inpatient |
| Service Delivery Point (Facility) by Age: >15 Inpatient |
| Service Delivery Point (Facility) by Age: <15 Outpatient |
| Service Delivery Point (Facility) by Age: >15 Outpatient |
| Service Delivery Point (Facility) by Age: <15 Pediatroc |
| Service Delivery Point (Facility) by Age: >15 Pediatroc |
| Service Delivery Point (Facility) by Age: <15 Malnutrition facilities |
| Service Delivery Point (Facility) by Age: >15 Malnutrition facilities |
| Service Delivery Point (Facility) by Age: <15 Other PITC |
| Service Delivery Point (Facility) by Age: >15 Other PITC |
| Service Delivery Point (Facility) by Age: <15 VCT |
| Service Delivery Point (Facility) by Age: >15 VCT |
| Service Delivery Point (Facility) by Age: <15 VMMC |
| Service Delivery Point (Facility) by Age: >15 VMMC |



| | Service Delivery Point (Facility) by Age: <15 PMTCT | |
|------------|--|----|
| | Service Delivery Point (Facility) by Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: <15 Index testing | |
| | Service Delivery Point (Facility) by Age: >15 Index testing | |
| | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 94 |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | Age/sex: 50+ Male | |
| HTC_TST_TA | Age/sex: 5-9 Female | |
| | Age/sex: 10-14 Female | |
| | Age/sex: 15-19 Female | |
| | Age/sex: 20-24 Female | |
| | Age/sex: 25-49 Female | |
| | Age/sex: 50+ Female | |
| | Test Result by Age and Sex: | |
| | Positive: 10-14 Male | |
| | Test Result by Age and Sex: | |
| | Positive: 15-19 Male | |
| | Test Result by Age and Sex: | |



| Positive: 20-24 Male |
|-----------------------------|
| Test Result by Age and Sex: |
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |
| Negative: 25-49 Male |
| Test Result by Age and Sex: |
| Negative: 50+ Male |
| Test Result by Age and Sex: |
| Negative: <1 Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Female |
| Test Result by Age and Sex: |
| Negative: 15-19 Female |
| Test Result by Age and Sex: |
| Negative: 20-24 Female |
| Test Result by Age and Sex: |



| Negative: 25-49 Female | |
|-----------------------------------|----|
| Test Result by Age and Sex: | |
| Negative: 50+ Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 Male | |
| Aggregated Age/sex - USE WITH | 94 |
| HQ PERMISSION ONLY: 15+ Male | 94 |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 | |
| Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: 15+ | |
| Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Female | |
| Test Result by Aggregated Age | |
| and Sex: Positive <15 Male | |
| Test Result by Aggregated Age | 14 |
| and Sex: Positive 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Positive <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Positive 15+ Female | |
| Test Result by Age: Positive: <1 | |
| Test Result by Age: Positive: 1-9 | |
| Age/sex: <1 | |
| Age/sex: 1-9 | |
| Service Delivery Point | |
| | |



| (Community): Index testing | |
|------------------------------------|----|
| Service Delivery Point | |
| (Community): Homebased testing | |
| Service Delivery Point | |
| (Community): Mobile testing | |
| Service Delivery Point | |
| (Community): Other | 14 |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Facility): | |
| Inpatient | |
| Service Delivery Point (Facility): | |
| Outpatient | |
| Service Delivery Point (Facility): | |
| Pediatric | |
| Service Delivery Point (Facility): | |
| Malnutrition facilities | |
| Service Delivery Point (Facility): | |
| Other PITC | |
| Service Delivery Point (Facility): | |
| | |



| VCT |
|--|
| Service Delivery Point (Facility): VMMC |
| Service Delivery Point (Facility): PMTCT |
| Service Delivery Point (Facility): TB Clinics |
| Service Delivery Point (Facility): Index testing |
| Service Delivery Point (Facility) by Age: <15 Inpatient |
| Service Delivery Point (Facility) by Age: >15 Inpatient |
| Service Delivery Point (Facility) by Age: <15 Outpatient |
| Service Delivery Point (Facility) by Age: >15 Outpatient |
| Service Delivery Point (Facility) by Age: <15 Pediatroc |
| Service Delivery Point (Facility) by Age: >15 Pediatroc |
| Service Delivery Point (Facility) by Age: <15 Malnutrition facilities |
| Service Delivery Point (Facility) by Age: >15 Malnutrition facilities |
| Service Delivery Point (Facility) by Age: <15 Other PITC |
| Service Delivery Point (Facility) by Age: >15 Other PITC |
| Service Delivery Point (Facility) by Age: <15 VCT |
| Service Delivery Point (Facility) by Age: >15 VCT |
| Service Delivery Point (Facility) by |



| | Age: <15 VMMC | |
|------------|--|--------|
| | Service Delivery Point (Facility) by | |
| | Age: >15 VMMC Service Delivery Point (Facility) by | |
| | Age: <15 PMTCT Service Delivery Point (Facility) by | |
| | Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: <15 Index testing | |
| | Service Delivery Point (Facility) by Age: >15 Index testing | |
| | Number of adults and children receiving antiretroviral therapy | 12,728 |
| | (ART) | |
| | Age/Sex: <1 Male | |
| | Age/Sex: 1-4 Male | |
| | Age/Sex: 5-14 Male | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 20+ Male | |
| TX_CURR_TA | Age/Sex: <1 Female | |
| TA_CORK_TA | Age/Sex: 1-4 Female | |
| | Age/Sex: 5-14 Female | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Sum of Age/Sex disaggregations | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | |
| | Aggregated Age/Sex: 1-14 Male | |



| | Aggregated Age/Sex: 15+ Male | 6,109 |
|------------|----------------------------------|----------------|
| | Aggregated Age/Sex: <15 Female | |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 6,620 |
| | Sum of Aggregated Age/Sex <15 | |
| | Sum of Aggregated Age/Sex 15+ | 12,729 |
| | Sum of Aggregated Age/Sex | 10 - 00 |
| | disaggregates | 12,729 |
| | Age/Sex: <1 | |
| | Age/Sex: 1-9 | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 10-14 Female | |
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children | |
| | newly enrolled on antiretroviral | 1,220 |
| | therapy (ART) | |
| | By Age/Sex: <1 | |
| TX_NEW_DSD | By Age/Sex: 1-9 | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |



| | By Age/Sex: 20-24 Female | |
|-----------|--|-------|
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <a><15 Male | |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 585 |
| | Aggregated Grouping by Age/Sex: <pre><1 Female</pre> | |
| | Aggregated Grouping by Age/Sex: <a><15 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 635 |
| | Sum of Aggregated Age/Sex disaggregates | 1,220 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 2,217 |
| TX_NEW_TA | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: <1 Male | |
| | By Age/Sex: 1-4 Male | |
| | By Age/Sex: 5-9 Male | |



| E | By Age/Sex: 10-14 Male | |
|---|--|-------|
| E | By Age/Sex: 15-19 Male | |
| E | By Age/Sex: 20-24 Male | |
| E | By Age/Sex: 25-49 Male | |
| E | By Age/Sex: 50+ Male | |
| E | By Age/Sex: <1 Female | |
| E | By Age/Sex: 1-4 Female | |
| E | By Age/Sex: 5-9 Female | |
| E | By Age/Sex: 10-14 Female | |
| E | By Age/Sex: 15-19 Female | |
| E | By Age/Sex: 20-24 Female | |
| E | By Age/Sex: 25-49 Female | |
| E | By Age/Sex: 50+ Female | |
| S | Sum of Age/Sex disaggregates | |
| Α | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <15 Male | 80 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 1,034 |
| | Aggregated Grouping by Age: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | 26 |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 1,083 |
| | Sum of Aggregated Age/Sex lisaggregates | 2,223 |



| | Pregnancy status | |
|------------|---------------------------------------|--------|
| | Breastfeeding status | |
| | TX_PVLS_TA Percentage of ART | |
| | patients with a viral load result | |
| | documented in the medical record | |
| | and/or laboratory information | n/a |
| | systems (LIS) within the past 12 | |
| | months with a suppressed viral | |
| | load (<1000 copies/ml) | |
| | Number of adults and pediatric | |
| | patients on ART with suppressed | |
| | viral load results (<1,000 copies/ml) | 10,181 |
| | documented in the medical records | 10,101 |
| | and /or supporting laboratory | |
| | results within the past 12 months. | |
| | Number of adult and pediatric ART | |
| | patients with a viral load result | |
| | documented in the patient medical | 12,728 |
| TX_PVLS_TA | record and /or laboratory records | |
| | in the past 12 months. | |
| | Numerator: Age/Sex by Indication: | |
| | <1 Routine | |
| | Numerator: Age/Sex by Indication: | |
| | <1 Targeted | |
| | Numerator: Age/Sex by Indication: | |
| | 1-9 Routine | |
| | Numerator: Age/Sex by Indication: | |
| | 1-9 Targeted | |
| | Numerator: Age/Sex by Indication: | |
| | 10-14 Female Routine | |
| | Numerator: Age/Sex by Indication: | |
| | 10-14 Female Targeted | |
| | Numerator: Age/Sex by Indication: | |
| | 10-14 Male Routine | |
| | Numerator: Age/Sex by Indication: | |



| 10-14 Male Targeted | |
|-----------------------------------|--|
| Numerator: Age/Sex by Indication: | |
| 15-19 Female Routine | |
| Numerator: Age/Sex by Indication: | |
| 15-19 Female Targeted | |
| Numerator: Age/Sex by Indication: | |
| 15-19 Male Routine | |
| Numerator: Age/Sex by Indication: | |
| 15-19 Male Targeted | |
| Numerator: Age/Sex by Indication: | |
| 20-24 Female Routine | |
| Numerator: Age/Sex by Indication: | |
| 20-24 Female Targeted | |
| Numerator: Age/Sex by Indication: | |
| 20-24 Male Routine | |
| Numerator: Age/Sex by Indication: | |
| 20-24 Male Targeted | |
| Numerator: Age/Sex by Indication: | |
| 25-49 Female Routine | |
| Numerator: Age/Sex by Indication: | |
| 25-49 Female Targeted | |
| Numerator: Age/Sex by Indication: | |
| 25-49 Male Routine | |
| Numerator: Age/Sex by Indication: | |
| 25-49 Male Targeted | |
| Numerator: Age/Sex by Indication: | |
| 50+ Female Routine | |
| Numerator: Age/Sex by Indication: | |
| 50+ Female Targeted | |
| Numerator: Age/Sex by Indication: | |
| 50+ Male Routine | |
| Numerator: Age/Sex by Indication: | |
| 50+ Male Targeted | |
| Numerator: Aggregate Age/Sex by | |



| 1 | |
|-----------------------------------|--|
| Indication: <15 Female Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Targeted | |
| Numerator: Indication: Routine | |
| Numerator: Indication: Targeted | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Routine | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Targeted | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Routine | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Targeted | |
| Denominator: Indication: Routine | |
| Denominator: Indication: Targeted | |
| Denominator: Age/Sex by | |
| Indication: <1 Routine | |
| Denominator: Age/Sex by | |
| Indication: <1 Targeted | |
| Denominator: Age/Sex by | |
| Indication: 1-9 Routine | |
| Denominator: Age/Sex by | |
| | |



| Indication: 1-9 Targeted |
|-----------------------------------|
| Denominator: Age/Sex by |
| Indication: 10-14 Female Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 15-19 Female Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 20-24 Female Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Female Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| Denominator: Age/Sex by |



| Indication: 50+ Female Routine | |
|------------------------------------|-------|
| Denominator: Age/Sex by | |
| Indication: 50+ Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Targeted | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Routine | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Targeted | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Routine | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Targeted | |
| Numerator Aggregated Age/Sex: | |
| <15 Male | |
| Numerator Aggregated Age/Sex: | 4,886 |
| | |



| | 15+ Male | |
|-----------|--|-------|
| | Numerator Aggregated Age/Sex: <15 Female | |
| | Numerator Aggregated Age/Sex: 15+ Female | 5,295 |
| | Denominator Aggregated Age/Sex: <15 Male | |
| | Denominator Aggregated Age/Sex: 15+ Male | 6,109 |
| | Denominator Aggregated Age/Sex: <15 Female | |
| | Denominator Aggregated Age/Sex: 15+ Female | 6,619 |
| | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an | |
| | analyte-specific proficiency testing (PT) program | |
| | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 4 |
| | CD4: Number of laboratories that participate in this PT program | 4 |
| LAB_PT_TA | CD4: Number of laboratories that perform this testing | 4 |
| | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| | Early infant diagnostics: Number of laboratories that perform this | 1 |



| testing | | |
|------------|-----------------------------|----|
| | ogic/diagnostic testing: | |
| | of laboratories that | |
| | cceptable successful | 18 |
| | riteria in this PT program | |
| | ogic/diagnostic testing: | |
| | of laboratories that | 18 |
| | e in this PT program | |
| | ogic/diagnostic testing: | |
| | of laboratories that | 18 |
| | his testing | |
| · | load: Number of | |
| | es that achieve | |
| | le successful passing | 1 |
| - | this PT program | |
| | load: Number of | |
| | es that participate in this | 1 |
| PT progra | | |
| | load: Number of | |
| | es that perform this | 1 |
| testing | | |
| TB diagn | ostics (AFB microscopy): | |
| Number o | of laboratories that | C |
| achieve a | cceptable successful | 6 |
| passing c | riteria in this PT program | |
| TB diagn | ostics (AFB microscopy): | |
| Number o | of laboratories that | 6 |
| participat | e in this PT program | |
| TB diagn | ostics (AFB microscopy): | |
| Number o | of laboratories that | 6 |
| perform t | his testing | |
| TB diagn | ostics (Xpert MTB/RIF): | |
| Number o | of laboratories that | 0 |
| achieve a | cceptable successful | 0 |
| passing c | riteria in this PT program | |



| | TB diagnostics (Xpert MTB/RIF): | |
|-----------|--------------------------------------|-------|
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| HRH_PRE | Number of new HCW who | |
| | graduated from a pre-service | |
| | training institution or program as a | 6 |
| | result of PEPFAR-supported | U |
| | strengthening efforts, within the | |
| | reporting period, by select cadre | |
| | By Graduates: Doctors | |
| | By Graduates: Nurses | |
| | By Graduates: Midwives | |
| | By Graduates: Social service | |
| | workers | |
| | By Graduates: Laboratory | |
| | professionals | |
| | By Graduates: Other | |
| | Sum of Graduates disaggreagtes | |
| | PEPFAR resources used for | |
| INVS_COMD | HIV-program related commodities: | |
| | planned & purchased in the last 12 | 6,299 |
| | months by Implementing Partner | |
| | | |



| Number of LUV/ Test Kite numbers of | 1 000 |
|-------------------------------------|---------|
| Number of HIV Test Kits purchased | 1,889 |
| Number of HIV CD4 Reagents | |
| purchased | |
| Number of Condoms purchased | |
| Number of HIV Viral Load | 0.007 |
| Reagents purchased | 3,067 |
| Number of HIV ARVs purchased | 1,343 |
| Number of Second Line HIV ARVs | |
| purchased | |
| HIV Test Kits: Dollars planned | 10.400 |
| (COP)/ spent (Actual) | 10,198 |
| HIV CD4 Tests: Dollars planned | 50.000 |
| (COP)/ spent (Actual) | 50,000 |
| HIV Viral Load: Dollars planned | 400 500 |
| (COP)/ spent (Actual) | 130,580 |
| Condoms: Dollars planned (COP)/ | |
| spent (Actual) | |
| HIV ARVs: Dollars planned (COP)/ | |
| spent (Actual) | 161,160 |



Technical Area Summary Indicators and Targets

St. Kitts and Nevis

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Lucia

(No data provided.)

Approved



Technical Area Summary Indicators and Targets

St. Vincent and the Grenadines

(No data provided.)



Technical Area Summary Indicators and Targets

Suriname

| Indicator Number | Label | 2017 |
|------------------|---|-------|
| | KP_PREV_DSD Percentage of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the | n/a |
| | minimum standards required (DSD) Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 1,345 |
| | Total estimated number of key population in the catchment area | 9,260 |
| KP_PREV_DSD | By key population type: Men who have sex with men who are sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | |
| | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet | 595 |



| the minimum standards required) | |
|---------------------------------------|-----|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | |
| level HIV preventive interventions | 750 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| · · · · · · · · · · · · · · · · · · · | |



| populations reached with individual | |
|-------------------------------------|-------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 6,800 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | 2,460 |
| Total estimated number of key | |
| • | |



| | population in the catchment area) | |
|-------------|--|-----|
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | ` number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | Number of individuals who received | |
| | T&C services for HIV and received | 255 |
| | their test results during the past 12 months | |
| | | |
| HTC_TST_DSD | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |



| Age/sex:50+ MaleAge/sex:5-9 FemaleAge/sex:10-14 FemaleAge/sex:10-14 FemaleAge/sex:20-24 FemaleAge/sex:20-24 FemaleAge/sex:50+ FemaleAge/sex:50+ FemaleTest Result by Age and Sex:Positive:Positive:10-14 MaleTest Result by Age and Sex:Positive:Positive:15-19 MaleTest Result by Age and Sex:Positive:Positive:20-24 Male | |
|---|---|
| Age/sex: 10-14 FemaleAge/sex: 15-19 FemaleAge/sex: 20-24 FemaleAge/sex: 20-24 FemaleAge/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male | |
| Age/sex: 15-19 FemaleAge/sex: 20-24 FemaleAge/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male | |
| Age/sex: 20-24 Female Age/sex: 25-49 Female Age/sex: 50+ Female Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Age/sex: 25-49 FemaleAge/sex: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Positive: 15-19 MaleTest Result by Age and Sex:Positive: 20-24 Male | |
| Age/sex: 50+ Female Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Test Result by Age and Sex: Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Positive: 10-14 Male Test Result by Age and Sex: Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Positive: 15-19 Male Test Result by Age and Sex: Positive: 20-24 Male | |
| Test Result by Age and Sex: Positive: 20-24 Male | |
| Positive: 20-24 Male | l |
| | |
| | |
| Test Result by Age and Sex: | |
| Positive: 25-49 Male | |
| Test Result by Age and Sex: | |
| Positive: 50+ Male | |
| Test Result by Age and Sex: | |
| Positive: 10-14 Female | |
| Test Result by Age and Sex: | |
| Positive: 15-19 Female | |
| Test Result by Age and Sex: | |
| Positive: 20-24 Female | |
| Test Result by Age and Sex: | |
| Positive: 25-49 Female | |
| Test Result by Age and Sex: Positive: 50+ Female | |
| Test Result by Age and Sex: | |
| Negative: 10-14 Male | |
| Test Result by Age and Sex: | |
| Negative: 15-19 Male | |
| Test Result by Age and Sex: | |
| Negative: 20-24 Male | |
| Test Result by Age and Sex: | |



| N | legative: 25-49 Male | |
|-----|---|-----|
| | est Result by Age and Sex: | |
| | legative: 50+ Male | |
| Т | est Result by Age and Sex: | |
| N | legative: 10-14 Female | |
| | est Result by Age and Sex: | |
| N | legative: 15-19 Female | |
| Т | est Result by Age and Sex: | |
| N | legative: 20-24 Female | |
| T | est Result by Age and Sex: | |
| N | legative: 25-49 Female | |
| Te | est Result by Age and Sex: | |
| N | legative: 50+ Female | |
| A | ggregated Age/sex - USE WITH | |
| H H | IQ PERMISSION ONLY: <15 Male | |
| | ggregated Age/sex - USE WITH | 95 |
| | IQ PERMISSION ONLY: 15+ Male | |
| | ggregated Age/sex - USE WITH | |
| | IQ PERMISSION ONLY: <15 | |
| | emale | |
| | ggregated Age/sex - USE WITH | 400 |
| | IQ PERMISSION ONLY: 15+ emale | 160 |
| | | |
| | est Result by Aggregated Age nd Sex: Negative <15 Male | |
| | est Result by Aggregated Age | |
| | nd Sex: Negative 15+ Male | |
| | est Result by Aggregated Age | |
| | nd Sex: Negative <15 Female | |
| | est Result by Aggregated Age | |
| | nd Sex: Negative 15+ Female | |
| | est Result by Aggregated Age | |
| | nd Sex: Positive <15 Male | |
| Т | est Result by Aggregated Age | 10 |



| | and Sex: Positive 15+ Male | |
|---|------------------------------------|-----|
| | Test Result by Aggregated Age | |
| | and Sex: Positive <15 Female | |
| | Test Result by Aggregated Age | 0 |
| | and Sex: Positive 15+ Female | 8 |
| | Test Result by Age: Positive: <1 | |
| | Test Result by Age: Positive: 1-9 | |
| | Age/sex: <1 | |
| | Age/sex: 1-9 | |
| | Service Delivery Point | |
| | (Community): Index testing | |
| | Service Delivery Point | |
| | (Community): Homebased testing | |
| | Service Delivery Point | 055 |
| | (Community): Mobile testing | 255 |
| | Service Delivery Point | |
| | (Community): Other | |
| | Service Delivery Point (Community) | |
| | by Age: <15 index testing | |
| | Service Delivery Point (Community) | |
| | by Age: 15+ index testing | |
| | Service Delivery Point (Community) | |
| | by Age: <15 homebased testing | |
| | Service Delivery Point (Community) | |
| | by Age: 15+ homebased testing | |
| | Service Delivery Point (Community) | |
| | by Age: <15 mobile testing | |
| | Service Delivery Point (Community) | |
| | by Age: 15+ mobile testing | |
| | Service Delivery Point (Community) | |
| | by Age: <15 other | |
| | Service Delivery Point (Community) | |
| b | by Age: <15 other | |
| S | Service Delivery Point (Facility): | |
| | | |



| Inpatient |
|--|
| Service Delivery Point (Facility): |
| Outpatient |
| Service Delivery Point (Facility): |
| Pediatric |
| Service Delivery Point (Facility): |
| Malnutrition facilities |
| Service Delivery Point (Facility): |
| Other PITC |
| Service Delivery Point (Facility): |
| VCT |
| Service Delivery Point (Facility): |
| VMMC |
| Service Delivery Point (Facility): |
| |
| Service Delivery Point (Facility): TB |
| |
| Service Delivery Point (Facility): Index testing |
| |
| Service Delivery Point (Facility) by Age: <15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: <15 Outpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Outpatient |
| Service Delivery Point (Facility) by |
| Age: <15 Pediatroc |
| Service Delivery Point (Facility) by |
| Age: >15 Pediatroc |
| Service Delivery Point (Facility) by |
| Age: <15 Malnutrition facilities |
| Service Delivery Point (Facility) by |



| | Age: >15 Malnutrition facilities | |
|------------|---------------------------------------|-----|
| | Service Delivery Point (Facility) by | |
| | Age: <15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Index testing | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Index testing | |
| | Number of individuals who received | |
| HTC_TST_TA | T&C services for HIV and received | 527 |
| | their test results during the past 12 | |
| | months | |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |



| Age/sex: 50+ Male |
|-----------------------------|
| Age/sex: 5-9 Female |
| Age/sex: 10-14 Female |
| Age/sex: 15-19 Female |
| Age/sex: 20-24 Female |
| Age/sex: 25-49 Female |
| Age/sex: 50+ Female |
| Test Result by Age and Sex: |
| Positive: 10-14 Male |
| Test Result by Age and Sex: |
| Positive: 15-19 Male |
| Test Result by Age and Sex: |
| Positive: 20-24 Male |
| Test Result by Age and Sex: |
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |



| Negative: 25-49 Male | |
|--|-----|
| Test Result by Age and Sex: | |
| Negative: 50+ Male | |
| Test Result by Age and Sex: | |
| Negative: <1 Female | |
| Test Result by Age and Sex: | |
| Negative: 10-14 Female | |
| Test Result by Age and Sex: | |
| Negative: 15-19 Female | |
| Test Result by Age and Sex: | |
| Negative: 20-24 Female | |
| Test Result by Age and Sex: | |
| Negative: 25-49 Female | |
| Test Result by Age and Sex: | |
| Negative: 50+ Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 Male | |
| Aggregated Age/sex - USE WITH | 234 |
| HQ PERMISSION ONLY: 15+ Male | |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 | |
| Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: 15+ | 293 |
| Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Female | |
| Test Result by Aggregated Age | |



| and Sex: Positive <15 Male | |
|------------------------------------|----|
| Test Result by Aggregated Age | 14 |
| and Sex: Positive 15+ Male | 14 |
| Test Result by Aggregated Age | |
| and Sex: Positive <15 Female | |
| Test Result by Aggregated Age | 14 |
| and Sex: Positive 15+ Female | 14 |
| Test Result by Age: Positive: <1 | |
| Test Result by Age: Positive: 1-9 | |
| Age/sex: <1 | |
| Age/sex: 1-9 | |
| Service Delivery Point | |
| (Community): Index testing | |
| Service Delivery Point | |
| (Community): Homebased testing | |
| Service Delivery Point | |
| (Community): Mobile testing | |
| Service Delivery Point | |
| (Community): Other | |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |



| by Age: <15 other | |
|---------------------------------------|--|
| Service Delivery Point (Facility): | |
| Inpatient | |
| Service Delivery Point (Facility): | |
| Outpatient | |
| Service Delivery Point (Facility): | |
| Pediatric | |
| Service Delivery Point (Facility): | |
| Malnutrition facilities | |
| Service Delivery Point (Facility): | |
| Other PITC | |
| Service Delivery Point (Facility): 95 | |
| VCT 95 | |
| Service Delivery Point (Facility): | |
| VMMC | |
| Service Delivery Point (Facility): | |
| PMTCT | |
| Service Delivery Point (Facility): TB | |
| Clinics | |
| Service Delivery Point (Facility): | |
| Index testing | |
| Service Delivery Point (Facility) by | |
| Age: <15 Inpatient | |
| Service Delivery Point (Facility) by | |
| Age: >15 Inpatient | |
| Service Delivery Point (Facility) by | |
| Age: <15 Outpatient | |
| Service Delivery Point (Facility) by | |
| Age: >15 Outpatient | |
| Service Delivery Point (Facility) by | |
| Age: <15 Pediatroc | |
| Service Delivery Point (Facility) by | |
| Age: >15 Pediatroc | |
| | |



| Age: <15 Malnutrition facilities Service Delivery Point (Facility) by Age: >15 Malnutrition facilities Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT Service Delivery Point (Facility) by Age: <15 VMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT Service Delivery Point (Facility) by Age: <15 PMTCT Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 TB Clinics Service Delivery Point (Facility) by Age: <15 Index testing Service Delivery Point (Facility) by Age: <15 Index testing | | - | |
|---|------------|--------------------------------------|-----|
| Age: >15 Malnutrition facilities Service Delivery Point (Facility) by Age: <15 Other PITC | | Age: <15 Malnutrition facilities | |
| Service Delivery Point (Facility) by Age: <15 Other PITC | | Service Delivery Point (Facility) by | |
| Age: <15 Other PITC | | Age: >15 Malnutrition facilities | |
| Service Delivery Point (Facility) by Age: >15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT | | Service Delivery Point (Facility) by | |
| Age: >15 Other PITC Service Delivery Point (Facility) by Age: <15 VCT | | Age: <15 Other PITC | |
| Service Delivery Point (Facility) by Age: <15 VCT | | Service Delivery Point (Facility) by | |
| Age: <15 VCT | | Age: >15 Other PITC | |
| Service Delivery Point (Facility) by Age: >15 VCT Service Delivery Point (Facility) by Age: <15 VMMC | | Service Delivery Point (Facility) by | |
| Age: >15 VCT Service Delivery Point (Facility) by Age: <15 VMMC | | Age: <15 VCT | |
| Service Delivery Point (Facility) by Age: <15 VMMC | | Service Delivery Point (Facility) by | |
| Age: <15 VMMC | | Age: >15 VCT | |
| Service Delivery Point (Facility) by Age: >15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT | | Service Delivery Point (Facility) by | |
| Age: >15 VMMC Service Delivery Point (Facility) by Age: <15 PMTCT | | Age: <15 VMMC | |
| Service Delivery Point (Facility) by Age: <15 PMTCT | | Service Delivery Point (Facility) by | |
| Age: <15 PMTCT | | Age: >15 VMMC | |
| TX_CURR_TA Service Delivery Point (Facility) by Age: <15 | | Service Delivery Point (Facility) by | |
| Age: >15 PMTCT Service Delivery Point (Facility) by Age: <15 TB Clinics | | Age: <15 PMTCT | |
| TX_CURR_TA Age/Sex: 5-14 Male Age/Sex: 5-14 Male Age/Sex: 5-14 Male | | Service Delivery Point (Facility) by | |
| Age: <15 TB Clinics | | Age: >15 PMTCT | |
| TX_CURR_TA Age/Sex: <1 Male | | Service Delivery Point (Facility) by | |
| Age: >15 TB Clinics Service Delivery Point (Facility) by Age: <15 Index testing | | Age: <15 TB Clinics | |
| Service Delivery Point (Facility) by Age: <15 Index testing | | Service Delivery Point (Facility) by | |
| Age: <15 Index testing | | Age: >15 TB Clinics | |
| Service Delivery Point (Facility) by Age: >15 Index testing Number of adults and children receiving antiretroviral therapy 464 (ART) TX_CURR_TA Age/Sex: <1 Male | | Service Delivery Point (Facility) by | |
| Age: >15 Index testing Number of adults and children receiving antiretroviral therapy 464 (ART) TX_CURR_TA Age/Sex: <1 Male | | Age: <15 Index testing | |
| Number of adults and children 464 receiving antiretroviral therapy 464 (ART) 464 TX_CURR_TA Age/Sex: <1 Male | | Service Delivery Point (Facility) by | |
| receiving antiretroviral therapy 464 (ART) Age/Sex: <1 Male | | Age: >15 Index testing | |
| TX_CURR_TA (ART) Age/Sex: <1 Male Age/Sex: 1-4 Male Age/Sex: 5-14 Male | | Number of adults and children | |
| TX_CURR_TA Age/Sex: <1 Male | | | 464 |
| Age/Sex: 1-4 Male | | (ART) | |
| Age/Sex: 5-14 Male | TX_CURR_TA | Age/Sex: <1 Male | |
| | | Age/Sex: 1-4 Male | |
| Age/Sex: 15-19 Male | | Age/Sex: 5-14 Male | |
| | | Age/Sex: 15-19 Male | |



| Age/Sex: 20+ Male Age/Sex: <1 Female Age/Sex: 1-4 Female Age/Sex: 5-14 Female Age/Sex: 15-19 Female Age/Sex: 20+ Female | |
|---|--|
| Age/Sex: 1-4 Female Age/Sex: 5-14 Female Age/Sex: 15-19 Female | |
| Age/Sex: 5-14 Female Age/Sex: 15-19 Female | |
| Age/Sex: 15-19 Female | |
| | |
| Age/Sex: 20+ Female | |
| | |
| Sum of Age/Sex disaggregations | |
| Aggregated Age/Sex: <1 Male | |
| Aggregated Age/Sex: <1 Female | |
| Aggregated Age/Sex: <15 Male | |
| Aggregated Age/Sex: 1-14 Male | |
| Aggregated Age/Sex: 15+ Male 231 | |
| Aggregated Age/Sex: <15 Female | |
| Aggregated Age/Sex: 1-14 Female | |
| Aggregated Age/Sex: 15+ Female 233 | |
| Sum of Aggregated Age/Sex <15 | |
| Sum of Aggregated Age/Sex 15+ 464 | |
| Sum of Aggregated Age/Sex | |
| disaggregates 464 | |
| Age/Sex: <1 | |
| Age/Sex: 1-9 | |
| Age/Sex: 10-14 Male | |
| Age/Sex: 10-14 Female | |
| Sum of Aggregated Age/Sex (<1 | |
| and 1-14) <15 | |
| Age/Sex: 20-24 Male | |
| Age/Sex: 25-49 Male | |
| Age/Sex: 50+ Male | |
| Age/Sex: 20-24 Female | |
| Age/Sex: 25-49 Female | |
| Age/Sex: 50+ Female | |
| TX_NEW_TA Number of adults and children 366 | |



| newly enrolled on antiretroviral | |
|--|-----|
| therapy (ART) | |
| By Age/Sex: <1 | |
| By Age/Sex: 1-9 | |
| By Age/Sex: <1 Male | |
| By Age/Sex: 1-4 Male | |
| By Age/Sex: 5-9 Male | |
| By Age/Sex: 10-14 Male | |
| By Age/Sex: 15-19 Male | |
| By Age/Sex: 20-24 Male | |
| By Age/Sex: 25-49 Male | |
| By Age/Sex: 50+ Male | |
| By Age/Sex: <1 Female | |
| By Age/Sex: 1-4 Female | |
| By Age/Sex: 5-9 Female | |
| By Age/Sex: 10-14 Female | |
| By Age/Sex: 15-19 Female | |
| By Age/Sex: 20-24 Female | |
| By Age/Sex: 25-49 Female | |
| By Age/Sex: 50+ Female | |
| Sum of Age/Sex disaggregates | |
| Aggregated Grouping by Age: <1 | |
| Aggregated Grouping by Age: <1 Male | |
| Aggregated Grouping by Age/Sex: <15 Male | |
| Aggregated Grouping by Age/Sex: 1-14 Male | |
| Aggregated Grouping by Age/Sex: 15+ Male | 184 |
| Aggregated Grouping by Age: <1 Female | |
| Aggregated Grouping by Age/Sex: | |



| | <15 Female | |
|------------|--|-----|
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 182 |
| | Sum of Aggregated Age/Sex disaggregates | 366 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral | n/a |
| | load (<1000 copies/ml) | |
| TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 325 |
| | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 464 |
| | Numerator: Age/Sex by Indication: <1 Routine | |
| | Numerator: Age/Sex by Indication: <1 Targeted | |
| | Numerator: Age/Sex by Indication: 1-9 Routine | |
| | Numerator: Age/Sex by Indication: 1-9 Targeted | |



| Numerator: Age/Sex by Indication: 10-14 Female Routine |
|--|
| Numerator: Age/Sex by Indication: 10-14 Female Targeted |
| Numerator: Age/Sex by Indication: 10-14 Male Routine |
| Numerator: Age/Sex by Indication: 10-14 Male Targeted |
| Numerator: Age/Sex by Indication: 15-19 Female Routine |
| Numerator: Age/Sex by Indication: 15-19 Female Targeted |
| Numerator: Age/Sex by Indication: 15-19 Male Routine |
| Numerator: Age/Sex by Indication: 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: 20-24 Female Routine |
| Numerator: Age/Sex by Indication: 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: 20-24 Male Routine |
| Numerator: Age/Sex by Indication: 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| Numerator: Age/Sex by Indication: 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: 25-49 Male Routine |
| Numerator: Age/Sex by Indication: 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: 50+ Female Routine |



| Numerator: Age/Sex by Indication: 50+ Female Targeted |
|--|
| Numerator: Age/Sex by Indication: 50+ Male Routine |
| Numerator: Age/Sex by Indication: 50+ Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
| Numerator: Indication: Routine Numerator: Indication: Targeted |
| Numerator: Preg/BF by Indication: Breastfeeding Routine |
| Numerator: Preg/BF by Indication: Breastfeeding Targeted |
| Numerator: Preg/BF by Indication: Pregnant Routine |
| Numerator: Preg/BF by Indication: Pregnant Targeted |
| Denominator: Indication: Routine |
| Denominator: Indication: Targeted |



| Denominator: Age/Sex by Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by | ۱ | |
|--|-----------------------------------|--|
| Denominator: Age/Sex by Indication: <1 Targeted | Denominator: Age/Sex by | |
| Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: <1 Routine | |
| Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Hale Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Denominator: Age/Sex by | |
| Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Indication: <1 Targeted | |
| Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: 1-9 Routine | |
| Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Helle Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Indication: 1-9 Targeted | |
| Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: 10-14 Female Routine | |
| Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Male RoutineDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Female Targeted | |
| Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Male Routine | |
| Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Male Targeted | |
| Denominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male Targeted | Indication: 15-19 Female Routine | |
| Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Female Targeted | |
| Denominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Male Routine | |
| Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Male Targeted | |
| Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Female Routine | |
| Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Female Targeted | |
| Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Male Routine | |
| Denominator: Age/Sex by | Denominator: Age/Sex by | |
| | Indication: 20-24 Male Targeted | |
| | Denominator: Age/Sex by | |
| | Indication: 25-49 Female Routine | |



| Denominator: Age/Sex by |
|------------------------------------|
| Indication: 25-49 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Female Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Female Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Male Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Targeted |
| Denominator: Preg/BF by |
| Indication: Breastfeeding Routine |
| Denominator: Preg/BF by |
| Indication: Breastfeeding Targeted |



| | Denominator: Preg/BF by | |
|-----------|--------------------------------------|-----|
| | Indication: Pregnant Routine | |
| | Denominator: Preg/BF by | |
| | Indication: Pregnant Targeted | |
| | Numerator Aggregated Age/Sex: | |
| | <15 Male | |
| | Numerator Aggregated Age/Sex: | 162 |
| | 15+ Male | 102 |
| | Numerator Aggregated Age/Sex: | |
| | <15 Female | |
| | Numerator Aggregated Age/Sex: | 100 |
| | 15+ Female | 163 |
| | Denominator Aggregated Age/Sex: | |
| | <15 Male | |
| | Denominator Aggregated Age/Sex: | |
| | 15+ Male | 231 |
| | Denominator Aggregated Age/Sex: | |
| | <15 Female | |
| | Denominator Aggregated Age/Sex: | |
| | 15+ Female | 233 |
| | Percentage of laboratories and | |
| | POC testing sites that perform HIV | |
| | diagnostic testing that participate | |
| | and successfully pass in an | |
| | analyte-specific proficiency testing | |
| | (PT) program | |
| | CD4: Number of laboratories that | |
| LAB_PT_TA | achieve acceptable successful | 1 |
| | passing criteria in this PT program | |
| | CD4: Number of laboratories that | |
| | participate in this PT program | 1 |
| | CD4: Number of laboratories that | |
| | perform this testing | 1 |
| | Early infant diagnostics: Number of | 1 |
| | | • |



| laboratories that achieve | |
|---|---|
| acceptable successful passing | |
| criteria in this PT program | |
| Early infant diagnostics: Number of | |
| laboratories that participate in this | 1 |
| PT program | |
| Early infant diagnostics: Number of | |
| laboratories that perform this | 1 |
| testing | |
| HIV serologic/diagnostic testing: | |
| Number of laboratories that | |
| achieve acceptable successful | 8 |
| passing criteria in this PT program | |
| HIV serologic/diagnostic testing: | |
| Number of laboratories that | 8 |
| participate in this PT program | - |
| HIV serologic/diagnostic testing: | |
| Number of laboratories that | 8 |
| perform this testing | - |
| HIV viral load: Number of | |
| laboratories that achieve | |
| acceptable successful passing | 1 |
| criteria in this PT program | |
| HIV viral load: Number of | |
| laboratories that participate in this | 1 |
| PT program | |
| HIV viral load: Number of | |
| laboratories that perform this | 1 |
| testing | · |
| | |
| TB diagnostics (AFB microscopy): Number of laboratories that | |
| achieve acceptable successful | 3 |
| passing criteria in this PT program | |
| | |
| TB diagnostics (AFB microscopy): | 3 |
| Number of laboratories that | |



| | participate in this PT program | |
|---------|--------------------------------------|---|
| | TB diagnostics (AFB microscopy): | |
| | Number of laboratories that | 3 |
| | perform this testing | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | Number of new HCW who | |
| | graduated from a pre-service | |
| | training institution or program as a | 0 |
| | result of PEPFAR-supported | 2 |
| | strengthening efforts, within the | |
| HRH_PRE | reporting period, by select cadre | |
| | By Graduates: Doctors | |
| | By Graduates: Nurses | |
| | By Graduates: Midwives | |
| | By Graduates: Social service | |
| | workers | |
| | | |



| | By Graduates: Laboratory professionals | |
|-----------|---|--------|
| | By Graduates: Other | |
| | Sum of Graduates disaggreagtes | |
| | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 1,034 |
| | Number of HIV Test Kits purchased | |
| | Number of HIV CD4 Reagents purchased | |
| | Number of Condoms purchased | |
| | Number of HIV Viral Load Reagents purchased | 1,034 |
| | Number of HIV ARVs purchased | |
| INVS_COMD | Number of Second Line HIV ARVs purchased | |
| | HIV Test Kits: Dollars planned (COP)/ spent (Actual) | |
| | HIV CD4 Tests: Dollars planned (COP)/ spent (Actual) | |
| | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 30,000 |
| | Condoms: Dollars planned (COP)/ spent (Actual) | |
| | HIV ARVs: Dollars planned (COP)/ spent (Actual) | |



Technical Area Summary Indicators and Targets

Trinidad and Tobago

| Indicator Number | Label | 2017 |
|------------------|-------------------------------------|--------|
| | KP_PREV_DSD Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | n/a |
| | based on evidence and/or meet the | |
| | minimum standards required (DSD) | |
| | Number of key populations reached | |
| | with individual and/or small group | |
| | level HIV preventive interventions | 1,000 |
| | that are based on evidence and/or | 1,000 |
| | meet the minimum standards | |
| | required | |
| | Total estimated number of key | 17,444 |
| | population in the catchment area | 17,444 |
| KP_PREV_DSD | By key population type: Men who | |
| | have sex with men who are sex | |
| | workers (Numerator: Number of | |
| | key populations reached with | |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men who are NOT | |
| | sex workers (Numerator: Number | |
| | of key populations reached with | 400 |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |



| the minimum standards required) | |
|-------------------------------------|-----|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | 000 |
| level HIV preventive interventions | 600 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| | |



| populations reached with individual | |
|--------------------------------------|--------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 6,616 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| ` number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | 10,828 |
| Total estimated number of key | 10,020 |
| I Olai Estimateu number or key | |



| | population in the catchment area) | |
|------------|---------------------------------------|----------|
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | Number of individuals who received | |
| | T&C services for HIV and received | <u> </u> |
| HTC_TST_TA | their test results during the past 12 | 600 |
| | months | |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | Myersen. 20-43 Male | |



| Age/sex: 50+ Male |
|-----------------------------|
| Age/sex: 5-9 Female |
| Age/sex: 10-14 Female |
| Age/sex: 15-19 Female |
| Age/sex: 20-24 Female |
| Age/sex: 25-49 Female |
| Age/sex: 50+ Female |
| Test Result by Age and Sex: |
| Positive: 10-14 Male |
| Test Result by Age and Sex: |
| Positive: 15-19 Male |
| Test Result by Age and Sex: |
| Positive: 20-24 Male |
| Test Result by Age and Sex: |
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |



| Negative: 25-49 Male | |
|--|-----|
| Test Result by Age and Sex: | |
| Negative: 50+ Male | |
| Test Result by Age and Sex: | |
| Negative: <1 Female | |
| Test Result by Age and Sex: | |
| Negative: 10-14 Female | |
| Test Result by Age and Sex: | |
| Negative: 15-19 Female | |
| Test Result by Age and Sex: | |
| Negative: 20-24 Female | |
| Test Result by Age and Sex: | |
| Negative: 25-49 Female | |
| Test Result by Age and Sex: | |
| Negative: 50+ Female | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 Male | |
| Aggregated Age/sex - USE WITH | 360 |
| HQ PERMISSION ONLY: 15+ Male | |
| Aggregated Age/sex - USE WITH | |
| HQ PERMISSION ONLY: <15 | |
| | |
| Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ | 240 |
| Female | 240 |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Male | |
| Test Result by Aggregated Age | |
| and Sex: Negative <15 Female | |
| Test Result by Aggregated Age | |
| and Sex: Negative 15+ Female | |
| Test Result by Aggregated Age | |



| and Sex: Positive <15 Male | |
|------------------------------------|----|
| Test Result by Aggregated Age | 22 |
| and Sex: Positive 15+ Male | 22 |
| Test Result by Aggregated Age | |
| and Sex: Positive <15 Female | |
| Test Result by Aggregated Age | 10 |
| and Sex: Positive 15+ Female | 12 |
| Test Result by Age: Positive: <1 | |
| Test Result by Age: Positive: 1-9 | |
| Age/sex: <1 | |
| Age/sex: 1-9 | |
| Service Delivery Point | |
| (Community): Index testing | |
| Service Delivery Point | |
| (Community): Homebased testing | |
| Service Delivery Point | |
| (Community): Mobile testing | |
| Service Delivery Point | |
| (Community): Other | |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |



| by Age: <15 other |
|---|
| Service Delivery Point (Facility): |
| Inpatient |
| Service Delivery Point (Facility): |
| Outpatient |
| Service Delivery Point (Facility): |
| Pediatric |
| Service Delivery Point (Facility): Malnutrition facilities |
| Service Delivery Point (Facility): Other PITC |
| Service Delivery Point (Facility): VCT |
| Service Delivery Point (Facility): VMMC |
| Service Delivery Point (Facility): PMTCT |
| Service Delivery Point (Facility): TB Clinics |
| Service Delivery Point (Facility): |
| Index testing |
| Service Delivery Point (Facility) by |
| Age: <15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: <15 Outpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Outpatient |
| Service Delivery Point (Facility) by Age: <15 Pediatroc |
| Service Delivery Point (Facility) by |
| Age: >15 Pediatroc |
| Service Delivery Point (Facility) by |
| |



| | 1 | |
|------------|--------------------------------------|-------|
| | Age: <15 Malnutrition facilities | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Malnutrition facilities | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Other PITC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 VMMC | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: <15 Index testing | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 Index testing | |
| | Number of adults and children | |
| | receiving antiretroviral therapy | 1,291 |
| | (ART) | |
| TX_CURR_TA | Age/Sex: <1 Male | |
| | Age/Sex: 1-4 Male | |
| | Age/Sex: 5-14 Male | |
| | Age/Sex: 15-19 Male | |



| | Age/Sex: 20+ Male | |
|-----------|---------------------------------|-------|
| | Age/Sex: <1 Female | |
| | Age/Sex: 1-4 Female | |
| | Age/Sex: 5-14 Female | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Sum of Age/Sex disaggregations | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | |
| | Aggregated Age/Sex: 1-14 Male | |
| | Aggregated Age/Sex: 15+ Male | 645 |
| | Aggregated Age/Sex: <15 Female | |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 646 |
| | Sum of Aggregated Age/Sex <15 | |
| | Sum of Aggregated Age/Sex 15+ | 1,291 |
| | Sum of Aggregated Age/Sex | 1 001 |
| | disaggregates | 1,291 |
| | Age/Sex: <1 | |
| | Age/Sex: 1-9 | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 10-14 Female | |
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| TX_NEW_TA | Number of adults and children | 724 |
| | | |



| newly enrolled on antiretroviral | |
|--|-----|
| therapy (ART) | |
| By Age/Sex: <1 | |
| By Age/Sex: 1-9 | |
| By Age/Sex: <1 Male | |
| By Age/Sex: 1-4 Male | |
| By Age/Sex: 5-9 Male | |
| By Age/Sex: 10-14 Male | |
| By Age/Sex: 15-19 Male | |
| By Age/Sex: 20-24 Male | |
| By Age/Sex: 25-49 Male | |
| By Age/Sex: 50+ Male | |
| By Age/Sex: <1 Female | |
| By Age/Sex: 1-4 Female | |
| By Age/Sex: 5-9 Female | |
| By Age/Sex: 10-14 Female | |
| By Age/Sex: 15-19 Female | |
| By Age/Sex: 20-24 Female | |
| By Age/Sex: 25-49 Female | |
| By Age/Sex: 50+ Female | |
| Sum of Age/Sex disaggregates | |
| Aggregated Grouping by Age: <1 | |
| Aggregated Grouping by Age: <1 Male | |
| Aggregated Grouping by Age/Sex: <15 Male | |
| Aggregated Grouping by Age/Sex: 1-14 Male | |
| Aggregated Grouping by Age/Sex: 15+ Male | 374 |
| Aggregated Grouping by Age: <1 Female | |
| Aggregated Grouping by Age/Sex: | |



| | <15 Female | |
|------------|--|-------|
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 350 |
| | Sum of Aggregated Age/Sex disaggregates | 724 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml) | n/a |
| | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 1,162 |
| TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,291 |
| | Numerator: Age/Sex by Indication: <1 Routine | |
| | Numerator: Age/Sex by Indication: <1 Targeted | |
| | Numerator: Age/Sex by Indication: 1-9 Routine | |
| | Numerator: Age/Sex by Indication: 1-9 Targeted | |



| Numerator: Age/Sex by Indication: 10-14 Female Routine |
|--|
| Numerator: Age/Sex by Indication: 10-14 Female Targeted |
| Numerator: Age/Sex by Indication: 10-14 Male Routine |
| Numerator: Age/Sex by Indication: 10-14 Male Targeted |
| Numerator: Age/Sex by Indication: 15-19 Female Routine |
| Numerator: Age/Sex by Indication: 15-19 Female Targeted |
| Numerator: Age/Sex by Indication: 15-19 Male Routine |
| Numerator: Age/Sex by Indication: 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: 20-24 Female Routine |
| Numerator: Age/Sex by Indication: 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: 20-24 Male Routine |
| Numerator: Age/Sex by Indication: 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| Numerator: Age/Sex by Indication: 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: 25-49 Male Routine |
| Numerator: Age/Sex by Indication: 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: 50+ Female Routine |



| Numerator: Age/Sex by Indication: 50+ Female Targeted |
|--|
| Numerator: Age/Sex by Indication: 50+ Male Routine |
| Numerator: Age/Sex by Indication: 50+ Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Routine |
| Numerator: Aggregate Age/Sex by Indication: <15 Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Routine |
| Numerator: Aggregate Age/Sex by Indication: 15+ Female Targeted |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male Routine |
| Numerator: Aggregate Age/Sex by Indication: 15+ Male Targeted |
| Numerator: Indication: Routine Numerator: Indication: Targeted |
| Numerator: Preg/BF by Indication: Breastfeeding Routine |
| Numerator: Preg/BF by Indication: Breastfeeding Targeted |
| Numerator: Preg/BF by Indication: Pregnant Routine |
| Numerator: Preg/BF by Indication: Pregnant Targeted |
| Denominator: Indication: Routine |
| Denominator: Indication: Targeted |



| Denominator: Age/Sex by Indication: <1 Routine Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by | ۱ | |
|--|-----------------------------------|--|
| Denominator: Age/Sex by Indication: <1 Targeted | Denominator: Age/Sex by | |
| Indication: <1 Targeted Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: <1 Routine | |
| Denominator: Age/Sex by Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Hale Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Denominator: Age/Sex by | |
| Indication: 1-9 Routine Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Indication: <1 Targeted | |
| Denominator: Age/Sex by Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 1-9 Targeted Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: 1-9 Routine | |
| Denominator: Age/Sex by Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Female Routine Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Helle Routine Denominator: Age/Sex by Indication: 20-24 Male Routine | Indication: 1-9 Targeted | |
| Denominator: Age/Sex by Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Female Targeted Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Indication: 10-14 Female Routine | |
| Denominator: Age/Sex by Indication: 10-14 Male Routine Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Male RoutineDenominator: Age/Sex byIndication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Female Targeted | |
| Denominator: Age/Sex by Indication: 10-14 Male Targeted Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 10-14 Male TargetedDenominator: Age/Sex byIndication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Male Routine | |
| Denominator: Age/Sex by Indication: 15-19 Female Routine Denominator: Age/Sex by Indication: 15-19 Female Targeted Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Female RoutineDenominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Indication: 10-14 Male Targeted | |
| Denominator: Age/Sex byIndication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Female TargetedDenominator: Age/Sex byIndication: 15-19 Male RoutineDenominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male Targeted | Indication: 15-19 Female Routine | |
| Denominator: Age/Sex by Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Male Routine Denominator: Age/Sex by Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Female Targeted | |
| Denominator: Age/Sex byIndication: 15-19 Male TargetedDenominator: Age/Sex byIndication: 20-24 Female RoutineDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Female TargetedDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male RoutineDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex byIndication: 20-24 Male TargetedDenominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 15-19 Male Targeted Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Male Routine | |
| Denominator: Age/Sex by Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Female Routine Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 15-19 Male Targeted | |
| Denominator: Age/Sex by Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Female Targeted Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Female Routine | |
| Denominator: Age/Sex by Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Male Routine Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Female Targeted | |
| Denominator: Age/Sex by Indication: 20-24 Male Targeted Denominator: Age/Sex by | Denominator: Age/Sex by | |
| Indication: 20-24 Male Targeted Denominator: Age/Sex by | Indication: 20-24 Male Routine | |
| Denominator: Age/Sex by | Denominator: Age/Sex by | |
| | Indication: 20-24 Male Targeted | |
| | Denominator: Age/Sex by | |
| | Indication: 25-49 Female Routine | |



| Denominator: Age/Sex by |
|------------------------------------|
| Indication: 25-49 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Female Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Female Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Male Routine |
| Denominator: Age/Sex by |
| Indication: 50+ Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: <15 Male Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Female Targeted |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Routine |
| Denominator: Aggregate Age/Sex |
| by Indication: 15+ Male Targeted |
| Denominator: Preg/BF by |
| Indication: Breastfeeding Routine |
| Denominator: Preg/BF by |
| Indication: Breastfeeding Targeted |



| passing criteria in this PT program CD4: Number of laboratories that 4 4 4 4 | | | |
|--|-----------|--|-----|
| LAB_PT_TA Denominator: Preg/BF by Indication: Pregnant Targeted Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Male Numerator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Female Denominator Aggregated Age/Sex: <15 Male Denominator Aggregated Age/Sex: <15 Female Denominator Aggregater Age/Sex: <1646 Denominator Aggregater Age/ | | | |
| Indication: Pregnant Targeted Numerator Aggregated Age/Sex: <15 Male | | Indication: Pregnant Routine | |
| Numerator Aggregated Age/Sex: <15 Male | | | |
| 15+ Male 581 Numerator Aggregated Age/Sex: <15 Female | | Numerator Aggregated Age/Sex: | |
| <15 Female | | | 581 |
| 15+ Female 581 Denominator Aggregated Age/Sex: <15 Male | | | |
| <15 Male | | | 581 |
| 15+ Male 645 Denominator Aggregated Age/Sex: <15 Female | | | |
| <15 Female | | | 645 |
| 15+ Female 646 Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program LAB_PT_TA CD4: Number of laboratories that achieve acceptable successful 4 passing criteria in this PT program CD4: Number of laboratories that | | | |
| POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing (PT) program (PT) program CD4: Number of laboratories that 4 passing criteria in this PT program CD4: Number of laboratories that CD4: Number of laboratories that 4 | | | 646 |
| LAB_PT_TA achieve acceptable successful 4 passing criteria in this PT program 2 CD4: Number of laboratories that 4 | | POC testing sites that perform HIV diagnostic testing that participate and successfully pass in an analyte-specific proficiency testing | |
| 4 | LAB_PT_TA | achieve acceptable successful | 4 |
| participate in this PT program | | CD4: Number of laboratories that participate in this PT program | 4 |
| CD4: Number of laboratories that 4 | | | 4 |
| Early infant diagnostics: Number of 1 | | Early infant diagnostics: Number of | 1 |



| laboratories that achieve | |
|---------------------------------------|---|
| acceptable successful passing | |
| criteria in this PT program | |
| Early infant diagnostics: Number of | |
| laboratories that participate in this | 1 |
| PT program | |
| Early infant diagnostics: Number of | |
| laboratories that perform this | 1 |
| testing | |
| HIV serologic/diagnostic testing: | |
| Number of laboratories that | |
| achieve acceptable successful | 9 |
| passing criteria in this PT program | |
| | |
| HIV serologic/diagnostic testing: | 0 |
| Number of laboratories that | 9 |
| participate in this PT program | |
| HIV serologic/diagnostic testing: | |
| Number of laboratories that | 9 |
| perform this testing | |
| HIV viral load: Number of | |
| laboratories that achieve | 1 |
| acceptable successful passing | · |
| criteria in this PT program | |
| HIV viral load: Number of | |
| laboratories that participate in this | 1 |
| PT program | |
| HIV viral load: Number of | |
| laboratories that perform this | 1 |
| testing | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | |
| achieve acceptable successful | 6 |
| passing criteria in this PT program | |
| TB diagnostics (AFB microscopy): | |
| | 6 |
| Number of laboratories that | |



| | participate in this PT program | |
|---------|--------------------------------------|---|
| | TB diagnostics (AFB microscopy): | |
| | Number of laboratories that | 6 |
| | perform this testing | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Xpert MTB/RIF): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | achieve acceptable successful | 0 |
| | passing criteria in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | participate in this PT program | |
| | TB diagnostics (Culture/DST): | |
| | Number of laboratories that | 0 |
| | perform this testing | |
| | Number of new HCW who | |
| | graduated from a pre-service | |
| HRH_PRE | training institution or program as a | 4 |
| | result of PEPFAR-supported | 4 |
| | strengthening efforts, within the | |
| | reporting period, by select cadre | |
| | By Graduates: Doctors | |
| | By Graduates: Nurses | |
| | By Graduates: Midwives | |
| | By Graduates: Social service | |
| | workers | |
| | | |



| | By Graduates: Laboratory professionals | |
|-----------|---|--------|
| | By Graduates: Other | |
| | Sum of Graduates disaggreagtes | |
| | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 1,764 |
| | Number of HIV Test Kits purchased | |
| | Number of HIV CD4 Reagents purchased | |
| | Number of Condoms purchased | |
| INVS_COMD | Number of HIV Viral Load Reagents purchased | 1,764 |
| | Number of HIV ARVs purchased | |
| | Number of Second Line HIV ARVs purchased | |
| | HIV Test Kits: Dollars planned (COP)/ spent (Actual) | |
| | HIV CD4 Tests: Dollars planned (COP)/ spent (Actual) | 30,000 |
| | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 60,000 |
| | Condoms: Dollars planned (COP)/ spent (Actual) | |
| | HIV ARVs: Dollars planned (COP)/ spent (Actual) | |



Technical Area Summary Indicators and Targets

Caribbean Region

| Indicator Number | Label | 2017 |
|------------------|-------------------------------------|---------|
| | KP_PREV_DSD Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | n/a |
| | based on evidence and/or meet the | |
| | minimum standards required (DSD) | |
| | Number of key populations reached | |
| | with individual and/or small group | |
| | level HIV preventive interventions | 0.404 |
| | that are based on evidence and/or | 8,184 |
| | meet the minimum standards | |
| | required | |
| | Total estimated number of key | 07.4.40 |
| | population in the catchment area | 67,142 |
| KP_PREV_DSD | By key population type: Men who | |
| | have sex with men who are sex | |
| | workers (Numerator: Number of | |
| | key populations reached with | |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men who are NOT | |
| | sex workers (Numerator: Number | |
| | of key populations reached with | 3,921 |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |



| the minimum standards required) | |
|-------------------------------------|-------|
| By key population type: | |
| Transgender who are sex workers | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Numerator: Number of | |
| key populations reached with | |
| individual and/or small group level | |
| HIV preventive interventions that | |
| are based on evidence and/or meet | |
| the minimum standards required) | |
| By key population type: Female | |
| sex workers (FSW) (Numerator: | |
| Number of key populations reached | |
| with individual and/or small group | 1 000 |
| level HIV preventive interventions | 4,263 |
| that are based on evidence and/or | |
| meet the minimum standards | |
| required) | |
| By key population type: Males who | |
| inject drugs (Male PWID) | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Females | |
| who inject drugs (Female PWID) | |
| (Numerator: Number of key | |
| | |



| populations reached with individual | |
|--------------------------------------|--------|
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: People in | |
| prisons and enclosed settings | |
| (Numerator: Number of key | |
| populations reached with individual | |
| and/or small group level HIV | |
| preventive interventions that are | |
| based on evidence and/or meet the | |
| minimum standards required) | |
| By key population type: Men who | |
| have sex with men who are sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area | |
| By key population type: Men who | |
| have sex with men who are NOT | |
| sex workers (Denominator: Total | 35,496 |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: | |
| Transgender who are sex workers | |
| (Denominator: Total estimated | |
| ` number of key population in the | |
| catchment area) | |
| By key population type: | |
| Transgender who are NOT sex | |
| workers (Denominator: Total | |
| estimated number of key | |
| population in the catchment area) | |
| By key population type: Female | |
| sex workers (FSW) (Denominator: | 31,646 |
| Total estimated number of key | 51,040 |
| I GIAI ESUINALEU NUMBEI OI KEY | |



| | | I |
|------------|---------------------------------------|-----|
| | population in the catchment area) | |
| | By key population type: Males who | |
| | inject drugs (Male PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By Service: KP known status | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: REturniong | |
| | beneficiary within the current report | |
| | period | |
| | KP_PREV_TA Percentage of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | n/a |
| KP_PREV_TA | based on evidence and/or meet the | |
| | minimum standards required | |
| | (TA-only) | |
| | Number of key populations reached | |
| | with individual and/or small group | 118 |
| | | |



| level HIV preventive interventions that are based on evidence and/or meet the minimum standards required Total estimated number of key population in the catchment area By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominato | | |
|--|------------------------------------|-----|
| meet the minimum standards required376Total estimated number of key population in the catchment area376By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population sreached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population inpe: Males who | level HIV preventive interventions | |
| required 376 Total estimated number of key 376 population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population | that are based on evidence and/or | |
| Total estimated number of key 376 population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: </td <td>meet the minimum standards</td> <td></td> | meet the minimum standards | |
| population in the catchment area 376 By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female <td< td=""><td>required</td><td></td></td<> | required | |
| population in the catchment area By key population type: Sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evide | Total estimated number of key | |
| sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | population in the catchment area | 376 |
| sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | By key population type: Female | |
| Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female OWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in t | | |
| that are based on evidence and/or meet the minimum standards required) By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex do ne vidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | • · | |
| meet the minimum standards required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| required)By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type: Males who | | |
| By key population type: Males who inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| inject drugs (Male PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | , · | |
| preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| based on evidence and/or meet the minimum standards required) By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| minimum standards required)By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type: Males who | | |
| By key population type: Females who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required)By key population type:Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area)By key population type:Males who | | |
| who inject drugs (Female PWID) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | , | |
| and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| preventive interventions that are based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| based on evidence and/or meet the minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | • . | |
| minimum standards required) By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) By key population type: Males who | | |
| Total estimated number of key population in the catchment area)By key population type: Males who | | |
| population in the catchment area) By key population type: Males who | | |
| By key population type: Males who | - | |
| | population in the catchment area) | |
| inject drugs (Male PWID) | By key population type: Males who | |
| | inject drugs (Male PWID) | |



| í | | |
|---|-------------------------------------|-----|
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Females | |
| | who inject drugs (Female PWID) | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: Men who | |
| | have sex with men and are sex | |
| | workers (Numerator: Number of | |
| | key populations reached with | |
| | individual and/or small group level | |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men and are NOT | |
| | sex workers (Numerator: Number | |
| | of key populations reached with | |
| | individual and/or small group level | 118 |
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: | |
| | Transgender who are sex workers | |
| | (Numerator: Number of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | |
| | based on evidence and/or meet the | |
| | minimum standards required) | |
| | By key population type: | |
| | Transgender who are NOT sex | |
| | workers (Numerator: Number of | |
| | | |
| | key populations reached with | |



| i | individual and/or small group level | |
|---|-------------------------------------|---------------------------------------|
| | HIV preventive interventions that | |
| | are based on evidence and/or meet | |
| | the minimum standards required) | |
| | By key population type: Men who | |
| | have sex with men and are sex | |
| | workers (Denominator: Total | |
| | estimated number of key | |
| | population in the catchment area) | |
| | By key population type: Men who | |
| | have sex with men and are NOT | |
| | sex workers (Denominator: Total | 376 |
| | estimated number of key | |
| | population in the catchment area) | |
| | By key population type: | |
| | Transgender who are sex workers | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | catchment area) | |
| | By key population type: | |
| | Transgender who are NOT sex | |
| , | workers (Denominator: Total | |
| | estimated number of key | |
| | population in the catchment area) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Numerator: Number of key | |
| | populations reached with individual | |
| | and/or small group level HIV | |
| | preventive interventions that are | |
| | based on evidence and/or meet the | |
| | minimum standards required) | |
| | By key population type: People in | |
| | prisons and enclosed settings | |
| | (Denominator: Total estimated | |
| | number of key population in the | |
| | | · · · · · · · · · · · · · · · · · · · |



| | catchment area) | |
|-------------|---|-------|
| | By Service: KP known positive | |
| | By Service: KP was tested as part | |
| | of the program and/or KP was | |
| | referred for testing as part of the | |
| | program | |
| | By New Client Status: New | |
| | beneficiary | |
| | By New Client Status: Returning | |
| | beneficiary within the current report | |
| | period | |
| | Number of individuals who received T&C services for HIV and received | |
| | their test results during the past 12 | 6,721 |
| | months | |
| | Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| HTC_TST_DSD | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | Age/sex: 50+ Male | |
| | Age/sex: 5-9 Female | |
| | Age/sex: 10-14 Female | |
| | Age/sex: 15-19 Female | |
| | Age/sex: 20-24 Female | |
| | Age/sex: 25-49 Female | |
| | Age/sex: 50+ Female | |
| | Test Result by Age and Sex: | |
| | Positive: 10-14 Male | |
| | Test Result by Age and Sex: | |
| | Positive: 15-19 Male | |
| | Test Result by Age and Sex: | |
| | Positive: 20-24 Male | |



| Test Result by Age and Sex: |
|-----------------------------|
| Positive: 25-49 Male |
| Test Result by Age and Sex: |
| Positive: 50+ Male |
| Test Result by Age and Sex: |
| Positive: 10-14 Female |
| Test Result by Age and Sex: |
| Positive: 15-19 Female |
| Test Result by Age and Sex: |
| Positive: 20-24 Female |
| Test Result by Age and Sex: |
| Positive: 25-49 Female |
| Test Result by Age and Sex: |
| Positive: 50+ Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Male |
| Test Result by Age and Sex: |
| Negative: 15-19 Male |
| Test Result by Age and Sex: |
| Negative: 20-24 Male |
| Test Result by Age and Sex: |
| Negative: 25-49 Male |
| Test Result by Age and Sex: |
| Negative: 50+ Male |
| Test Result by Age and Sex: |
| Negative: 10-14 Female |
| Test Result by Age and Sex: |
| Negative: 15-19 Female |
| Test Result by Age and Sex: |
| Negative: 20-24 Female |
| Test Result by Age and Sex: |
| Negative: 25-49 Female |
| Test Result by Age and Sex: |
| Negative: 50+ Female |
| |



| Aggregated Age/sex - USE WITH 83 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 3,238 Aggregated Age/sex - USE WITH 13,238 Aggregated Age/sex - USE WITH 73 Female 73 Female 3,327 Test Result by Aggregated Age 3,327 Female Test Result by Aggregated Age and Sex: Negative 15 + Male 1 Test Result by Aggregated Age 6 and Sex: Nogative 15 + Female 229 and Sex: Positive 15 + Male 229 and Sex: Positive 15 + Female 131 Test Result by Aggregated Age 4 < | | |
|---|--|-------|
| HQ PERMISSION ONLY: 15+ Male3,238Aggregated Age/sex - USE WITHHQ PERMISSION ONLY: <15 | | 83 |
| HQ PERMISSION ONLY: <1573FemaleAggregated Age/sex - USE WITHHQ PERMISSION ONLY: 15+3,327FemaleTest Result by Aggregated Ageand Sex: Negative <15 Male | | 3,238 |
| HQ PERMISSION ONLY: 15+ Female3,327FemaleTest Result by Aggregated Age and Sex: Negative <15 Male | HQ PERMISSION ONLY: <15 | 73 |
| and Sex: Negative <15 Male | HQ PERMISSION ONLY: 15+ | 3,327 |
| and Sex: Negative 15+ MaleTest Result by Aggregated Ageand Sex: Negative <15 Female | | |
| and Sex: Negative <15 Female | , | |
| and Sex: Negative 15+ FemaleTest Result by Aggregated Age and Sex: Positive <15 Male | | |
| and Sex: Positive <15 Male6Test Result by Aggregated Age and Sex: Positive 15+ Male229Test Result by Aggregated Age and Sex: Positive <15 Female | , | |
| and Sex: Positive 15+ Male229Test Result by Aggregated Age and Sex: Positive <15 Female | , | 6 |
| and Sex: Positive <15 Female | | 229 |
| and Sex: Positive 15+ Female131Test Result by Age: Positive: <1 | | 4 |
| Test Result by Age: Positive: 1-9 Age/sex: <1 | | 131 |
| Age/sex: <1 | Test Result by Age: Positive: <1 | |
| Age/sex: 1-9 Service Delivery Point (Community): Index testing Service Delivery Point | Test Result by Age: Positive: 1-9 | |
| Service Delivery Point (Community): Index testing Service Delivery Point | Age/sex: <1 | |
| (Community): Index testing 150 Service Delivery Point | Age/sex: 1-9 | |
| | - | 150 |
| | Service Delivery Point (Community): Homebased testing | |



| Service Delivery Point | |
|------------------------------------|-------|
| (Community): Mobile testing | 1,994 |
| Service Delivery Point | |
| (Community): Other | 2,562 |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Facility): | |
| Inpatient | |
| Service Delivery Point (Facility): | |
| Outpatient | |
| Service Delivery Point (Facility): | |
| Pediatric | |
| Service Delivery Point (Facility): | |
| Malnutrition facilities | |
| Service Delivery Point (Facility): | 1,655 |
| Other PITC | ., |
| Service Delivery Point (Facility): | |
| VCT | |
| Service Delivery Point (Facility): | |
| VMMC | |



| Service Delivery Point (Facility): PMTCT | |
|--|-----|
| Service Delivery Point (Facility): TB Clinics | |
| Service Delivery Point (Facility): Index testing | 300 |
| Service Delivery Point (Facility) by Age: <15 Inpatient | |
| Service Delivery Point (Facility) by Age: >15 Inpatient | |
| Service Delivery Point (Facility) by Age: <15 Outpatient | |
| Service Delivery Point (Facility) by Age: >15 Outpatient | |
| Service Delivery Point (Facility) by Age: <15 Pediatroc | |
| Service Delivery Point (Facility) by Age: >15 Pediatroc | |
| Service Delivery Point (Facility) by Age: <15 Malnutrition facilities | |
| Service Delivery Point (Facility) by Age: >15 Malnutrition facilities | |
| Service Delivery Point (Facility) by Age: <15 Other PITC | |
| Service Delivery Point (Facility) by Age: >15 Other PITC | |
| Service Delivery Point (Facility) by Age: <15 VCT | |
| Service Delivery Point (Facility) by Age: >15 VCT | |
| Service Delivery Point (Facility) by Age: <15 VMMC | |
| Service Delivery Point (Facility) by Age: >15 VMMC | |



| | Service Delivery Point (Facility) by Age: <15 PMTCT | |
|------------|--|-------|
| | Service Delivery Point (Facility) by Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by | |
| | Age: >15 TB Clinics Service Delivery Point (Facility) by | |
| | Age: <15 Index testing Service Delivery Point (Facility) by | |
| | Age: >15 Index testing Number of individuals who received T&C services for HIV and received their test results during the past 12 | 2,103 |
| | months Age/sex: 5-9 Male | |
| | Age/sex: 10-14 Male | |
| | Age/sex: 15-19 Male | |
| | Age/sex: 20-24 Male | |
| | Age/sex: 25-49 Male | |
| | Age/sex: 50+ Male | |
| HTC_TST_TA | Age/sex: 5-9 Female | |
| | Age/sex: 10-14 Female | |
| | Age/sex: 15-19 Female | |
| | Age/sex: 20-24 Female | |
| | Age/sex: 25-49 Female | |
| | Age/sex: 50+ Female | |
| | Test Result by Age and Sex: | |
| | Positive: 10-14 Male | |
| | Test Result by Age and Sex: Positive: 15-19 Male | |
| | Test Result by Age and Sex: | |
| | • | |



| Positive: 20-24 MaleTest Result by Age and Sex:Positive: 25-49 MaleTest Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 50+ Male |
|---|
| Positive: 25-49 MaleTest Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Positive: 10-14 MaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 50+ MaleTest Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 10-14 FemaleTest Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 15-19 FemaleTest Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 20-24 FemaleTest Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 25-49 FemaleTest Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Positive: 50+ FemaleTest Result by Age and Sex:Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex: Negative: 10-14 MaleTest Result by Age and Sex: Negative: 15-19 MaleTest Result by Age and Sex: Negative: 20-24 MaleTest Result by Age and Sex: Negative: 25-49 MaleTest Result by Age and Sex: Negative: 25-49 MaleTest Result by Age and Sex: Negative: 25-49 Male |
| Negative: 10-14 MaleTest Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Negative: 15-19 MaleTest Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Test Result by Age and Sex:Negative: 20-24 MaleTest Result by Age and Sex:Negative: 25-49 MaleTest Result by Age and Sex: |
| Negative: 20-24 Male Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: |
| Test Result by Age and Sex: Negative: 25-49 Male Test Result by Age and Sex: |
| Negative: 25-49 Male Test Result by Age and Sex: |
| Test Result by Age and Sex: |
| |
| Negative: 50+ Male |
| |
| Test Result by Age and Sex: |
| Negative: <1 Female |
| Test Result by Age and Sex: |
| Negative: 10-14 Female |
| Test Result by Age and Sex: |
| Negative: 15-19 Female |
| Test Result by Age and Sex: |
| Negative: 20-24 Female |
| |



| | Negative: 25-49 Female | |
|----|-----------------------------------|-------|
| | Test Result by Age and Sex: | |
| 1 | Negative: 50+ Female | |
| | Aggregated Age/sex - USE WITH | |
| ŀ | HQ PERMISSION ONLY: <15 Male | |
| | Aggregated Age/sex - USE WITH | 982 |
| ŀ | HQ PERMISSION ONLY: 15+ Male | 302 |
| | Aggregated Age/sex - USE WITH | |
| | HQ PERMISSION ONLY: <15 | |
| | Female | |
| I | Aggregated Age/sex - USE WITH | |
| | HQ PERMISSION ONLY: 15+ | 1,121 |
| 1 | Female | |
| | Test Result by Aggregated Age | |
| | and Sex: Negative <15 Male | |
| | Test Result by Aggregated Age | |
| i | and Sex: Negative 15+ Male | |
| | Test Result by Aggregated Age | |
| 2 | and Sex: Negative <15 Female | |
| | Test Result by Aggregated Age | |
| ć | and Sex: Negative 15+ Female | |
| | Test Result by Aggregated Age | |
| | and Sex: Positive <15 Male | |
| I | Test Result by Aggregated Age | 68 |
| | and Sex: Positive 15+ Male | ~~ |
| | Test Result by Aggregated Age | |
| | and Sex: Positive <15 Female | |
| | Test Result by Aggregated Age | 56 |
| | and Sex: Positive 15+ Female | |
| | Test Result by Age: Positive: <1 | |
| | Test Result by Age: Positive: 1-9 | |
| ł | Age/sex: <1 | |
| Α | Age/sex: 1-9 | |
| Se | ervice Delivery Point | |
| 4 | | |



| (Community): Index testing | |
|------------------------------------|-----|
| Service Delivery Point | |
| (Community): Homebased testing | |
| Service Delivery Point | |
| (Community): Mobile testing | |
| Service Delivery Point | 4.4 |
| (Community): Other | 14 |
| Service Delivery Point (Community) | |
| by Age: <15 index testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ index testing | |
| Service Delivery Point (Community) | |
| by Age: <15 homebased testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ homebased testing | |
| Service Delivery Point (Community) | |
| by Age: <15 mobile testing | |
| Service Delivery Point (Community) | |
| by Age: 15+ mobile testing | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Community) | |
| by Age: <15 other | |
| Service Delivery Point (Facility): | |
| Inpatient | |
| Service Delivery Point (Facility): | |
| Outpatient | |
| Service Delivery Point (Facility): | |
| Pediatric | |
| Service Delivery Point (Facility): | |
| Malnutrition facilities | |
| Service Delivery Point (Facility): | |
| Other PITC | |
| Service Delivery Point (Facility): | 95 |
| | |



| VCT |
|---------------------------------------|
| Service Delivery Point (Facility): |
| VMMC |
| Service Delivery Point (Facility): |
| РМТСТ |
| Service Delivery Point (Facility): TB |
| Clinics |
| Service Delivery Point (Facility): |
| Index testing |
| Service Delivery Point (Facility) by |
| Age: <15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Inpatient |
| Service Delivery Point (Facility) by |
| Age: <15 Outpatient |
| Service Delivery Point (Facility) by |
| Age: >15 Outpatient |
| Service Delivery Point (Facility) by |
| Age: <15 Pediatroc |
| Service Delivery Point (Facility) by |
| Age: >15 Pediatroc |
| Service Delivery Point (Facility) by |
| Age: <15 Malnutrition facilities |
| Service Delivery Point (Facility) by |
| Age: >15 Malnutrition facilities |
| Service Delivery Point (Facility) by |
| Age: <15 Other PITC |
| Service Delivery Point (Facility) by |
| Age: >15 Other PITC |
| Service Delivery Point (Facility) by |
| Age: <15 VCT |
| Service Delivery Point (Facility) by |
| Age: >15 VCT |
| Service Delivery Point (Facility) by |



| | Age: <15 VMMC | |
|--------------|--|-----|
| | Service Delivery Point (Facility) by Age: >15 VMMC | |
| | Service Delivery Point (Facility) by Age: <15 PMTCT | |
| | Service Delivery Point (Facility) by Age: >15 PMTCT | |
| | Service Delivery Point (Facility) by Age: <15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: >15 TB Clinics | |
| | Service Delivery Point (Facility) by Age: <15 Index testing | |
| | Service Delivery Point (Facility) by Age: >15 Index testing | |
| | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 162 |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 15-17 Male | |
| | By: Age/sex: Male 18-24 | |
| | By: Age/sex: Male 25+ | |
| OVC_SERV_DSD | Age/Sex: 18+ Male | 52 |
| | Age/Sex: 10-14 Female | |
| | Age/Sex: 15-17 Female | |
| | By: Age/sex: 18-24 Female | |
| | By: Age/sex: 25+ Female | |
| | Age/Sex: 18+ Female | 83 |
| | Sum of Age/Sex disaggregates | 135 |
| | Required only for DREAMS | |
| | countries - By service, age and | |
| | sex: Education Support Female <1 | |



| Required only for DREAMS | |
|-----------------------------------|--|
| countries - By service, age and | |
| sex: Education Support Female | |
| 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female | |
| 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Male 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Female <1 | |
| | |



| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 10-14 Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs | |
|--|--|
| Female 15-17 Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 18-24 | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Female 25+ | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male <1 | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 10-14 | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 15-17 | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs Male 18-24 | |
| Required only for DREAMS countries - By service, age and sex: Parenting/Caregiver Programs | |



| Male 25+ | |
|-----------------------------------|--|
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Female | |
| 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Female | |
| 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Female | |
| 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Female 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Male 25+ | |
| Required only for DREAMS | |



| countries - By service, age and | |
|----------------------------------|--|
| sex: Economic Strengthening | |
| Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening | |
| Female 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| 18-24 | |
| | |



| r | 1 |
|----------------------------------|---|
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Female <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Female 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Female 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Female 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Female 25+ | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male <1 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male 10-14 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male 15-17 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male 18-24 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male 25+ | |
| Age/Sex: <1 | |
| | |



| | [] |
|-----------------------------------|----|
| Age/Sex: 1-9 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support 1-9 Male | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Parenting/Caregiver Programs | |
| Male 1-9 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Social Protection Programs | |
| Male 1-9 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Economic Strengthening Male | |
| 1-9 | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Other Services Male 1-9 | |
| Program Completion: Active | |
| Program Completion: Graduation | |
| Program Completion: Transferred | |
| Program Completion: Exited | |
| without graduation | |
| By Aggregated Age/Sex: <18 Male | 12 |
| By Aggregated Age/Sex: 18+ Male | |
| By Aggregated Age/Sex: <18 | |
| Female | 15 |
| By Aggregated Age/Sex: 18+ | |
| Female | |
| Required only for DREAMS | |
| countries - By service, age and | |
| sex: Education Support Female 1-9 | |
| Required only for DREAMS | |
| | |



| | countries - By service, age and sex: Parenting/Caregiver Programs | |
|-----------------|--|-------|
| | Female 1-9 Required only for DREAMS countries - By service, age and sex: Social Protection Programs | |
| | Female 1-9 | |
| | Required only for DREAMS countries - By service, age and sex: Economic Strengthening Female 1-9 | |
| | Required only for DREAMS countries - By service, age and sex: Other Services Female 1-9 | |
| | The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period. | 1,718 |
| | Screened for TB by Age/Sex:<15 Male | 9 |
| TB_SCREENDX_DSD | Screened for TB by Age/Sex: 15+ Male | 644 |
| | Screened for TB by Age/Sex:<15 Female | 35 |
| | Screened for TB by Age/Sex: 15+ Female | 1,030 |
| | Screen Result: Screened Positive for TB | 35 |
| | TB Positive by Age/Sex: <15 Male | |
| | TB Positive by Age/Sex: 15+ Male | |
| | TB Positive by Age/Sex: <15 Female | |
| | TB Positive by Age/Sex: 15+ Female | |



| | [Sub-Disagg of Screen Result] | |
|----------------|---------------------------------------|-------|
| | Specimen Sent: Specimen sent for | 35 |
| | bacteriologic diagnosis of active TB | |
| | [Sub-Disagg of Specimen Sent] | 07 |
| | Diagnostic Test: Smear only | 27 |
| | [Sub-Disagg of Specimen Sent] | |
| | Diagnostic Test: Xpert MTB/RIF | 8 |
| | assay | |
| | [Sub-Disagg of Specimen Sent] | |
| | Diagnostic Test: other (not Xpert) | |
| | The number of PLHIV who were | |
| | screened for TB symptoms at the | |
| | last clinical visit at a HIV facility | 1,861 |
| | during the reporting period. | |
| | Screened for TB by Age/Sex: <15 | |
| | Male | 100 |
| | Screened for TB by Age/Sex: 15+ | |
| | Male | 837 |
| | Screened for TB by Age/Sex: <15 | |
| | Female | 94 |
| | Screened for TB by Age/Sex: 15+ | |
| | Female | 830 |
| TB_SCREENDX_TA | Screen Results: Screened Positive | |
| | for TB | 38 |
| | TB Positive by Age/Sex: <15 Male | |
| | TB Positive by Age/Sex: 15+ Male | |
| | TB Positive by Age/Sex: <15 | |
| | Female | |
| | TB Positive by Age/Sex: 15+ | |
| | Female | |
| | [Sub-Disagg of Screen Results] | |
| | Specimen Sent: Specimen sent for | 38 |
| | bacteriologic diagnosis of active TB | |
| | [Sub-disagg of Specimen Sent] | 29 |
| | [Oub disagg of Opecimen Cent] | 25 |



| | Diagnostic Test: Smear Only | |
|--------------|---------------------------------------|-----|
| | [Sub-disagg of Specimen Sent] | |
| | Diagnostic Test: Xpert MTB/RIF | 9 |
| | assay | |
| | [Sub-disagg of Specimen Sent] | |
| | Diagnostic Test: Other (Not Xpert) | |
| | PMTCT_EID_TA Percent of infants | |
| | born to HIV-positive women that | |
| | receive a virological HIV test within | n/a |
| | 12 months of birth (TA) | |
| | Number of infants who had a | |
| | virologic HIV test within 12 months | |
| | of birth during the reporting period | |
| | Number of HIV- positive pregnant | |
| | women identified during the | |
| | reporting period (include known | |
| | HIV-positive women at entry into | |
| | PMTCT) | |
| | By infants who received a virologic | |
| | test within 2 months of birth | 38 |
| PMTCT_EID_TA | By infants who received their first | |
| | virologic HIV test between 2 and 12 | 2 |
| | months of age | |
| | Sum of Infant Age disaggregates | 40 |
| | By infants with a positive virologic | |
| | test result within 12 months of birth | |
| | Number of infants with a positive | |
| | virological test result within 2 | 0 |
| | months of birth | |
| | Number of infants with a negative | |
| | virological test result within 2 | |
| | months of birth | |
| | Number of infants with a positive | |
| | virological test result between 2 | |
| | and 12 months of birth | |
| | | |



| | Number of infants with a negative | |
|-------------|-----------------------------------|-------|
| | virological test result between 2 | |
| | and 12 months of birth | |
| | Number of infants with a positive | |
| | virological test result within 12 | 0 |
| | months of birth | |
| | Number of adults and children | |
| | receiving antiretroviral therapy | 1,718 |
| | (ART) | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | 9 |
| | Aggregated Age/Sex: 15+ Male | 644 |
| | Aggregated Age/Sex: <15 Female | 35 |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 1,030 |
| TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 44 |
| | Sum of Aggregated Age/Sex 15+ | 1,674 |
| | Sum of Aggregated Age/Sex | |
| | disaggregates | 1,718 |
| | Age/Sex: <1 | |
| | Age/Sex: <1-9 | |
| | Age/Sex: 10-14 Male | |
| | Age/Sex: 10-14 Female | |
| | Aggregated Age/Sex: 1-14 Male | |
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | |
| | Age/Sex: 50+ Male | |
| | | |



| | Age/Sex: 20-24 Female | |
|------------|----------------------------------|--------|
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children | |
| | receiving antiretroviral therapy | 17,922 |
| | (ART) | |
| | Age/Sex: <1 Male | |
| | Age/Sex: 1-4 Male | |
| | Age/Sex: 5-14 Male | |
| | Age/Sex: 15-19 Male | |
| | Age/Sex: 20+ Male | |
| | Age/Sex: <1 Female | |
| | Age/Sex: 1-4 Female | |
| | Age/Sex: 5-14 Female | |
| | Age/Sex: 15-19 Female | |
| | Age/Sex: 20+ Female | |
| | Sum of Age/Sex disaggregations | |
| TX_CURR_TA | Aggregated Age/Sex: <1 Male | |
| | Aggregated Age/Sex: <1 Female | |
| | Aggregated Age/Sex: <15 Male | 94 |
| | Aggregated Age/Sex: 1-14 Male | |
| | Aggregated Age/Sex: 15+ Male | 8,714 |
| | Aggregated Age/Sex: <15 Female | 100 |
| | Aggregated Age/Sex: 1-14 Female | |
| | Aggregated Age/Sex: 15+ Female | 9,015 |
| | Sum of Aggregated Age/Sex <15 | 194 |
| | Sum of Aggregated Age/Sex 15+ | 17,729 |
| | Sum of Aggregated Age/Sex | 17,923 |
| | disaggregates | |
| | Age/Sex: <1 | |
| | Age/Sex: 1-9 | |
| | Age/Sex: 10-14 Male | |



| | Age/Sex: 10-14 Female | |
|------------|--|-------|
| | Sum of Aggregated Age/Sex (<1 | |
| | and 1-14) <15 | |
| | Age/Sex: 20-24 Male | |
| | Age/Sex: 25-49 Male | _ |
| | Age/Sex: 50+ Male | |
| | Age/Sex: 20-24 Female | |
| | Age/Sex: 25-49 Female | |
| | Age/Sex: 50+ Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 1,706 |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| TX_NEW_DSD | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |
| | By Age/Sex: 50+ Female | |
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <a><15 Male | 2 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: | 814 |



| | 15+ Male | |
|-----------|--|-------|
| | Aggregated Grouping by Age/Sex: <1 Female | |
| | Aggregated Grouping by Age/Sex: <15 Female | 2 |
| | Aggregated Grouping by Age/Sex: 15+ Female | 888 |
| | Sum of Aggregated Age/Sex disaggregates | 1,706 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 3,902 |
| | By Age/Sex: <1 | |
| | By Age/Sex: 1-9 | |
| | By Age/Sex: <1 Male | |
| | By Age/Sex: 1-4 Male | |
| | By Age/Sex: 5-9 Male | |
| | By Age/Sex: 10-14 Male | |
| | By Age/Sex: 15-19 Male | |
| TX_NEW_TA | By Age/Sex: 20-24 Male | |
| | By Age/Sex: 25-49 Male | |
| | By Age/Sex: 50+ Male | |
| | By Age/Sex: <1 Female | |
| | By Age/Sex: 1-4 Female | |
| | By Age/Sex: 5-9 Female | |
| | By Age/Sex: 10-14 Female | |
| | By Age/Sex: 15-19 Female | |
| | By Age/Sex: 20-24 Female | |
| | By Age/Sex: 25-49 Female | |



| | By Age/Sex: 50+ Female | |
|-------------|---|-------|
| | Sum of Age/Sex disaggregates | |
| | Aggregated Grouping by Age: <1 | |
| | Aggregated Grouping by Age: <1 Male | |
| | Aggregated Grouping by Age/Sex: <15 Male | 82 |
| | Aggregated Grouping by Age/Sex: 1-14 Male | |
| | Aggregated Grouping by Age/Sex: 15+ Male | 1,869 |
| | Aggregated Grouping by Age: <1 Female | |
| | Aggregated Grouping by Age/Sex: <pre><15 Female</pre> | 28 |
| | Aggregated Grouping by Age/Sex: 1-14 Female | |
| | Aggregated Grouping by Age/Sex: 15+ Female | 1,929 |
| | Sum of Aggregated Age/Sex disaggregates | 3,908 |
| | Pregnancy status | |
| | Breastfeeding status | |
| | TX_PVLS_DSD Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information | n/a |
| | systems (LIS) within the past 12 | n/a |
| TX_PVLS_DSD | months with a suppressed viral | |
| | load (<1000 copies/ml) | |
| | Number of adults and pediatric | |
| | patients on ART with suppressed | 4.400 |
| | viral load results (<1,000 copies/ml) | 1,160 |
| | documented in the medical records | |



| and /or supporting laboratory | |
|--|-------|
| results within the past 12 months. | |
| Number of adult and pediatric ART patients with a viral load result | 1,546 |
| documented in the patient medical record and /or laboratory records in the past 12 months. | 1,040 |
| Numerator: Indication: Routine | 1,160 |
| Numerator: Indication: Targeted | |
| Numerator: Preg/BF by Indication: Pregnant Routine | |
| Numerator: Preg/BF by Indication: Breastfeeding Routine | |
| Numerator: Preg/BF by Indication: Pregnant Targeted | |
| Numerator: Preg/BF by Indication: Breastfeeding Targeted | |
| Numerator: Age/Sex by Indication: <1 Routine | |
| Numerator: Age/Sex by Indication: 1-9 Routine | |
| Numerator: Age/Sex by Indication: 10-14 Male Routine | |
| Numerator: Age/Sex by Indication: 15-19 Male Routine | |
| Numerator: Age/Sex by Indication: 20-24 Male Routine | |
| Numerator: Age/Sex by Indication: 25-49 Male Routine | |
| Numerator: Age/Sex by Indication: 50+ Male Routine | |
| | |
| Numerator: Age/Sex by Indication: 10-14 Female Routine | |



| 15-19 Female Routine |
|---|
| |
| Numerator: Age/Sex by Indication: 20-24 Female Routine |
| |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| |
| Numerator: Age/Sex by Indication: |
| 50+ Female Routine |
| Numerator: Age/Sex by Indication: |
| <1 Targeted |
| Numerator: Age/Sex by Indication: |
| 1-9 Targeted |
| Numerator: Age/Sex by Indication: |
| 10-14 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: |
| 50+ Male Targeted |
| Numerator: Age/Sex by Indication: |
| 10-14 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 15-19 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: |
| 50+ Female Targeted |
| Numerator: Aggregate Age/Sex by |
| Indication: <15 Male Targeted |
| Numerator: Aggregate Age/Sex by |



| | Indication: 15+ Male Targeted | |
|---|------------------------------------|-------|
| | Numerator: Aggregate Age/Sex by | |
| | Indication: <15 Female Targeted | |
| | Numerator: Aggregate Age/Sex by | |
| | Indication: 15+ Female Targeted | |
| | Numerator: Aggregate Age/Sex by | |
| | Indication: <15 Male Routine | |
| | Numerator: Aggregate Age/Sex by | |
| | Indication: 15+ Male Routine | |
| | Numerator: Aggregate Age/Sex by | |
| | Indication: <15 Female Routine | |
| | Numerator: Aggregate Age/Sex by | |
| | Indication: 15+ Female Routine | |
| | Denominator: Indication: Routine | 1,546 |
| | Denominator: Indication: Targeted | |
| | Denominator: Preg/BF by | |
| ļ | Indication: Pregnant Routine | |
| | Denominator: Preg/BF by | |
| ļ | Indication: Breastfeeding Routine | |
| | Denominator: Preg/BF by | |
| | Indication: Pregnant Targeted | |
| | Denominator: Preg/BF by | |
| | Indication: Breastfeeding Targeted | |
| | Denominator: Age/Sex by | |
| | Indication: <1 Routine | |
| | Denominator: Age/Sex by | |
| | Indication: 1-9 Routine | |
| | Denominator: Age/Sex by | |
| | Indication: 10-14 Male Routine | |
| | Denominator: Age/Sex by | |
| ļ | Indication: 15-19 Male Routine | |
| | Denominator: Age/Sex by | |
| | Indication: 20-24 Male Routine | |
| _ | Denominator: Age/Sex by | |
| | | |



| Indication: 25-4 | 49 Male Routine |
|-----------------------|--------------------|
| Denominator: / | Age/Sex by |
| Indication: 50+ | - Male Routine |
| Denominator: / | Age/Sex by |
| Indication: 10-7 | 14 Female Routine |
| Denominator: / | Age/Sex by |
| Indication: 15-7 | 19 Female Routine |
| Denominator: <i>i</i> | Age/Sex by |
| Indication: 20-2 | 24 Female Routine |
| Denominator: <i>i</i> | Age/Sex by |
| Indication: 25-4 | 49 Female Routine |
| Denominator: <i>i</i> | Age/Sex by |
| Indication: 50+ | - Female Routine |
| Denominator: <i>i</i> | Age/Sex by |
| Indication: <1 | Targeted |
| Denominator: / | Age/Sex by |
| Indication: 1-9 | Targeted |
| Denominator: / | Age/Sex by |
| Indication: 10- | 14 Male Targeted |
| Denominator: / | Age/Sex by |
| Indication: 15- | 19 Male Targeted |
| Denominator: / | Age/Sex by |
| Indication: 20-2 | 24 Male Targeted |
| Denominator: A | Age/Sex by |
| Indication: 25-4 | 49 Male Targeted |
| Denominator: A | Age/Sex by |
| Indication: 50+ | - Male Targeted |
| Denominator: A | Age/Sex by |
| Indication: 10- | 14 Female Targeted |
| Denominator: A | Age/Sex by |
| Indication: 15- | 19 Female Targeted |
| Denominator: A | Age/Sex by |
| Indication: 20-2 | 24 Female Targeted |
| Denominator: <i>i</i> | Ago/Cox by |



| | Indication: 25-49 Female Targeted | |
|----|------------------------------------|-----|
| | Denominator: Age/Sex by | |
| | Indication: 50+ Female Targeted | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: <15 Male Targeted | |
| | Denominator: Aggregate Age/Sex | |
| ļ | by Indication: 15+ Male Targeted | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: <15 Female Targeted | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: 15+ Female Targeted | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: <15 Male Routine | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: 15+ Male Routine | |
| | Denominator: Aggregate Age/Sex | |
| | by Indication: <15 Female Routine | |
| | Denominator: Aggregate Age/Sex | |
| 1 | by Indication: 15+ Female Routine | |
| | Numerator Aggregated Age/Sex: | 29 |
| | <15 Male | 23 |
| | Numerator Aggregated Age/Sex: | 543 |
| | 15+ Male | 070 |
| | Numerator Aggregated Age/Sex: | 29 |
| | <15 Female | 23 |
| | Numerator Aggregated Age/Sex: | 559 |
| ļ | 15+ Female | |
| | Denominator Aggregated Age/Sex: | 38 |
| | <15 Male | |
| | Denominator Aggregated Age/Sex: | 715 |
| ŀ | 15+ Male | |
| | Denominator Aggregated Age/Sex: | 40 |
| < | 15 Female | |
| De | enominator Aggregated Age/Sex: | 753 |
| | | |



| | 15+ Female | |
|------------|--|--------|
| | TX_PVLS_TA Percentage of ART patients with a viral load result documented in the medical record and/or laboratory information systems (LIS) within the past 12 months with a suppressed viral load (<1000 copies/ml) | n/a |
| | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 14,186 |
| TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 17,736 |
| | Numerator: Age/Sex by Indication: <1 Routine | |
| | Numerator: Age/Sex by Indication: <1 Targeted | |
| | Numerator: Age/Sex by Indication: 1-9 Routine | |
| | Numerator: Age/Sex by Indication: 1-9 Targeted | |
| | Numerator: Age/Sex by Indication: 10-14 Female Routine | |
| | Numerator: Age/Sex by Indication: 10-14 Female Targeted | |
| | Numerator: Age/Sex by Indication: 10-14 Male Routine | |
| | Numerator: Age/Sex by Indication: 10-14 Male Targeted | |



| Numerator: Age/Sex by Indication: 15-19 Female Routine |
|---|
| Numerator: Age/Sex by Indication: 15-19 Female Targeted |
| Numerator: Age/Sex by Indication: 15-19 Male Routine |
| Numerator: Age/Sex by Indication: 15-19 Male Targeted |
| Numerator: Age/Sex by Indication: 20-24 Female Routine |
| Numerator: Age/Sex by Indication: 20-24 Female Targeted |
| Numerator: Age/Sex by Indication: 20-24 Male Routine |
| Numerator: Age/Sex by Indication: 20-24 Male Targeted |
| Numerator: Age/Sex by Indication: 25-49 Female Routine |
| Numerator: Age/Sex by Indication: 25-49 Female Targeted |
| Numerator: Age/Sex by Indication: 25-49 Male Routine |
| Numerator: Age/Sex by Indication: 25-49 Male Targeted |
| Numerator: Age/Sex by Indication: 50+ Female Routine |
| Numerator: Age/Sex by Indication: 50+ Female Targeted |
| Numerator: Age/Sex by Indication: 50+ Male Routine |
| Numerator: Age/Sex by Indication: 50+ Male Targeted |
| Numerator: Aggregate Age/Sex by Indication: <15 Female Routine |



| L | |
|-----------------------------------|-------|
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: <15 Male Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Female Targeted | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Routine | |
| Numerator: Aggregate Age/Sex by | |
| Indication: 15+ Male Targeted | |
| Numerator: Indication: Routine | 1,256 |
| Numerator: Indication: Targeted | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Routine | |
| Numerator: Preg/BF by Indication: | |
| Breastfeeding Targeted | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Routine | |
| Numerator: Preg/BF by Indication: | |
| Pregnant Targeted | |
| Denominator: Indication: Routine | 1,675 |
| Denominator: Indication: Targeted | |
| Denominator: Age/Sex by | |
| Indication: <1 Routine | |
| Denominator: Age/Sex by | |
| Indication: <1 Targeted | |
| Denominator: Age/Sex by | |
| Indication: 1-9 Routine | |
| Denominator: Age/Sex by | |
| Indication: 1-9 Targeted | |
| | |



| Denominator: Age/Sex by |
|-----------------------------------|
| |
| Indication: 10-14 Female Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Routine |
| Denominator: Age/Sex by |
| Indication: 10-14 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 15-19 Female Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Routine |
| Denominator: Age/Sex by |
| Indication: 15-19 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 20-24 Female Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Routine |
| Denominator: Age/Sex by |
| Indication: 20-24 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Female Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Female Targeted |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Routine |
| Denominator: Age/Sex by |
| Indication: 25-49 Male Targeted |
| Denominator: Age/Sex by |
| Indication: 50+ Female Routine |



| Denominator: Age/Sex by | |
|------------------------------------|------------|
| Indication: 50+ Female Targeted | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Routine | |
| Denominator: Age/Sex by | |
| Indication: 50+ Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: <15 Male Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Female Targeted | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Routine | |
| Denominator: Aggregate Age/Sex | |
| by Indication: 15+ Male Targeted | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Routine | |
| Denominator: Preg/BF by | |
| Indication: Breastfeeding Targeted | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Routine | |
| Denominator: Preg/BF by | |
| Indication: Pregnant Targeted | |
| Numerator Aggregated Age/Sex: | F (|
| <15 Male | 51 |
| Numerator Aggregated Age/Sex: | 0.007 |
| 15+ Male | 6,897 |
| | |



| | Numerator Aggregated Age/Sex: <15 Female | 73 |
|------------|---|-------|
| | Numerator Aggregated Age/Sex: 15+ Female | 7,165 |
| | Denominator Aggregated Age/Sex: <15 Male | 77 |
| | Denominator Aggregated Age/Sex: 15+ Male | 8,629 |
| | Denominator Aggregated Age/Sex: <15 Female | 91 |
| | Denominator Aggregated Age/Sex: 15+ Female | 8,939 |
| | TX_RET_DSD Percent of adults and children known to be alive and on treatment 12 months after initiation of antiretroviral therapy | n/a |
| | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 151 |
| TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 178 |
| | Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART | |
| | Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 10-14 Male (Numerator: | |



| Number of adults and children who | |
|-------------------------------------|--|
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 15-19 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sed: 20-24 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 25-49 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 50+ Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART | |
| Age/Sex: 10-14 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART | |
| Age/Sex: 15-19 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART | |
| Age/Sex: 20-24 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART | |
| Age/Sex: 25-49 Female | |
| | |



| (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: s1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | | |
|--|--------------------------------------|--|
| treatment at 12 months after initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those died those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those period, period, including those period, period, including those prior to the beginning of the reporting period, including those period, period, including those prior to the beginning of the reporting period, including the reporting period, including those period, period, including those peri | (Numerator: Number of adults and | |
| initiating ART Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART, in the 12 months prior to the beginning of the reporting period, including those who have died, ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of < | children who are still alive and on | |
| Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, <t< td=""><td>treatment at 12 months after</td><td></td></t<> | treatment at 12 months after | |
| Number of adults and children who are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) | initiating ART | |
| are still alive and on treatment at 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) | Age/Sex: 50+ Female (Numerator: | |
| 12 months after initiating ART Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) | Number of adults and children who | |
| Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | are still alive and on treatment at | |
| number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART, and those lost to follow-up) | 12 months after initiating ART | |
| initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | Age/Sex: >1 (Denominator: Total | |
| to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have follow-up) | number of adults and children who | |
| period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | initiated ART in the 12 months prior | |
| died, those who have stopped ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | to the beginning of the reporting | |
| ART, and those lost to follow-up) Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | period, including those who have | |
| Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated | died, those who have stopped | |
| number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | ART, and those lost to follow-up) | |
| initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | Age/Sex: 1-9 (Denominator: Total | |
| to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | number of adults and children who | |
| period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | initiated ART in the 12 months prior | |
| died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | to the beginning of the reporting | |
| ART, and those lost to follow-up) Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the | period, including those who have | |
| Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up)Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | died, those who have stopped | |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | ART, and those lost to follow-up) | |
| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | Age/Sex: 10-14 Male | |
| ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | (Denominator: Total number of | |
| beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | adults and children who initiated | |
| including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | ART in the 12 months prior to the | |
| those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | beginning of the reporting period, | |
| those lost to follow-up) Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | including those who have died, | |
| Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | those who have stopped ART, and | |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | those lost to follow-up) | |
| adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, | Age/Sex: 15-19 Male | |
| ART in the 12 months prior to the beginning of the reporting period, | (Denominator: Total number of | |
| beginning of the reporting period, | adults and children who initiated | |
| | ART in the 12 months prior to the | |
| including those who have died, | beginning of the reporting period, | |
| | including those who have died, | |



| those who have stopped ART, and |
|---|
| those lost to follow-up) |
| Age/Sex: 20-24 Male |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 25-49 Male |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| |
| Age/Sex: 50+ Male (Denominator: |
| Age/Sex: 50+ Male (Denominator: Total number of adults and children |
| - |
| Total number of adults and children |
| Total number of adults and children who initiated ART in the 12 months |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
| Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and |



| adults and children who initiated |
|-------------------------------------|
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 20-24 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 25-49 Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 50+ Female |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Aggregated Age: <15 (Numerator: |
| Number of adults and children who |
| are still alive and on treatment at |
| |
| 12 months after initiating ART) |
| Aggregated Age: 15+ (Numerator: |
| Number of adults and children who |



| are still alive and on treatment at | |
|-------------------------------------|----|
| 12 months after initiating ART) | |
| Aggregated Age: <15 | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age: 15+ | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Numerator by Status: Pregnant | |
| Numerator by Status: | |
| Breastfeeding | |
| Denominator by Status: Pregnant | |
| Denominator by Status: | |
| Breastfeeding | |
| Aggregated Age/Sex: <15 Male | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 7 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: 15+ Male | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 64 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: <15 Female | 8 |



| (Numerator: Number of adults and children who are still alive and on treatment at 12 months after | |
|---|----|
| initiating ART) | |
| Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and | |
| children who are still alive and on | 72 |
| treatment at 12 months after | 12 |
| initiating ART) | |
| | |
| Aggregated Age/Sex: <15 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | 8 |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age/Sex: 15+ Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | 70 |
| beginning of the reporting period, | 76 |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age/Sex: <15 Female | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | 10 |
| beginning of the reporting period, | 10 |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age/Sex: 15+ Female | |
| (Denominator: Total number of | 84 |
| adults and children who initiated | |
| | L |



| <u> </u> | | |
|-----------|--------------------------------------|------|
| ٩ | ART in the 12 months prior to the | |
| d | beginning of the reporting period, | |
| ir | ncluding those who have died, | |
| ti | hose who have stopped ART, and | |
| ti | hose lost to follow-up) | |
| Т | TX_RET_TA Percent of adults and | |
| c | children known to be alive and on | - (- |
| tı | reatment 12 months after initiation | n/a |
| 0 | of antiretroviral therapy | |
| | Number of adults and children who | |
| a | are still alive and on treatment at | 200 |
| 1 | 12 months after initiating ART | |
| Т | Fotal number of adults and children | |
| w | who initiated ART in the 12 months | |
| p | prior to the beginning of the | |
| r. | eporting period, including those | 227 |
| w | who have died, those who have | |
| s | stopped ART, and those lost to | |
| fo | ollow-up | |
| | Age/Sex: <1 (Numerator: Number | |
| TX_RET_TA | of adults and children who are still | |
| a | alive and on treatment at 12 | |
| n | months after initiating ART) | |
| 4 | Age/Sex: 1-9 (Numerator: Number | |
| 0 | of adults and children who are still | |
| a | alive and on treatment at 12 | |
| n n | months after initiating ART) | |
| A | Age/Sex: 10-14 Male (Numerator: | |
| | Number of adults and children who | |
| a | are still alive and on treatment at | |
| 1 | 12 months after initiating ART) | |
| | Age/Sex: 15-19 Male (Numerator: | |
| | Number of adults and children who | |
| | are still alive and on treatment at | |
| la | | |



| Age/Sex: 20-24 Male (Numerator: | |
|-------------------------------------|--|
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 25-49 Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 50+ Male (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Age/Sex: 10-14 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 15-19 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 20-24 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 25-49 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | |
| treatment at 12 months after | |
| initiating ART) | |
| Age/Sex: 50+ Female (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| 5 / | |



| Age/Sex: <1 (Denominator: Total | |
|--------------------------------------|--|
| number of adults and children who | |
| initiated ART in the 12 months prior | |
| to the beginning of the reporting | |
| period, including those who have | |
| died, those who have stopped | |
| ART, and those lost to follow-up) | |
| Age/Sex: 1-9 (Denominator: Total | |
| number of adults and children who | |
| initiated ART in the 12 months prior | |
| to the beginning of the reporting | |
| period, including those who have | |
| died, those who have stopped | |
| ART, and those lost to follow-up) | |
| Age/Sex: 10-14 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 15-19 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 20-24 Male | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| | |



| those who have stopped ART, and |
|---|
| those lost to follow-up) |
| Age/Sex: 25-49 Male |
| (Denominator: Total number of |
| adults and children who initiated |
| ART in the 12 months prior to the |
| beginning of the reporting period, |
| including those who have died, |
| those who have stopped ART, and |
| those lost to follow-up) |
| Age/Sex: 50+ Male (Denominator: |
| Total number of adults and children |
| who initiated ART in the 12 months |
| prior to the beginning of the |
| reporting period, including those |
| who have died, those who have |
| stopped ART, and those lost to |
| follow-up) |
| |
| Age/Sex: 10-14 Female |
| Age/Sex: 10-14 Female (Denominator: Total number of |
| _ |
| (Denominator: Total number of |
| (Denominator: Total number of adults and children who initiated |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) |
| (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and |



| adults and children who initiated | |
|-------------------------------------|---|
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 25-49 Female | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Age/Sex: 50+ Female | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age: <15 (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| Aggregated Age: 15+ (Numerator: | |
| Number of adults and children who | |
| are still alive and on treatment at | |
| 12 months after initiating ART) | |
| | _ |
| Aggregated Age: <15 | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |



| | 1 |
|--|----|
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Aggregated Age: 15+ | |
| (Denominator: Total number of | |
| adults and children who initiated | |
| ART in the 12 months prior to the | |
| beginning of the reporting period, | |
| including those who have died, | |
| those who have stopped ART, and | |
| those lost to follow-up) | |
| Numerator by Status: Pregnant | |
| Numerator by Status: | |
| Breastfeeding | |
| Denominator by Status: Pregnant | |
| Denominator by Status: | |
| Breastfeeding | |
| Aggregated Age/Sex: <15 Male | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 10 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: 15+ Male | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 86 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: <15 Female | |
| (Numerator: Number of adults and | |
| children who are still alive and on | 10 |
| treatment at 12 months after | |
| initiating ART) | |
| Aggregated Age/Sex: 15+ Female | |
| (Numerator: Number of adults and | |
| ` children who are still alive and on | 94 |
| treatment at 12 months after | |
| | 1 |



| | initiating ART) | |
|-----------|--|-----|
| | Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 9 |
| | Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 95 |
| | Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 14 |
| | Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 109 |
| LAB_PT_TA | Percentage of laboratories and POC testing sites that perform HIV diagnostic testing that participate | |



| a | and successfully pass in an | |
|------------|--------------------------------------|----|
| a | analyte-specific proficiency testing | |
| <u>(</u> F | PT) program | |
| c | CD4: Number of laboratories that | |
| a | achieve acceptable successful | 11 |
| р | passing criteria in this PT program | |
| c | CD4: Number of laboratories that | |
| p | participate in this PT program | 11 |
| C | CD4: Number of laboratories that | |
| р | perform this testing | 11 |
| E | Early infant diagnostics: Number of | |
| la | aboratories that achieve | _ |
| a | acceptable successful passing | 5 |
| С | riteria in this PT program | |
| E | Early infant diagnostics: Number of | |
| la | aboratories that participate in this | 5 |
| Р | PT program | |
| E | Early infant diagnostics: Number of | |
| la | aboratories that perform this | 5 |
| te | esting | |
| н | HV serologic/diagnostic testing: | |
| N | Number of laboratories that | |
| a | achieve acceptable successful | 44 |
| p | passing criteria in this PT program | |
| н | HV serologic/diagnostic testing: | |
| | Number of laboratories that | 44 |
| p | participate in this PT program | |
| н | HV serologic/diagnostic testing: | |
| | Number of laboratories that | 44 |
| | perform this testing | |
| | HV viral load: Number of | |
| | aboratories that achieve | |
| | acceptable successful passing | 5 |
| | riteria in this PT program | |
| | HV viral load: Number of | 5 |
| | | 5 |



| | 1 |
|---------------------------------------|----|
| laboratories that participate in this | |
| PT program | |
| HIV viral load: Number of | |
| laboratories that perform this | 5 |
| testing | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | 17 |
| achieve acceptable successful | 17 |
| passing criteria in this PT program | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | 17 |
| participate in this PT program | |
| TB diagnostics (AFB microscopy): | |
| Number of laboratories that | 17 |
| perform this testing | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | |
| achieve acceptable successful | 0 |
| passing criteria in this PT program | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | 0 |
| participate in this PT program | |
| TB diagnostics (Xpert MTB/RIF): | |
| Number of laboratories that | 0 |
| perform this testing | |
| TB diagnostics (Culture/DST): | |
| Number of laboratories that | |
| achieve acceptable successful | 0 |
| passing criteria in this PT program | |
| TB diagnostics (Culture/DST): | |
| Number of laboratories that | 0 |
| participate in this PT program | |
| TB diagnostics (Culture/DST): | |
| Number of laboratories that | 0 |
| perform this testing | |
| | |



| | Number of new HCW who | |
|-----------|--------------------------------------|---------|
| | graduated from a pre-service | |
| | training institution or program as a | 40 |
| | result of PEPFAR-supported | 12 |
| | strengthening efforts, within the | |
| | reporting period, by select cadre | |
| | By Graduates: Doctors | |
| HRH_PRE | By Graduates: Nurses | |
| | By Graduates: Midwives | |
| | By Graduates: Social service | |
| | workers | |
| | By Graduates: Laboratory | |
| | professionals | |
| | By Graduates: Other | |
| | Sum of Graduates disaggreagtes | |
| | PEPFAR resources used for | |
| | HIV-program related commodities: | 10,930 |
| | planned & purchased in the last 12 | 10,330 |
| | months by Implementing Partner | |
| | Number of HIV Test Kits purchased | 1,889 |
| | Number of HIV CD4 Reagents | |
| | purchased | |
| | Number of Condoms purchased | |
| | Number of HIV Viral Load | 7 609 |
| INVS_COMD | Reagents purchased | 7,698 |
| | Number of HIV ARVs purchased | 1,343 |
| | Number of Second Line HIV ARVs | |
| | purchased | |
| | HIV Test Kits: Dollars planned | 10.400 |
| | (COP)/ spent (Actual) | 10,198 |
| | HIV CD4 Tests: Dollars planned | 80,000 |
| | (COP)/ spent (Actual) | 00,000 |
| | HIV Viral Load: Dollars planned | 285 590 |
| | (COP)/ spent (Actual) | 285,580 |



| Condoms: Dollars planned (COP)/ spent (Actual) | |
|--|---------|
| HIV ARVs: Dollars planned (COP)/ spent (Actual) | 161,160 |



Partners and Implementing Mechanisms

Partner List

| Mech ID | Partner Name | Organization Type | Agency | Funding Source | Planned Funding |
|---------|---|--------------------------------------|---|----------------|-----------------|
| 12542 | University of California at San Francisco | University | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 300,000 |
| 12567 | Jamaica Ministry of Health (MOH) | Host Country Government Agency | U.S. Agency for International Development | GHP-State | 3,105,000 |
| 12570 | Bahamas MoH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 12575 | Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office (PHCO) | Implementing Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 350,000 |
| 12587 | US Embassies | Other USG Agency | U.S. Department of State/Bureau of Western Hemisphere | GHP-State | 200,000 |



| | | | Affairs | | |
|-------|--|--------------------------------------|---|-----------|---------|
| 12588 | Caribbean Community (CARICOM) Pan Caribbean Partnership Against AIDS | Multi-lateral Agency | U.S. Agency for International Development | GHP-USAID | 200,000 |
| 12594 | HRM | Other USG Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 12606 | Barbados MOH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 12642 | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention (HHS/CDC) | Implementing Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 12645 | World Learning | NGO | U.S. Agency for International Development | GHP-USAID | 0 |
| 12668 | Trinidad MoH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers | GHP-State | 0 |



| | | | for Disease | | |
|-------|-------------------|--------------------|------------------|-----------|---------|
| | | | Control and | | |
| | | | Prevention | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | Caribbean | | Human | | |
| 12688 | Regional Public | Parastatal | Services/Centers | GHP-State | 0 |
| | Health Agency | | for Disease | | |
| | | | Control and | | |
| | | | Prevention | | |
| | | Other USG | | | _ |
| 12971 | U.S. Peace Corps | Agency | U.S. Peace Corps | GHP-State | 0 |
| | | | U.S. Agency for | | |
| 13319 | Futures Group | Private Contractor | | GHP-USAID | 0 |
| | | | Development | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | African Field | | Human | | |
| 13335 | | NGO | Services/Centers | GHP-State | 0 |
| | Network | | for Disease | | - |
| | | | Control and | | |
| | | | Prevention | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | National Alliance | | Human | | |
| 13534 | of State and | NGO | Services/Centers | GHP-State | 250,000 |
| | Territorial AIDS | | for Disease | | , |
| | Directors | | Control and | | |
| | | | Prevention | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | | Host Country | Human | | |
| 13593 | SURINAME MOH | - | Services/Centers | GHP-State | 1 |
| | | Agency | for Disease | | |
| | | | Control and | | |
| | 1 | 1 | 1 | 1 | 1 |



| 16482 | Population Services International | NGO | U.S. Department of Defense | GHP-State | 0 |
|-------|--|---------------------|---|-----------|-----------|
| 16661 | Caribbean Regional Public Health Agency | Parastatal | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 366,938 |
| 17366 | FHI 360 | NGO | U.S. Agency for International Development | GHP-USAID | 1,674,565 |
| 17469 | Abt Associates | Private Contractor | U.S. Agency for International Development | GHP-USAID | 675,000 |
| 17760 | FHI 360 | NGO | U.S. Agency for International Development | GHP-State | 845,000 |
| 17808 | TBD | TBD | Redacted | Redacted | Redacted |
| 17809 | Johns Hopkins University Center for Communication Programs | University | U.S. Agency for International Development | GHP-USAID | 350,000 |
| 17810 | Management Sciences for Health | NGO | U.S. Agency for International Development | GHP-USAID | 0 |
| 17878 | US Embassies | Other USG Agency | U.S. Agency for International Development | GHP-State | 85,010 |
| 17902 | Palladium Group | NGO | U.S. Agency for International Development | GHP-State | 710,000 |
| 17919 | African Society for | NGO | U.S. Department | GHP-State | 0 |



| | Laboratory | | of Health and | | |
|-------|------------------|--------------------|------------------|-----------|-----------|
| | Medicine | | Human | | |
| | | | Services/Centers | | |
| | | | for Disease | | |
| | | | Control and | | |
| | | | Prevention | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | | | Human | | |
| 17921 | University of | University | Services/Health | GHP-State | 2,008,000 |
| | Washington | | Resources and | | |
| | | | Services | | |
| | | | Administration | | |
| | Partnership for | | U.S. Agency for | | |
| 18183 | Supply Chain | Private Contractor | International | GHP-USAID | 0 |
| | Management | | Development | | |
| | U.S. Department | | | | |
| 18184 | of Defense | Other USG | U.S. Department | GHP-State | 0 |
| | (Defense) | Agency | of Defense | | |
| | | | U.S. Department | | |
| | | | of Health and | | |
| | Davis Memorial | | Human | | |
| 18185 | Hospital and | FBO | Services/Centers | GHP-State | 0 |
| | Clinic | | for Disease | | |
| | | | Control and | | |
| | | | Prevention | | |
| 10400 | | Other USG | | | |
| 18186 | U.S. Peace Corps | Agency | U.S. Peace Corps | GHP-State | 0 |
| | | | U.S. Agency for | | |
| 18187 | John Snow Inc | | International | GHP-USAID | 1,000,000 |
| | (JSI) | Agency | Development | | |
| | | | U.S. Department | | |
| | Caribbean | | of Health and | | |
| 18188 | Regional Public | Parastatal | Human | GHP-State | 0 |
| | Health Agency | | Services/Centers | | |
| | | | for Disease | | |



| | | | Control and | | |
|-------|---|--------------------------------------|---|-----------|----------|
| | | | Prevention | | |
| 18189 | TBD | TBD | Redacted | Redacted | Redacted |
| 18190 | Ministry of Health, Guyana | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 0 |
| 18392 | Barbados MOH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1 |
| 18393 | Bahamas MoH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 270,000 |
| 18394 | Trinidad MoH | Host Country Government Agency | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1 |
| 18395 | TBD | TBD | Redacted | Redacted | Redacted |
| 18396 | Caribbean Regional Public Health Agency | Parastatal | U.S. Department of Health and Human Services/Centers | GHP-State | 369,000 |

Custom 2017-04-11 10:08 EDT Page 226 of 335

FACTS Info v3.8.21.10



| | | | for Disease Control and Prevention | | |
|-------|--|--------------------|---|-------------------------|-----------|
| 18398 | Global Data Analysis and Technical Assistance | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 545,157 |
| 18405 | American Society of Clinical Pathology | NGO | U.S. Department of Health and Human Services/Centers for Disease Control and Prevention | GHP-State | 1,262,000 |
| 18406 | TBD | TBD | Redacted | Redacted | Redacted |
| 18427 | Global Health Supply Chain Program | Private Contractor | U.S. Agency for International Development | GHP-State, GHP-USAID | 1,233,936 |



Implementing Mechanism(s)

Implementing Mechanism Details

| Mechanism ID: 12542 | Mechanism Name: University of California, San Francisco (UCSF-SITAC) CoAg GH000977 |
|---|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: University of California at San | Francisco |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount | |
|---------------------|-----------------------------------|--|
| Jamaica | 100,000 | |
| Suriname | 125,000 | |
| Trinidad and Tobago | 50,000 | |
| Guyana | 0 | |

| Total All Funding Sources: 300,000 | | |
|---------------------------------------|-----------|----------------|
| Applied Pipeline Amount: 50,000 | | |
| Total All Funding Sources and A | | |
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-State | 300,000 |

Cross-Cutting Budget Attribution(s)

| Gender: Gender Equality | 5,000 | |
|-------------------------|--|--|
| Focus Area: | Equity in HIV prevention, care, treatment and | |
| | support | |
| Sub Area: | Collection and Use of Gender-related Strategic | |
| | Information | |



| Sub Area: | Monitoring and Evaluation |
|-----------------------------|---|
| Sub Area: | Operation Research |
| Key Populations: FSW | 20,000 |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Focus Area: | Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Key Populations: MSM and TG | 250,000 |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |

| Mechanism ID: | 12542 | | | |
|---------------------------|--|---------|---|--|
| Mechanism Name: | University of California, San Francisco (UCSF-SITAC) CoAg GH000977 | | | |
| Prime Partner Name: | University of California at San Francisco | | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | |
| Governance and Systems | HVSI | 300,000 | 0 | |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 12567 | Mechanism Name: Jamaica MOH |
|-----------------------|-----------------------------|
| Funding Agency: USAID | Procurement Type: Grant |



| Prime Partner Name: Jamaica Ministry of Health (MOH) | | |
|---|--|--|
| Agreement Start Date: Redacted Agreement End Date: Redacted | | |
| TBD: No New Mechanism: No | | |
| G2G: Yes Managing Agency: USAID | | |

| Benefiting Country | Benefiting Country Planned Amount | |
|--------------------|-----------------------------------|--|
| Jamaica | 0 | |

| Total All Funding Sources: 3,105,000 | | |
|---|-----------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| 3,105,000 | | |
| Managing Country Funding Source | | Funding Amount |
| Jamaica | GHP-State | 3,105,000 |

| Key Populations: MSM and TG | 1,500,000 |
|-----------------------------|---|
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Key Populations: FSW | 750,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |



| Focus Area: | Training of health workers and community outreach | |
|-------------|--|--|
| | workers | |
| | Collection and use of strategic information on SWs | |
| | and clients | |
| Focus Area: | Monitoring and evaluation of SW programs | |

| Mechanism ID: 12567 | | | |
|---------------------------|-------------------------|----------------|----------------|
| Mechanism Name: | e: Jamaica MOH | | |
| Prime Partner Name: | Jamaica Ministry of Hea | alth (MOH) | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 1,775,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 105,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 280,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 145,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 800,000 | 0 |

Implementing Mechanism Indicator Information



| OU | Indicator Number | Label | 2017 |
|---------|------------------|--|--------|
| Jamaica | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 1,909 |
| Jamaica | KP_PREV_DSD | Total estimated number of key population in the catchment area | 31,807 |
| Jamaica | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,092 |
| Jamaica | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 817 |
| Jamaica | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 18,190 |
| Jamaica | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | 13,617 |
| Jamaica | HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,717 |
| Jamaica | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 982 |



| | | 1 | |
|---------|-------------|---|--------|
| Jamaica | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 735 |
| Jamaica | HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 1,717 |
| Jamaica | HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 1,717 |
| Jamaica | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Male | 98 |
| Jamaica | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Female | 22 |
| Jamaica | HTC_TST_DSD | Service Delivery Point (Community): Other | 1,717 |
| Jamaica | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 12,728 |
| Jamaica | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 6,108 |
| Jamaica | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 6,620 |
| Jamaica | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 12,728 |
| Jamaica | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 12,728 |
| Jamaica | TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 1,220 |
| Jamaica | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 585 |
| Jamaica | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 635 |
| Jamaica | TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 1,220 |
| Jamaica | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 770 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 377 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 393 |
| Jamaica | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 770 |
| Jamaica | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 4,575 |
| Jamaica | INVS_COMD | Number of HIV Test Kits purchased | 1,889 |
| | | | |



| Jamaica | INVS_COMD | Number of HIV Viral Load Reagents purchased | 1,343 |
|---------|-----------|--|---------|
| Jamaica | INVS_COMD | Number of HIV ARVs purchased | 1,343 |
| Jamaica | INVS_COMD | HIV Test Kits: Dollars planned (COP)/ spent (Actual) | 10,198 |
| Jamaica | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 80,580 |
| Jamaica | INVS_COMD | HIV ARVs: Dollars planned (COP)/ spent (Actual) | 161,160 |

Implementing Mechanism Details

| Mechanism ID: 12570 | Mechanism Name: Bahamas MOH | |
|---------------------------------|---|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Bahamas MoH | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: Yes | Managing Agency: HHS/CDC | |

| Benefiting Country | Benefiting Country Planned Amount | |
|--------------------|-----------------------------------|--|
| Bahamas | 0 | |

| Total All Funding Sources: 0 | | |
|---------------------------------|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)



| Mechanism ID: Mechanism Name: | | | |
|----------------------------------|-------------|----------------|----------------|
| Prime Partner Name: | Bahamas MoH | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------|------------------|---|--------|
| Bahamas | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 1,333 |
| Bahamas | INVS_COMD | Number of HIV Viral Load Reagents purchased | 1,333 |
| Bahamas | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 40,000 |

| Mechanism ID: 12575 | Mechanism Name: PAHO/PHCO Cooperative AgreementCK000346 | |
|--|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Pan American Health Organiza | ation (PAHO)/PAHO HIV Caribbean Office (PHCO) | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | | Benefiting C | Country Planned Amount |
|--------------------|--|-----------------|------------------------|
| | | | |
| Custom | | Page 235 of 335 | EACTS Info v3 8 21 10 |



| Barbados | 350,000 |
|----------|---------|
| Guyana | 0 |

| Total All Funding Sources: 350,000 | | |
|---------------------------------------|----------------|----------------|
| Applied Pipeline Amount: 150,00 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 350,000 |

| Key Populations: FSW | 50,000 |
|-----------------------------|--|
| Focus Area: | Collection and use of strategic information on SWs |
| | and clients |
| Key Populations: MSM and TG | 50,000 |
| Focus Area: | Collection and use of strategic information |

Budget Code Information

| Mechanism ID: Mechanism Name: Prime Partner Name: | PAHO/PHCO Cooperative AgreementCK000346 Pan American Health Organization (PAHO)/PAHO HIV Caribbean Office | | |
|---|---|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 115,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 235,000 | 0 |



Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 12587 | Mechanism Name: PEPFAR Small Grants Program |
|----------------------------------|--|
| Funding Agency: State/WHA | Procurement Type: Grant |
| Prime Partner Name: US Embassies | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 0 |
| Bahamas | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| St. Vincent and the Grenadines | 0 |

| Total All Funding Sources: 200,000 | | |
|--|-----------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 200,000 | | |
| Managing Country Funding Source | | Funding Amount |
| Bahamas | GHP-State | 30,000 |



| Barbados | GHP-State | 50,000 |
|---------------------|-----------|--------|
| Jamaica | GHP-State | 60,000 |
| Suriname | GHP-State | 30,000 |
| Trinidad and Tobago | GHP-State | 30,000 |

| Key Populations: MSM and TG | 100,000 |
|-----------------------------|---|
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current |
| | PEPFAR technical guidance |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Gender: GBV | 40,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic |

Budget Code Information

| Mechanism ID: | 12587 | | |
|---------------------|---|---------|---|
| Mechanism Name: | PEPFAR Small Grants Program | | |
| Prime Partner Name: | US Embassies | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | |
| Prevention | HVOP | 200,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

Custom 2017-04-11 10:08 EDT



| Mechanism ID: 12588 | Mechanism Name: CARICOM/PANCAP |
|---|--|
| Funding Agency: USAID | Procurement Type: Grant |
| Prime Partner Name: Caribbean Community (CARIC | OM) Pan Caribbean Partnership Against AIDS |
| Agreement Start Date: Redacted Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 0 |
| Bahamas | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| St. Vincent and the Grenadines | 0 |
| Guyana | 0 |

| Total All Funding Sources 200,000 | : | |
|--------------------------------------|------------------------------|----------------|
| Applied Pipeline Amount: | 0 | |
| Total All Funding Sources | and Applied Pipeline Amount: | 200,000 |
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-USAID | 200,000 |

| Gender: GBV | 50,000 |
|-------------|--------|
| | |



| Focus Area: | GBV Prevention |
|-----------------------------|--|
| Sub Area: | Collection and Use of Gender-related Strategic |
| | Information |
| Human Resources for Health | 50,000 |
| Key Populations: FSW | 50,000 |
| Focus Area: | Collection and use of strategic information on SWs |
| | and clients |
| Key Populations: MSM and TG | 50,000 |
| Focus Area: | Collection and use of strategic information |

| Mechanism ID: Mechanism Name: Prime Partner Name: | CARICOM/PANCAP Caribbean Community (CARICOM) Pan Caribbean Partnership Against | | | | |
|---|---|----------------|----------------|--|--|
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | | |
| Care | НВНС | 70,000 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Prevention | HVCT | 30,000 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Prevention | HVOP | 30,000 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Treatment | HTXS | 70,000 | 0 | | |

Implementing Mechanism Indicator Information

(No data provided.)

Custom 2017-04-11 10:08 EDT



Implementing Mechanism Details

| Mechanism ID: 12594 | Mechanism Name: SI Regional Training |
|--------------------------------|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: HRM | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Jamaica | 2,083 |
| Antigua and Barbuda | 2,084 |
| Bahamas | 2,084 |
| Barbados | 2,084 |
| Dominica | 2,084 |
| Grenada | 2,083 |
| Guyana | 2,083 |
| St. Kitts and Nevis | 2,083 |
| St. Lucia | 2,083 |
| St. Vincent and the Grenadines | 2,083 |
| Suriname | 2,083 |
| Trinidad and Tobago | 2,083 |

| Total All Funding Sources: 0 | | |
|---------------------------------|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

Key Populations: FSW

0

Custom



| Focus Area: | Monitoring and evaluation of SW programs |
|-----------------------------|--|
| Key Populations: MSM and TG | 0 |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |

| Mechanism ID: Mechanism Name: Prime Partner Name: | SI Regional Training | | |
|---|----------------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 12606 | Mechanism Name: Barbados MOH CoAg GH000637 |
|----------------------------------|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Barbados MOH | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: Yes | Managing Agency: HHS/CDC |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Barbados | 0 |
| | |



| Applied Pipeline Amount: 199,99 | | |
|---------------------------------|---|----------------|
| Total All Funding Sources and A | | |
| Managing Country Funding Source | | Funding Amount |
| Barbados | 0 | |

(No data provided.)

Budget Code Information

| Mechanism ID: 12606 | | | | | |
|--|---|----------------|----------------|--|--|
| Mechanism Name: Barbados MOH CoAg GH000637 | | | | | |
| Prime Partner Name: | _ | | | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | | |
| Care | HBHC | 0 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Governance and Systems | HLAB | 0 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Governance and Systems | HVSI | 0 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Governance and Systems | OHSS | 0 | 0 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | | |
| Prevention | HVCT | 0 | 0 | | |



Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|----------|------------------|---|--------|
| Barbados | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 500 |
| Barbados | INVS_COMD | Number of HIV Viral Load Reagents purchased | 500 |
| Barbados | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 25,000 |

Implementing Mechanism Details

| Mechanism ID: 12642 | Mechanism Name: Central Laboratory Support | |
|--|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Contract | |
| Prime Partner Name: U.S. Department of Health and Human Services/Centers for Disease Control and | | |
| Prevention (HHS/CDC) | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | | Benefiting Country Planned Amount | |
|--|----------------|-----------------------------------|----------------|
| Jamaica | | 0 | |
| | | | |
| Total All Funding Sources: 0 | | | |
| Applied Pipeline Amount: 0 | | | |
| Total All Funding Sources and Applied Pipeline Amount: 0 | | | |
| Managing Country | Funding Source | | Funding Amount |

GHP-State

Barbados

0

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

| Mechanism ID: Mechanism Name: Prime Partner Name: | Central Laboratory Support U.S. Department of Health and Human Services/Centers for Disease | | |
|---|--|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 12645 | Mechanism Name: Caribbean HIV Grants, Solicitation and Management Project |
|------------------------------------|--|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: World Learning | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Bahamas | 0 |
| Jamaica | 0 |

| Total All Funding Sources: 0 | | |
|------------------------------|-----------------|-----------------------|
| Custom | Page 245 of 335 | FACTS Info v3.8.21.10 |
| 2017-04-11 10:08 EDT | | |



| Applied Pipeline Amount: 0 | | |
|--|---|----------------|
| Total All Funding Sources and Applied Pipeline Amount: 0 | | |
| Managing Country Funding Source | | Funding Amount |
| Jamaica | 0 | |

(No data provided.)

Budget Code Information

| Mechanism ID: | 12645 | | |
|---------------------------|---|----------------|----------------|
| Mechanism Name: | Caribbean HIV Grants, Solicitation and Management Project | | |
| Prime Partner Name: | ame: World Learning | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 12668 | Mechanism Name: Trinidad and Tobago MOH (PS003108) |
|----------------------------------|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Trinidad MoH | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: Yes | Managing Agency: HHS/CDC |



| Total All Funding Sources: 0 | | |
|--|----------------|----------------|
| Applied Pipeline Amount: 199,99 | | |
| Total All Funding Sources and Applied Pipeline Amount: 199,999 | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 12668 | | |
|---------------------------|------------------------------------|----------------|----------------|
| Mechanism Name: | Trinidad and Tobago MOH (PS003108) | | |
| Prime Partner Name: | Trinidad MoH | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------------------|------------------|---|--------|
| Trinidad and Tobago | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 882 |
| Trinidad and Tobago | INVS_COMD | Number of HIV Viral Load Reagents purchased | 882 |
| Trinidad and Tobago | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 30,000 |

Custom 2017-04-11 10:08 EDT



Implementing Mechanism Details

| Mechanism ID: 12688 | Mechanism Name: CARPHA REPDU (formerly CHRC Caribbean Health Research Council | |
|---|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Caribbean Regional Public Health Agency | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Bahamas | 0 |
| Barbados | 0 |
| Jamaica | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |

| Total All Funding Sources: 0 | | |
|--|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 0 | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 12688 Mechanism Name: CARPHA REPDU (formerly CHRC Caribbean Health Research Council Prime Partner Name: Caribbean Regional Public Health Agency



| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
|---------------------------|-------------|----------------|----------------|
| Governance and Systems | HVSI | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 12971 | Mechanism Name: HVOP -Prevention | |
|--------------------------------------|----------------------------------|--|
| Funding Agency: PC | Procurement Type: USG Core | |
| Prime Partner Name: U.S. Peace Corps | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Jamaica | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 0 | |
| Managing Country | Funding Source | Funding Amount |
| Jamaica | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)



| Mechanism ID: | 12971 | | |
|---------------------|--------------------------|----------------|----------------|
| Mechanism Name: | HVOP - Prevention | | |
| Prime Partner Name: | U.S. Peace Corps | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 13319 | Mechanism Name: Health Policy Project | |
|-----------------------------------|---|--|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Futures Group | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| St. Vincent and the Grenadines | 0 |

| Total All Funding Sources: 0 | |
|------------------------------|--|
| Applied Pipeline Amount: 0 | |



| Total All Funding Sources and Applied Pipeline Amount: 0 | | |
|--|-----------|----------------|
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-USAID | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: Mechanism Name: Prime Partner Name: | Health Policy Project | | |
|---|-----------------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 13335 | Mechanism Name: Regional Laboratory Accreditation | | |
|--|--|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | | |
| Prime Partner Name: African Field Epidemiology Network | | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | | |
| TBD: No | New Mechanism: No | | |
| G2G: No | Managing Agency: | | |



| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 0 |
| Bahamas | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| St. Vincent and the Grenadines | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 0 | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 13335 | | | |
|---------------------------|------------------------------------|----------------|----------------|--|
| Mechanism Name: | Regional Laboratory Accreditation | | | |
| Prime Partner Name: | African Field Epidemiology Network | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | HLAB | 0 | 0 | |



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 13534 | Mechanism Name: NASTAD CoAg GH001508 |
|--|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: National Alliance of State and | Territorial AIDS Directors |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Trinidad and Tobago | 250,000 |
| Guyana | 0 |

| Total All Funding Sources: 250,000 | | |
|---------------------------------------|-----------|----------------|
| Applied Pipeline Amount: 100,00 | | |
| Total All Funding Sources and A | | |
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-State | 250,000 |

| Key Populations: FSW | 150,000 |
|----------------------|--|
| Focus Area: | Collection and use of strategic information on SWs |
| | and clients |
| Focus Area: | Conducting epidemiologic, social science, and |
| | operational research among SWs, their partners, |
| | and clients |



| Focus Area: | Monitoring and evaluation of SW programs |
|-----------------------------|--|
| Key Populations: MSM and TG | 100,000 |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |

| | NASTAD CoAg GH001508 | | |
|---------------------------|---|---------|---|
| Strategic Area | National Alliance of State and Territorial AIDS Directors Budget Code Planned Amount On Hold Amount | | |
| Governance and Systems | HVSI | 250,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 13593 | Mechanism Name: Suriname MOH CoAg GH000640 |
|----------------------------------|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: SURINAME MOH | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: Yes | Managing Agency: HHS/CDC |



| Benefiting Country Benefiting Country Planned Amo | |
|---|---|
| Barbados | 1 |
| Total All Funding Sourcess 4 | |

| Total All Funding Sources: 1 | | | | |
|----------------------------------|----------------|----------------|--|--|
| Applied Pipeline Amount: 194,999 | | | | |
| Total All Funding Sources and A | | | | |
| Managing Country | Funding Source | Funding Amount | | |
| Barbados | GHP-State | 1 | | |

| Key Populations: MSM and TG | 1 | |
|-----------------------------|--|--|
| Focus Area: | Collection and use of strategic information | |
| | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners | |
| Focus Area: | Monitoring and evaluation of MSM/TG programs | |

Budget Code Information

| Mechanism Name: | Mechanism ID: 13593 Mechanism Name: Suriname MOH CoAg GH000640 Prime Partner Name: SURINAME MOH | | |
|---------------------------|---|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| Treatment | HTXS | 0 | 0 |
|---------------------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 1 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|----------|------------------|---|--------|
| Suriname | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 288 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 144 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 144 |
| Suriname | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 288 |
| Suriname | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 1,034 |
| Suriname | INVS_COMD | Number of HIV Viral Load Reagents purchased | 1,034 |
| Suriname | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 30,000 |

| Mechanism ID: 16482 | Mechanism Name: PSI Caribbean |
|---|-------------------------------|
| Funding Agency: DOD | Procurement Type: Grant |
| Prime Partner Name: Population Services International | |



| Agreement Start Date: Redacted | Agreement End Date: Redacted |
|--------------------------------|------------------------------|
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Suriname | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|----------------|----------------|
| Applied Pipeline Amount: 400,00 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 16482 | | |
|---------------------|-----------------------------------|----------------|----------------|
| Mechanism Name: | PSI Caribbean | | |
| Prime Partner Name: | Population Services International | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 0 | 0 |

Implementing Mechanism Indicator Information

Custom 2017-04-11 10:08 EDT



| OU | Indicator Number | Label | 2017 |
|----------|------------------|--|-------|
| Suriname | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 805 |
| Suriname | KP_PREV_DSD | Total estimated number of key population in the catchment area | 5,160 |
| Suriname | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 315 |
| Suriname | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 490 |
| Suriname | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 4,000 |
| Suriname | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | 1,160 |
| Suriname | HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 255 |
| Suriname | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ | 95 |



| | PERMISSION ONLY: 15+ Male | |
|-------------|--|---|
| HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 160 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 255 |
| HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 255 |
| HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Male | 10 |
| HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Female | 8 |
| HTC_TST_DSD | Service Delivery Point (Community): Mobile testing | 255 |
| HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 95 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 10 |
| HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 85 |
| HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 95 |
| HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 95 |
| HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Male | 1 |
| HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Female | 4 |
| HTC_TST_TA | Service Delivery Point (Facility): VCT | 95 |
| | HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_DSD HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA HTC_TST_TA | HTC_TST_DSDAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ FemaleHTC_TST_DSDSum of Aggregated Age/Sex 15+HTC_TST_DSDSum of Aggregated Age/Sex disaggregatesHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDTest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_DSDService Delivery Point (Community): Mobile testingHTC_TST_TANumber of individuals who received T&C services for HIV and received their test results during the past 12 monthsHTC_TST_TAAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ MaleHTC_TST_TAAggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ FemaleHTC_TST_TASum of Aggregated Age/Sex 15+HTC_TST_TASum of Aggregated Age/Sex disaggregatesHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ FemaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ MaleHTC_TST_TATest Result by Aggregated Age and Sex: Positive 15+ Female |

| Mechanism ID: 16661 | Mechanism Name: CARPHA support CoAg GH001205 |
|---|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Caribbean Regional Public Hea | alth Agency |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |



| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 3,000 |
| Bahamas | 45,000 |
| Barbados | 45,000 |
| Dominica | 3,000 |
| Grenada | 3,000 |
| Jamaica | 146,000 |
| St. Kitts and Nevis | 3,000 |
| St. Lucia | 3,000 |
| Suriname | 45,500 |
| Trinidad and Tobago | 65,438 |
| St. Vincent and the Grenadines | 5,000 |

| Total All Funding Sources 366,938 | :: | |
|--------------------------------------|------------------------------|----------------|
| Applied Pipeline Amount: | 0 | |
| Total All Funding Sources | and Applied Pipeline Amount: | 366,938 |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 366,938 |

| Gender: Gender Equality | 50,000 |
|----------------------------|--|
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Collection and Use of Gender-related Strategic |
| Focus Area: | Increase gender-equitable access to income and productive resources, including education |
| Sub Area: | Capacity building |
| Human Resources for Health | 50,000 |



| Key Populations: MSM and TG | 25,000 |
|-----------------------------|--|
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |

| | 16661 CARPHA support CoAg GH001205 Caribbean Regional Public Health Agency | | | |
|---------------------------|--|----------------|----------------|--|
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | |
| Governance and Systems | HLAB | 56,680 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | HVSI | 310,258 | 0 | |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 17366 | Mechanism Name: Linkages |
|--------------------------------|---|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: FHI 360 | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | | Benefiting Country Planned Amount | |
|----------------------|---------|-----------------------------------|-----------------------|
| Custom | Page 26 | 1 of 335 | FACTS Info v3.8.21.10 |
| 2017-04-11 10:08 EDT | | | |



| Bahamas | 0 |
|---------------------|---|
| Barbados | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |

| Total All Funding Sources: 1,674,565 | | |
|---|-------------------------|-----------|
| Applied Pipeline Amount: 1,000, | | |
| Total All Funding Sources and A 2,675,100 | pplied Pipeline Amount: | |
| Managing Country | Funding Amount | |
| Barbados | GHP-USAID | 1,674,565 |

| Key Populations: MSM and TG | 360,000 |
|-----------------------------|---|
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Focus Area: | Procurement of condoms, lubricants, and other commodities essential to core HIV services for MSM/TG |
| Key Populations: FSW | 240,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Focus Area: | Training of health workers and community outreach |



| | workers |
|-------------|--|
| | WUIKEIS |
| Focus Area: | Collection and use of strategic information on SWs |
| | and clients |
| Focus Area: | Conducting epidemiologic, social science, and |
| | operational research among SWs, their partners, |
| | and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Focus Area: | Procurement of condoms, lubricants, and other |
| | commodities essential to core HIV services for SWs |
| Gender: GBV | 100,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Collection and Use of Gender-related Strategic |
| | Information |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Post GBV Care |
| Sub Area: | Collection and Use of Gender-related Strategic |
| | Information |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |

| Mechanism ID: Mechanism Name: Prime Partner Name: | Linkages | | |
|---|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 502,370 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and | OHSS | 167,455 | 0 |



| Systems | | | |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 251,185 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 251,185 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 502,370 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------|------------------|--|-------|
| Bahamas | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 1,102 |
| Bahamas | KP_PREV_DSD | Total estimated number of key population in the catchment area | 4,409 |
| Bahamas | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 372 |
| Bahamas | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards | 730 |



| | | required) | |
|----------|-------------|---|-------|
| Bahamas | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 1,489 |
| Bahamas | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | 2,920 |
| Bahamas | HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 882 |
| Bahamas | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 294 |
| Bahamas | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 588 |
| Bahamas | HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 882 |
| Bahamas | HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 882 |
| Bahamas | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Male | 18 |
| Bahamas | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Female | 30 |
| Bahamas | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 48 |
| Bahamas | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 18 |
| Bahamas | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 30 |
| Bahamas | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 48 |
| Suriname | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 540 |



| | | 1 | |
|----------|-------------|--|-------|
| Suriname | KP_PREV_DSD | Total estimated number of key population in the catchment area | 4,100 |
| Suriname | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 280 |
| Suriname | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 260 |
| Suriname | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 2,800 |
| Suriname | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Denominator: Total estimated number of key population in the catchment area) | 1,300 |
| Suriname | HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 432 |
| Suriname | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 224 |
| Suriname | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 208 |
| Suriname | HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 432 |
| Suriname | HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 432 |
| Suriname | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Male | 13 |



| Suriname | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Female | 10 |
|---------------------|-------------|--|--------|
| Suriname | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 23 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 13 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 10 |
| Suriname | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 23 |
| Trinidad and Tobago | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 1,000 |
| Trinidad and Tobago | KP_PREV_DSD | Total estimated number of key population in the catchment area | 17,444 |
| Trinidad and Tobago | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 400 |
| Trinidad and Tobago | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 600 |
| Trinidad and Tobago | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 6,616 |
| Trinidad and Tobago | KP_PREV_DSD | By key population type: Female sex | 10,828 |



| | | | 1 |
|---------------------|------------|--|-----|
| | | workers (FSW) (Denominator: Total | |
| | | estimated number of key population in the | |
| | | catchment area) | |
| | | Number of individuals who received T&C | |
| Trinidad and Tobago | HTC_TST_TA | services for HIV and received their test | 600 |
| | | results during the past 12 months | |
| Trinidad and Tobago | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 360 |
| Trinidad and Tobago | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 240 |
| Trinidad and Tobago | HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 600 |
| Trinidad and Tobago | HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 600 |
| Trinidad and Tobago | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Male | 22 |
| Trinidad and Tobago | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Female | 12 |
| Trinidad and Tobago | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 36 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 23 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 13 |
| Trinidad and Tobago | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 36 |

| Mechanism ID: 17469 | Mechanism Name: Health Finance and Governance |
|------------------------------------|--|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Abt Associates | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |



| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Bahamas | 0 |
| Barbados | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| Guyana | 0 |

| Total All Funding Sources: 675,000 Applied Pipeline Amount: 0 | | |
|---|---------------------------------|----------------|
| Total All Funding Sources and A | pplied Pipeline Amount: 675,000 | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-USAID | 675,000 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 17469 | | |
|---------------------|-------------------------------|----------------|----------------|
| Mechanism Name: | Health Finance and Governance | | |
| Prime Partner Name: | Abt Associates | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and | OHSS | 675,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)



Implementing Mechanism Details

| Mechanism ID: 17760 | Mechanism Name: Linkages |
|--------------------------------|---|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: FHI 360 | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Jamaica | 0 |

| Total All Funding Sources: 845,000 | | |
|---------------------------------------|---------------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 845,000 | |
| Managing Country | Funding Source | Funding Amount |
| Jamaica | GHP-State | 845,000 |

| Key Populations: MSM and TG | 845,000 |
|-----------------------------|---|
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Focus Area: | Procurement of condoms, lubricants, and other |



| commodities essential to core HIV services for |
|--|
| MSM/TG |

| Mechanism ID: Mechanism Name: | Linkages | | |
|----------------------------------|-------------|----------------|----------------|
| Prime Partner Name: | FHI 360 | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 625,000 | (|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 145,000 | (|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 75,000 | (|

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------|------------------|---|------|
| Jamaica | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 176 |
| Jamaica | KP_PREV_DSD | Total estimated number of key population in the catchment area | 564 |
| Jamaica | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations | 176 |



| | | reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | |
|---------|-------------|--|-----|
| Jamaica | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 564 |
| Jamaica | KP_PREV_TA | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 118 |
| Jamaica | KP_PREV_TA | Total estimated number of key population in the catchment area | 376 |
| Jamaica | KP_PREV_TA | By key population type: Men who have sex with men and are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 118 |
| Jamaica | KP_PREV_TA | By key population type: Men who have sex with men and are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 376 |
| Jamaica | HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 142 |
| Jamaica | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 142 |
| Jamaica | HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 142 |
| Jamaica | HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 142 |
| Jamaica | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Male | 22 |



| Jamaica | HTC_TST_DSD | Service Delivery Point (Community): Other | 82 |
|---------|-------------|---|----|
| Jamaica | HTC_TST_TA | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 94 |
| Jamaica | HTC_TST_TA | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 94 |
| Jamaica | HTC_TST_TA | Sum of Aggregated Age/Sex 15+ | 94 |
| Jamaica | HTC_TST_TA | Sum of Aggregated Age/Sex disaggregates | 94 |
| Jamaica | HTC_TST_TA | Test Result by Aggregated Age and Sex: Positive 15+ Male | 14 |
| Jamaica | HTC_TST_TA | Service Delivery Point (Community): Other | 14 |
| Jamaica | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 22 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 22 |
| Jamaica | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 22 |

Implementing Mechanism Details

| Mechanism ID: 17808 | TBD: Yes |
|---------------------|----------|
| REDACTED | |

| Mechanism ID: 17809 | Mechanism Name: Knowledge for Health II | |
|--|---|--|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Johns Hopkins University Center for Communication Programs | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Antigua and Barbuda | 0 |



| Bahamas | 0 |
|--------------------------------|---|
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| St. Vincent and the Grenadines | 0 |
| Guyana | 0 |

| Total All Funding Sources: 350,000 | | |
|---------------------------------------|-------------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources a | nd Applied Pipeline Amount: 3 | 50,000 |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-USAID | 350,000 |

| Gender: GBV | 100,000 |
|-----------------------------|--|
| Focus Area: | GBV Prevention |
| Sub Area: | Collection and Use of Gender-related Strategic Information |
| Focus Area: | Post GBV Care |
| Human Resources for Health | 50,000 |
| Key Populations: FSW | 100,000 |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Key Populations: MSM and TG | 100,000 |
| Focus Area: | Collection and use of strategic information |



| Mechanism ID: 17809 | | | |
|---------------------|-------------------------|--------------------------|----------------|
| | Knowledge for Health II | | |
| Prime Partner Name: | Johns Hopkins Univers | ity Center for Communica | ation Programs |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 122,500 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVCT | 52,500 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 52,500 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 122,500 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 17810 | Mechanism Name: Grant Management Solutions | |
|--|--|--|
| Funding Agency: USAID | Procurement Type: Contract | |
| Prime Partner Name: Management Sciences for Health | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |



| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 0 |
| Bahamas | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Jamaica | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| St. Vincent and the Grenadines | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 0 | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-USAID | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 17810 | | |
|---------------------------|--------------------------------|----------------|----------------|
| Mechanism Name: | Grant Management Solutions | | |
| Prime Partner Name: | Management Sciences for Health | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Approved



Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 17878 | Mechanism Name: Quarterly Consultation Meetings |
|----------------------------------|--|
| Funding Agency: USAID | Procurement Type: USG Core |
| Prime Partner Name: US Embassies | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Bahamas | 0 |
| Barbados | 0 |
| Jamaica | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |

| Total All Funding Sources: 85,010 | | |
|---|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 85,010 | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 85,010 |

| Key Populations: MSM and TG | 34,000 |
|-----------------------------|---|
| Focus Area: | Implementation of core HIV prevention interventions |



| | for MSM/TG that are consistent with the current PEPFAR technical guidance |
|----------------------|--|
| Key Populations: FSW | 20,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Gender: GBV | 20,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Implementation |

| Mechanism ID: | 17878 | | |
|---------------------|---|--------|---|
| Mechanism Name: | Quarterly Consultation Meetings | | |
| Prime Partner Name: | US Embassies | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | |
| Prevention | HVOP | 85,010 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 17902 | Mechanism Name: Health Policy Plus |
|-------------------------------------|------------------------------------|
| Funding Agency: USAID | Procurement Type: Contract |
| Prime Partner Name: Palladium Group | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |



| Benefiting Country | | Benefiting | Country Planned Amount |
|---------------------------------|-------------------|----------------|------------------------|
| Jamaica | | 0 | |
| | [| | |
| Total All Funding Sources: | | | |
| 710,000 | | | |
| Applied Pipeline Amount: 0 | | | |
| Total All Funding Sources and A | pplied Pipeline A | Mount: 710,000 | |
| Managing Country | Funding Source | | Funding Amount |
| Jamaica | GHP-State | | 710,000 |

| Key Populations: MSM and TG | 360,000 |
|-----------------------------|---|
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Conducting epidemiologic, social science, and operational research among MSM/TG and their sex partners |
| Key Populations: FSW | 180,000 |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Conducting epidemiologic, social science, and operational research among SWs, their partners, and clients |

Budget Code Information

| Mechanism ID: | 17902 | | |
|---------------------|--------------------|----------------|----------------|
| Mechanism Name: | Health Policy Plus | | |
| Prime Partner Name: | Palladium Group | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| Care HBHC 710.000 |
|-------------------|
|-------------------|

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 17919 | Mechanism Name: HIV Rapid Testing Quality Improvement Initiative (RTQII) | | |
|---|---|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | | |
| Prime Partner Name: African Society for Laboratory Medicine | | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | | |
| TBD: No | New Mechanism: No | | |
| G2G: No | Managing Agency: | | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Jamaica | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| Antigua and Barbuda | 0 |
| Barbados | 0 |
| Dominica | 0 |
| Grenada | 0 |
| Guyana | 0 |
| St. Kitts and Nevis | 0 |
| St. Lucia | 0 |
| St. Vincent and the Grenadines | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |

Approved



| Barbados | GHP-State | 0 |
|----------|------------|---|
| Baibauus | GITF-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

| Mechanism ID: | 17919 | | | |
|---------------------|--|----------------|----------------|--|
| Mechanism Name: | HIV Rapid Testing Quality Improvement Initiative (RTQII) | | | |
| Prime Partner Name: | Partner Name: African Society for Laboratory Medicine | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| | | | | |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------|------------------|--|------|
| Bahamas | LAB_PT_TA | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Bahamas | LAB_PT_TA | CD4: Number of laboratories that participate in this PT program | 1 |
| Bahamas | LAB_PT_TA | CD4: Number of laboratories that perform this testing | 1 |
| Bahamas | LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Bahamas | LAB_PT_TA | Early infant diagnostics: Number of | 1 |



| [| | | |
|---------|-----------|--|---|
| | | laboratories that participate in this PT program | |
| Bahamas | LAB_PT_TA | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| Bahamas | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 4 |
| Bahamas | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 4 |
| Bahamas | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 4 |
| Bahamas | LAB_PT_TA | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Bahamas | LAB_PT_TA | HIV viral load: Number of laboratories that participate in this PT program | 1 |
| Bahamas | LAB_PT_TA | HIV viral load: Number of laboratories that perform this testing | 1 |
| Bahamas | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Bahamas | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | 1 |
| Bahamas | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | 1 |
| Bahamas | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Bahamas | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT | 0 |



| | | program | |
|----------|-----------|--|---|
| Bahamas | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | 0 |
| Bahamas | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Bahamas | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program | 0 |
| Bahamas | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that perform this testing | 0 |
| Barbados | LAB_PT_TA | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Barbados | LAB_PT_TA | CD4: Number of laboratories that participate in this PT program | 1 |
| Barbados | LAB_PT_TA | CD4: Number of laboratories that perform this testing | 1 |
| Barbados | LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Barbados | LAB_PT_TA | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| Barbados | LAB_PT_TA | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| Barbados | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 5 |
| Barbados | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 5 |



| Barbados | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 5 |
|----------|-----------|---|---|
| Barbados | LAB_PT_TA | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Barbados | LAB_PT_TA | HIV viral load: Number of laboratories that participate in this PT program | 1 |
| Barbados | LAB_PT_TA | HIV viral load: Number of laboratories that perform this testing | 1 |
| Barbados | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Barbados | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | 1 |
| Barbados | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | 1 |
| Barbados | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Barbados | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program | 0 |
| Barbados | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | 0 |
| Barbados | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Barbados | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program | 0 |
| Barbados | LAB_PT_TA | TB diagnostics (Culture/DST): Number of | 0 |

Custom 2017-04-11 10:08 EDT Page 284 of 335

FACTS Info v3.8.21.10



| | | laboratories that perform this testing | |
|---------|-----------|--|----|
| Jamaica | LAB_PT_TA | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 4 |
| Jamaica | LAB_PT_TA | CD4: Number of laboratories that participate in this PT program | 4 |
| Jamaica | LAB_PT_TA | CD4: Number of laboratories that perform this testing | 4 |
| Jamaica | LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Jamaica | LAB_PT_TA | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| Jamaica | LAB_PT_TA | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| Jamaica | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 18 |
| Jamaica | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 18 |
| Jamaica | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 18 |
| Jamaica | LAB_PT_TA | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Jamaica | LAB_PT_TA | HIV viral load: Number of laboratories that participate in this PT program | 1 |
| Jamaica | LAB_PT_TA | HIV viral load: Number of laboratories that perform this testing | 1 |
| Jamaica | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable | 6 |



| | | successful passing criteria in this PT program | |
|----------|-----------|--|---|
| Jamaica | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | 6 |
| Jamaica | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | 6 |
| Jamaica | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Jamaica | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program | 0 |
| Jamaica | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | 0 |
| Jamaica | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Jamaica | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program | 0 |
| Jamaica | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that perform this testing | 0 |
| Suriname | LAB_PT_TA | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Suriname | LAB_PT_TA | CD4: Number of laboratories that participate in this PT program | 1 |
| Suriname | LAB_PT_TA | CD4: Number of laboratories that perform this testing | 1 |
| Suriname | LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT | 1 |



| | | program | |
|----------|-----------|--|---|
| Suriname | LAB_PT_TA | program Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| Suriname | LAB_PT_TA | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| Suriname | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 8 |
| Suriname | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program | 8 |
| Suriname | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 8 |
| Suriname | LAB_PT_TA | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Suriname | LAB_PT_TA | HIV viral load: Number of laboratories that participate in this PT program | 1 |
| Suriname | LAB_PT_TA | HIV viral load: Number of laboratories that perform this testing | 1 |
| Suriname | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 3 |
| Suriname | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | 3 |
| Suriname | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | 3 |
| Suriname | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |



| Suriname | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program | 0 |
|---------------------|-----------|--|---|
| Suriname | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | 0 |
| Suriname | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Suriname | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT program | 0 |
| Suriname | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that perform this testing | 0 |
| Trinidad and Tobago | LAB_PT_TA | CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 4 |
| Trinidad and Tobago | LAB_PT_TA | CD4: Number of laboratories that participate in this PT program | 4 |
| Trinidad and Tobago | LAB_PT_TA | CD4: Number of laboratories that perform this testing | 4 |
| Trinidad and Tobago | LAB_PT_TA | Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Trinidad and Tobago | LAB_PT_TA | Early infant diagnostics: Number of laboratories that participate in this PT program | 1 |
| Trinidad and Tobago | LAB_PT_TA | Early infant diagnostics: Number of laboratories that perform this testing | 1 |
| Trinidad and Tobago | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 9 |
| Trinidad and Tobago | LAB_PT_TA | HIV serologic/diagnostic testing: Number of | 9 |

Custom 2017-04-11 10:08 EDT Page 288 of 335

FACTS Info v3.8.21.10



| | | laboratories that participate in this PT | |
|---------------------|-----------|---|---|
| | | program | |
| Trinidad and Tobago | LAB_PT_TA | HIV serologic/diagnostic testing: Number of laboratories that perform this testing | 9 |
| Trinidad and Tobago | LAB_PT_TA | HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program | 1 |
| Trinidad and Tobago | LAB_PT_TA | HIV viral load: Number of laboratories that participate in this PT program | 1 |
| Trinidad and Tobago | LAB_PT_TA | HIV viral load: Number of laboratories that perform this testing | 1 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 6 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program | 6 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (AFB microscopy): Number of laboratories that perform this testing | 6 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that participate in this PT program | 0 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing | 0 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that achieve acceptable successful passing criteria in this PT program | 0 |
| Trinidad and Tobago | LAB_PT_TA | TB diagnostics (Culture/DST): Number of laboratories that participate in this PT | 0 |



| | | program | |
|---------------------|-----------|---|---|
| Trinidad and Tabaga | | TB diagnostics (Culture/DST): Number of | 0 |
| Trinidad and Tobago | LAB_PT_TA | laboratories that perform this testing | 0 |

Implementing Mechanism Details

| Mechanism ID: 17921 | Mechanism Name: International AIDS Education and Training Center | | |
|--|--|--|--|
| Funding Agency: HHS/HRSA | Procurement Type: Cooperative Agreement | | |
| Prime Partner Name: University of Washington | | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | | |
| TBD: No | New Mechanism: No | | |
| G2G: No | Managing Agency: | | |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Barbados | 0 |
| Jamaica | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |

| Total All Funding Sources: 2,008,000 | | |
|---|----------------|-----------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources ar 2,008,000 | | |
| Managing Country | Funding Amount | |
| Barbados | GHP-State | 2,008,000 |

Cross-Cutting Budget Attribution(s)

| Human Resources for Health 50,065 |
|-----------------------------------|
|-----------------------------------|



Budget Code Information

| Mechanism ID: Mechanism Name: Prime Partner Name: | International AIDS Education and Training Center | | | |
|---|--|----------------|----------------|--|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Care | HBHC | 288,000 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | OHSS | 50,065 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Treatment | HTXS | 1,669,935 | 0 | |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|----------|------------------|--|-------|
| Barbados | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 1,578 |
| Barbados | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 899 |
| Barbados | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 679 |
| Barbados | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 1,578 |
| Barbados | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 1,578 |
| Barbados | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 38 |
| Barbados | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 22 |
| Barbados | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 16 |
| Barbados | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 38 |

Custom 2017-04-11 10:08 EDT



| Barbados | TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 1,262 |
|----------|------------|--|--------|
| Barbados | TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,578 |
| Barbados | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Male | 719 |
| Barbados | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Female | 543 |
| Barbados | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Male | 899 |
| Barbados | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Female | 679 |
| Jamaica | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 12,728 |
| Jamaica | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 6,109 |
| Jamaica | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 6,619 |
| Jamaica | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 12,728 |
| Jamaica | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 12,728 |
| Jamaica | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 3,337 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 1,619 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 1,718 |
| Jamaica | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 3,337 |
| Jamaica | TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting | 10,181 |



| | | laboratory results within the past 12 | |
|----------|------------|--|--------|
| | | months. | |
| Jamaica | TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 12,728 |
| Jamaica | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Male | 4,886 |
| Jamaica | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Female | 5,295 |
| Jamaica | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Male | 6,109 |
| Jamaica | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Female | 6,619 |
| Jamaica | HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 6 |
| Suriname | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 464 |
| Suriname | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 231 |
| Suriname | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 233 |
| Suriname | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 464 |
| Suriname | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 464 |
| Suriname | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 55 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 27 |
| Suriname | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 28 |
| Suriname | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 55 |
| Suriname | TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the | 325 |



| Гг | | | |
|---------------------|------------|--|-------|
| | | medical records and /or supporting laboratory results within the past 12 months. | |
| Suriname | TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 464 |
| Suriname | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Male | 162 |
| Suriname | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Female | 163 |
| Suriname | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Male | 231 |
| Suriname | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Female | 233 |
| Suriname | HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 2 |
| Trinidad and Tobago | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 1,291 |
| Trinidad and Tobago | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 645 |
| Trinidad and Tobago | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 646 |
| Trinidad and Tobago | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 1,291 |
| Trinidad and Tobago | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 1,291 |
| Trinidad and Tobago | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 133 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 66 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 67 |
| Trinidad and Tobago | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 133 |
| Trinidad and Tobago | TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results | 1,162 |



| | | (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | |
|---------------------|------------|--|-------|
| Trinidad and Tobago | TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,291 |
| Trinidad and Tobago | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Male | 581 |
| Trinidad and Tobago | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Female | 581 |
| Trinidad and Tobago | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Male | 645 |
| Trinidad and Tobago | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Female | 646 |
| Trinidad and Tobago | HRH_PRE | Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre | 4 |

| Mechanism ID: 18183 | Mechanism Name: The Partnership for Supply Chain Management | |
|---|--|--|
| Funding Agency: USAID | Procurement Type: Contract | |
| Prime Partner Name: Partnership for Supply Chain Management | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Bahamas | 0 |
| Barbados | 0 |



| Guyana | 0 |
|---------------------|---|
| Suriname | 0 |
| Trinidad and Tobago | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 0 | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-USAID | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: Mechanism Name: | 18183 The Partnership for Sup | oply Chain Management | |
|----------------------------------|---|-----------------------|----------------|
| Prime Partner Name: | Partnership for Supply Chain Management | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 18184 | Mechanism Name: DoD Mech Guyana | |
|--|---------------------------------|--|
| Funding Agency: DOD | Procurement Type: USG Core | |
| Prime Partner Name: U.S. Department of Defense (Defense) | | |



| Agreement Start Date: Redacted | Agreement End Date: Redacted |
|--------------------------------|------------------------------|
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Guyana | 0 |

| Total All Funding Sources: 0 | | |
|---|----------------|----------------|
| Applied Pipeline Amount: 33,000 | | |
| Total All Funding Sources and Applied Pipeline Amount: 33,000 | | |
| Managing Country | Funding Source | Funding Amount |
| Guyana | GHP-State | 0 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 18184 | | |
|---------------------------|--------------------------------------|----------------|----------------|
| Mechanism Name: | DoD Mech Guyana | | |
| Prime Partner Name: | U.S. Department of Defense (Defense) | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |

Approved



| Prevention HVOP 0 |
|-------------------|
|-------------------|

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 18185 | Mechanism Name: Positively United to Support Humanity | |
|--|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Davis Memorial Hospital and Clinic | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Guyana | 0 |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | pplied Pipeline Amount: 0 | |
| Managing Country Funding Source | | Funding Amount |
| Guyana | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

Mechanism ID: 18185



| Mechanism Name: Prime Partner Name: | | | | |
|--|-------------|----------------|----------------|--|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Care | HBHC | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Care | PDCS | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | HVSI | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | OHSS | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Prevention | HVCT | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Prevention | HVOP | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Prevention | MTCT | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Treatment | HTXS | 0 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Treatment | PDTX | 0 | 0 | |

Implementing Mechanism Indicator Information

Custom 2017-04-11 10:08 EDT



| OU | Indicator Number | Label | 2017 |
|--------|---------------------|---|-------|
| Guyana | HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 1,955 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 71 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 745 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 67 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 1,072 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 138 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 1,817 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 1,955 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive <15 Male | 3 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Male | 38 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive <15 Female | 3 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Female | 34 |
| Guyana | HTC_TST_DSD | Service Delivery Point (Facility): Other PITC | 1,655 |
| Guyana | HTC_TST_DSD | Service Delivery Point (Facility): Index testing | 300 |
| Guyana | TB_SCREENDX_DS D | The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period. | 1,718 |
| Guyana | TB_SCREENDX_DS D | Screened for TB by Age/Sex:<15 Male | 9 |
| Guyana | TB_SCREENDX_DS D | Screened for TB by Age/Sex: 15+ Male | 644 |
| Guyana | TB_SCREENDX_DS | Screened for TB by Age/Sex:<15 Female | 35 |

Custom 2017-04-11 10:08 EDT Page 300 of 335

FACTS Info v3.8.21.10



| | D | | |
|--------|---------------------|---|-------|
| Guyana | TB_SCREENDX_DS D | Screened for TB by Age/Sex: 15+ Female | 1,030 |
| Guyana | TB_SCREENDX_DS D | Screen Result: Screened Positive for TB | 35 |
| Guyana | TB_SCREENDX_DS D | [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB | 35 |
| Guyana | TB_SCREENDX_DS D | [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only | 27 |
| Guyana | TB_SCREENDX_DS D | [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay | 8 |
| Guyana | PMTCT_EID_TA | By infants who received a virologic test within 2 months of birth | 38 |
| Guyana | PMTCT_EID_TA | By infants who received their first virologic HIV test between 2 and 12 months of age | 2 |
| Guyana | PMTCT_EID_TA | Sum of Infant Age disaggregates | 40 |
| Guyana | PMTCT_EID_TA | Number of infants with a positive virological test result within 2 months of birth | 0 |
| Guyana | PMTCT_EID_TA | Number of infants with a positive virological test result within 12 months of birth | 0 |
| Guyana | TX_CURR_DSD | Number of adults and children receiving antiretroviral therapy (ART) | 1,718 |
| Guyana | TX_CURR_DSD | Aggregated Age/Sex: <15 Male | 9 |
| Guyana | TX_CURR_DSD | Aggregated Age/Sex: 15+ Male | 644 |
| Guyana | TX_CURR_DSD | Aggregated Age/Sex: <15 Female | 35 |
| Guyana | TX_CURR_DSD | Aggregated Age/Sex: 15+ Female | 1,030 |
| Guyana | TX_CURR_DSD | Sum of Aggregated Age/Sex <15 | 44 |
| Guyana | TX_CURR_DSD | Sum of Aggregated Age/Sex 15+ | 1,674 |
| Guyana | TX_CURR_DSD | Sum of Aggregated Age/Sex disaggregates | 1,718 |
| Guyana | TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 322 |
| Guyana | TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Male | 2 |

Custom 2017-04-11 10:08 EDT



| Guyana | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 147 |
|--------|-------------|--|-------|
| Guyana | TX_NEW_DSD | Aggregated Grouping by Age/Sex: <15 Female | 2 |
| Guyana | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 171 |
| Guyana | TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 322 |
| Guyana | TX_PVLS_DSD | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 1,160 |
| Guyana | TX_PVLS_DSD | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,546 |
| Guyana | TX_PVLS_DSD | Numerator: Indication: Routine | 1,160 |
| Guyana | TX_PVLS_DSD | Denominator: Indication: Routine | 1,546 |
| Guyana | TX_PVLS_DSD | Numerator Aggregated Age/Sex: <15 Male | 29 |
| Guyana | TX_PVLS_DSD | Numerator Aggregated Age/Sex: 15+ Male | 543 |
| Guyana | TX_PVLS_DSD | Numerator Aggregated Age/Sex: <15 Female | 29 |
| Guyana | TX_PVLS_DSD | Numerator Aggregated Age/Sex: 15+ Female | 559 |
| Guyana | TX_PVLS_DSD | Denominator Aggregated Age/Sex: <15 Male | 38 |
| Guyana | TX_PVLS_DSD | Denominator Aggregated Age/Sex: 15+ Male | 715 |
| Guyana | TX_PVLS_DSD | Denominator Aggregated Age/Sex: <15 Female | 40 |
| Guyana | TX_PVLS_DSD | Denominator Aggregated Age/Sex: 15+ Female | 753 |
| Guyana | TX_RET_DSD | Number of adults and children who are still | 151 |



| | | | 1 |
|--------|------------|---|-----|
| | | alive and on treatment at 12 months after initiating ART | |
| Guyana | TX_RET_DSD | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up | 178 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 7 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 64 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 8 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 72 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 8 |
| Guyana | TX_RET_DSD | Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those | 76 |



| | | lost to follow-up) | |
|--------|------------|---|----|
| | | Aggregated Age/Sex: <15 Female | |
| | | (Denominator: Total number of adults and | |
| | | children who initiated ART in the 12 months | |
| Guyana | TX_RET_DSD | prior to the beginning of the reporting | 10 |
| | | period, including those who have died, | |
| | | those who have stopped ART, and those | |
| | | lost to follow-up) | |
| | | Aggregated Age/Sex: 15+ Female | |
| | | (Denominator: Total number of adults and | |
| | | children who initiated ART in the 12 months | |
| Guyana | TX_RET_DSD | prior to the beginning of the reporting | 84 |
| | | period, including those who have died, | |
| | | those who have stopped ART, and those | |
| | | lost to follow-up) | |

| Mechanism ID: 18186 | Mechanism Name: Peace Corps |
|--------------------------------------|------------------------------|
| Funding Agency: PC | Procurement Type: USG Core |
| Prime Partner Name: U.S. Peace Corps | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Guyana | 0 |

| Total All Funding Sources: 0 | | |
|---|-----------|----------------|
| Applied Pipeline Amount: 39,000 | | |
| Total All Funding Sources and Applied Pipeline Amount: 39,000 | | |
| Managing Country Funding Source | | Funding Amount |
| Guyana | GHP-State | 0 |

Approved



Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

| saaget eeae mierm | | | |
|---------------------------|------------------|----------------|----------------|
| Mechanism ID: | 18186 | | |
| Mechanism Name: | Peace Corps | | |
| Prime Partner Name: | U.S. Peace Corps | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Prevention | HVOP | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 18187 | Mechanism Name: Advancing Partners and Communities Project |
|---|---|
| Funding Agency: USAID | Procurement Type: Cooperative Agreement |
| Prime Partner Name: John Snow Inc (JSI) | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: No |
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| | |



| Guyana | 0 | |
|--|--------------------------|----------------|
| Total All Funding Sources: 1,000,000 | | |
| Applied Pipeline Amount: 300,0 | 00 | |
| Total All Funding Sources and A 1,300,000 | Applied Pipeline Amount: | |
| Managing Country | Funding Source | Funding Amount |
| Guyana | GHP-USAID | 1,000,000 |

| Croco Cutting Budget / turibution | |
|-----------------------------------|---|
| Key Populations: MSM and TG | 160,000 |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Implementation of core HIV prevention interventions for MSM/TG that are consistent with the current PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Key Populations: FSW | 130,000 |
| Focus Area: | Implementation of core HIV prevention interventions for SWs consistent with PEPFAR guidance on sexual prevention |
| Focus Area: | Training of health workers and community outreach workers |
| Focus Area: | Collection and use of strategic information on SWs and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Gender: GBV | 50,000 |
| Focus Area: | GBV Prevention |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| | |



| Sub Area: | Monitoring and Evaluation |
|-------------------------|---|
| Gender: Gender Equality | 50,000 |
| Focus Area: | Changing harmful gender norms and promoting positive gender norms |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |
| Focus Area: | Equity in HIV prevention, care, treatment and support |
| Sub Area: | Implementation |
| Sub Area: | Capacity building |
| Sub Area: | Monitoring and Evaluation |

Budget Code Information

| Mechanism ID: | 18187 | | | |
|---------------------------|--|----------------|----------------|--|
| Mechanism Name: | Mechanism Name: Advancing Partners and Communities Project | | | |
| Prime Partner Name: | John Snow Inc (JSI) | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Care | HBHC | 405,080 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Care | HKID | 97,193 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | OHSS | 100,000 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Prevention | HVCT | 152,449 | 0 | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |



| Prevention | HVOP | 71,673 | 0 |
|----------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 173,605 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|--------|------------------|--|-------|
| Guyana | KP_PREV_DSD | Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required | 2,652 |
| Guyana | KP_PREV_DSD | Total estimated number of key population in the catchment area | 3,658 |
| Guyana | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,286 |
| Guyana | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Numerator: Number of key populations reached with individual and/or small group level HIV preventive interventions that are based on evidence and/or meet the minimum standards required) | 1,366 |
| Guyana | KP_PREV_DSD | By key population type: Men who have sex with men who are NOT sex workers (Denominator: Total estimated number of key population in the catchment area) | 1,837 |



| Guyana | KP_PREV_DSD | By key population type: Female sex workers (FSW) (Denominator: Total | 1,821 |
|--------|--------------|---|-------|
| | | estimated number of key population in the catchment area) | |
| Guyana | HTC_TST_DSD | Number of individuals who received T&C services for HIV and received their test results during the past 12 months | 2,652 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male | 12 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male | 1,274 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female | 6 |
| Guyana | HTC_TST_DSD | Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female | 1,360 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex <15 | 18 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex 15+ | 2,634 |
| Guyana | HTC_TST_DSD | Sum of Aggregated Age/Sex disaggregates | 2,652 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive <15 Male | 3 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Male | 61 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive <15 Female | 1 |
| Guyana | HTC_TST_DSD | Test Result by Aggregated Age and Sex: Positive 15+ Female | 67 |
| Guyana | HTC_TST_DSD | Service Delivery Point (Community): Index testing | 150 |
| Guyana | HTC_TST_DSD | Service Delivery Point (Community): Mobile testing | 1,739 |
| Guyana | HTC_TST_DSD | Service Delivery Point (Community): Other | 763 |
| Guyana | OVC_SERV_DSD | Number of active beneficiaries served by PEPFAR OVC programs for children and families affected by HIV/AIDS | 162 |



| Guyana | OVC_SERV_DSD | Age/Sex: 18+ Male | 52 |
|--------|--------------|-----------------------------------|-----|
| Guyana | OVC_SERV_DSD | Age/Sex: 18+ Female | 83 |
| Guyana | OVC_SERV_DSD | Sum of Age/Sex disaggregates | 135 |
| Guyana | OVC_SERV_DSD | By Aggregated Age/Sex: <18 Male | 12 |
| Guyana | OVC_SERV_DSD | By Aggregated Age/Sex: <18 Female | 15 |

Implementing Mechanism Details

| Mechanism ID: 18188 | Mechanism Name: CARPHA Guyana CoAg GH001642 | |
|---|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Caribbean Regional Public Health Agency | | |
| reement Start Date: Redacted Agreement End Date: Redacted | | |
| TBD: No | New Mechanism: No | |
| G2G: No | Managing Agency: | |

| Total All Funding Sources: 0 | | |
|--|----------------|----------------|
| Applied Pipeline Amount: 250,00 | | |
| Total All Funding Sources and Applied Pipeline Amount: 250,000 | | |
| Managing Country | Funding Source | Funding Amount |
| Guyana | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

| Mechanism ID: | 18188 | | |
|---------------------|---|----------------|----------------|
| Mechanism Name: | CARPHA Guyana CoAg GH001642 | | |
| Prime Partner Name: | Caribbean Regional Public Health Agency | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |

Approved



| Governance and Systems | HLAB | 0 | 0 |
|---------------------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 18189 | TBD: Yes | |
|---------------------|----------|--|
| REDACTED | | |

Implementing Mechanism Details

| Mechanism ID: 18190 | Mechanism Name: Ministry of Health, Guyana CoAg GH001632 | |
|--|---|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Ministry of Health, Guyana | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: No | |
| G2G: Yes | Managing Agency: HHS/CDC | |

| Total All Funding Sources: 0 | | |
|---------------------------------|---------------------------------|----------------|
| Applied Pipeline Amount: 500,00 | 0 | |
| Total All Funding Sources and A | pplied Pipeline Amount: 500,000 | |
| Managing Country | Funding Source | Funding Amount |
| Guyana | GHP-State | 0 |

Cross-Cutting Budget Attribution(s)



(No data provided.)

Budget Code Information

| Mechanism ID: Mechanism Name: Prime Partner Name: | Ministry of Health, Guyana CoAg GH001632 | | |
|---|--|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | НВНС | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | PDCS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | PDTX | 0 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|--------|------------------|---------------------------------------|-------|
| Guyana | TB_SCREENDX_TA | The number of PLHIV who were screened | 1,861 |



| | | for TB symptoms at the last clinical visit at a | |
|--------|----------------|--|-------|
| | | HIV facility during the reporting period. | |
| Guyana | TB_SCREENDX_TA | Screened for TB by Age/Sex: <15 Male | 100 |
| Guyana | TB_SCREENDX_TA | Screened for TB by Age/Sex: 15+ Male | 837 |
| Guyana | TB_SCREENDX_TA | Screened for TB by Age/Sex: <15 Female | 94 |
| Guyana | TB_SCREENDX_TA | Screened for TB by Age/Sex: 15+ Female | 830 |
| Guyana | TB_SCREENDX_TA | Screen Results: Screened Positive for TB | 38 |
| Guyana | TB_SCREENDX_TA | [Sub-Disagg of Screen Results] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB | 38 |
| Guyana | TB_SCREENDX_TA | [Sub-disagg of Specimen Sent] Diagnostic Test: Smear Only | 29 |
| Guyana | TB_SCREENDX_TA | [Sub-disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay | 9 |
| Guyana | TX_CURR_TA | Number of adults and children receiving antiretroviral therapy (ART) | 1,861 |
| Guyana | TX_CURR_TA | Aggregated Age/Sex: <15 Male | 94 |
| Guyana | TX_CURR_TA | Aggregated Age/Sex: 15+ Male | 830 |
| Guyana | TX_CURR_TA | Aggregated Age/Sex: <15 Female | 100 |
| Guyana | TX_CURR_TA | Aggregated Age/Sex: 15+ Female | 837 |
| Guyana | TX_CURR_TA | Sum of Aggregated Age/Sex <15 | 194 |
| Guyana | TX_CURR_TA | Sum of Aggregated Age/Sex 15+ | 1,667 |
| Guyana | TX_CURR_TA | Sum of Aggregated Age/Sex disaggregates | 1,861 |
| Guyana | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 349 |
| Guyana | TX_NEW_TA | Aggregated Grouping by Age/Sex: <15 Male | 2 |
| Guyana | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 163 |
| Guyana | TX_NEW_TA | Aggregated Grouping by Age/Sex: <15 Female | 2 |
| Guyana | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 182 |



| Guyana | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 349 |
|--------|------------|--|-------|
| Guyana | TX_PVLS_TA | Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months. | 1,256 |
| Guyana | TX_PVLS_TA | Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months. | 1,675 |
| Guyana | TX_PVLS_TA | Numerator: Indication: Routine | 1,256 |
| Guyana | TX_PVLS_TA | Denominator: Indication: Routine | 1,675 |
| Guyana | TX_PVLS_TA | Numerator Aggregated Age/Sex: <15 Male | 51 |
| Guyana | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Male | 549 |
| Guyana | TX_PVLS_TA | Numerator Aggregated Age/Sex: <15 Female | 73 |
| Guyana | TX_PVLS_TA | Numerator Aggregated Age/Sex: 15+ Female | 583 |
| Guyana | TX_PVLS_TA | Denominator Aggregated Age/Sex: <15 Male | 77 |
| Guyana | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Male | 745 |
| Guyana | TX_PVLS_TA | Denominator Aggregated Age/Sex: <15 Female | 91 |
| Guyana | TX_PVLS_TA | Denominator Aggregated Age/Sex: 15+ Female | 762 |
| Guyana | TX_RET_TA | Number of adults and children who are still alive and on treatment at 12 months after initiating ART | 200 |
| Guyana | TX_RET_TA | Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have | 227 |



| | | stopped ART, and those lost to follow-up | |
|--------|-----------|---|----|
| Guyana | TX_RET_TA | Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 10 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 86 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 10 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) | 94 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 9 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 95 |
| Guyana | TX_RET_TA | Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, | 14 |



| | | those who have stopped ART, and those lost to follow-up) | |
|--------|-----------|---|-----|
| Guyana | TX_RET_TA | Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) | 109 |

Implementing Mechanism Details

| Mechanism ID: 18392 | Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637) | |
|----------------------------------|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | |
| Prime Partner Name: Barbados MOH | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: Yes | |
| G2G: Yes | Managing Agency: HHS/CDC | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Barbados | 1 |

| Total All Funding Sources: 1 | | |
|---------------------------------|-----------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-State | 1 |

Cross-Cutting Budget Attribution(s)

(No data provided.)



Budget Code Information

| Mechanism ID: 18392 Mechanism Name: Barbados MOH FOA GH16-1610 (Follow-on to CoAg GH000637) Prime Partner Name: Barbados MOH | | | |
|--|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 1 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 0 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|----------|------------------|--|------|
| Barbados | TX_NEW_DSD | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 164 |
| Barbados | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Male | 82 |
| Barbados | TX_NEW_DSD | Aggregated Grouping by Age/Sex: 15+ Female | 82 |



| Barbados | TX_NEW_DSD | Sum of Aggregated Age/Sex disaggregates | 164 |
|----------|------------|--|-----|
| Barbados | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 120 |
| Barbados | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 60 |
| Barbados | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 60 |
| Barbados | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 120 |

Implementing Mechanism Details

| Mechanism ID: 18393 | Mechanism Name: Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934) |
|---------------------------------|---|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Bahamas MoH | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted |
| TBD: No | New Mechanism: Yes |
| G2G: Yes | Managing Agency: HHS/CDC |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Bahamas | 270,000 |

| Total All Funding Sources: 270,000 | | |
|--|-----------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 270,000 | | |
| Managing Country Funding Source | | Funding Amount |
| Barbados | GHP-State | 270,000 |

Cross-Cutting Budget Attribution(s)

| Key Populations: MSM and TG | 80,000 |
|-----------------------------|---|
| Focus Area: | Training of health workers and community outreach |
| | workers |



| Focus Area: | Implementation of core HIV prevention interventions |
|----------------------|---|
| | for MSM/TG that are consistent with the current |
| | PEPFAR technical guidance |
| Focus Area: | Collection and use of strategic information |
| Focus Area: | Conducting epidemiologic, social science, and |
| | operational research among MSM/TG and their sex |
| | partners |
| Focus Area: | Monitoring and evaluation of MSM/TG programs |
| Focus Area: | Procurement of condoms, lubricants, and other |
| | commodities essential to core HIV services for |
| | MSM/TG |
| Key Populations: FSW | 80,000 |
| Focus Area: | Implementation of core HIV prevention interventions |
| | for SWs consistent with PEPFAR guidance on |
| | sexual prevention |
| Focus Area: | Training of health workers and community outreach |
| | workers |
| Focus Area: | Collection and use of strategic information on SWs |
| | and clients |
| Focus Area: | Conducting epidemiologic, social science, and |
| | operational research among SWs, their partners, |
| | and clients |
| Focus Area: | Monitoring and evaluation of SW programs |
| Focus Area: | Procurement of condoms, lubricants, and other |
| | commodities essential to core HIV services for SWs |

Budget Code Information

| Mechanism ID: | 18393 | | | |
|---------------------|--|--|--|--|
| Mechanism Name: | Bahamas MOH FOA GH16-1609 (Follow-on to CoAg PS002934) | | | |
| Prime Partner Name: | Bahamas MoH | | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | |



| Care | НВНС | 37,500 | 0 |
|---------------------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 50,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HVSI | 80,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 50,000 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 52,500 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------|------------------|--|------|
| Bahamas | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 192 |
| Bahamas | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 96 |
| Bahamas | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 96 |
| Bahamas | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 192 |

| Mechanism ID: 18394 | Mechanism Name: Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108) | | |
|----------------------------------|---|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | | |
| Prime Partner Name: Trinidad MoH | | | |



| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
|--------------------------------|------------------------------|--|
| TBD: No | New Mechanism: Yes | |
| G2G: Yes | Managing Agency: HHS/CDC | |

| Benefiting Country | Benefiting Country Planned Amount | |
|---------------------|-----------------------------------|--|
| Trinidad and Tobago | 1 | |

| Total All Funding Sources: 1 | | |
|---------------------------------|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 1 |

(No data provided.)

Budget Code Information

| Mechanism ID: Mechanism Name: | Trinidad and Tobago MOH FOA GH16-1608 (follow up to CoAg PS003108) | | |
|----------------------------------|---|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | НВНС | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 1 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |



| Governance and Systems | HVSI | 0 | 0 |
|---------------------------|-------------|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 0 | 0 |

Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------------------|------------------|--|------|
| Trinidad and Tobago | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 555 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Male | 285 |
| Trinidad and Tobago | TX_NEW_TA | Aggregated Grouping by Age/Sex: 15+ Female | 270 |
| Trinidad and Tobago | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 555 |

| Mechanism ID: 18395 | Mechanism Name: CDC Prevention FOA GH16-1607 | |
|--------------------------------|---|--|
| Funding Agency: HHS/CDC | Procurement Type: Umbrella Agreement | |
| Prime Partner Name: TBD | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No | New Mechanism: Yes | |
| G2G: No | Managing Agency: | |

| | Benefiting Country | | Benefiting Country | Planned Amount |
|--------|--------------------|---------|--------------------|-----------------------|
| Custom | | Page 32 | 2 of 335 | FACTS Info v3.8.21.10 |



| Bahamas | 1 |
|---------------------|---|
| Barbados | 0 |
| Jamaica | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |
| Guyana | 0 |

| Total All Funding Sources: 1 | | |
|---------------------------------|----------------|---|
| Applied Pipeline Amount: 596,69 | | |
| Total All Funding Sources and A | | |
| Managing Country | Funding Amount | |
| Barbados | GHP-State | 1 |

(No data provided.)

Budget Code Information

| | 18395 CDC Prevention FOA GH16-1607 | | |
|---------------------------------------|---------------------------------------|----------------|----------------|
| Prime Partner Name: Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Care | HBHC | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | OHSS | 0 | 0 |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Treatment | HTXS | 1 | 0 |



Implementing Mechanism Indicator Information

| OU | Indicator Number | Label | 2017 |
|---------------------|------------------|---|--------|
| Jamaica | TX_NEW_TA | Number of adults and children newly enrolled on antiretroviral therapy (ART) | 108 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: <15 Male | 80 |
| Jamaica | TX_NEW_TA | Aggregated Grouping by Age/Sex: <15 Female | 26 |
| Jamaica | TX_NEW_TA | Sum of Aggregated Age/Sex disaggregates | 106 |
| Jamaica | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 1,724 |
| Jamaica | INVS_COMD | Number of HIV Viral Load Reagents purchased | 1,724 |
| Jamaica | INVS_COMD | HIV Viral Load: Dollars planned (COP)/ spent (Actual) | 50,000 |
| Trinidad and Tobago | INVS_COMD | PEPFAR resources used for HIV-program related commodities: planned & purchased in the last 12 months by Implementing Partner | 882 |
| Trinidad and Tobago | INVS_COMD | Number of HIV Viral Load Reagents purchased | 882 |
| Trinidad and Tobago | INVS_COMD | HIV CD4 Tests: Dollars planned (COP)/ spent (Actual) | 30,000 |

| Mechanism ID: 18396 | Mechanism Name: CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688) |
|---|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement |
| Prime Partner Name: Caribbean Regional Public Health Agency | |
| Agreement Start Date: Redacted Agreement End Date: Redacted | |



| TBD: No | New Mechanism: Yes |
|---------|--------------------|
| G2G: No | Managing Agency: |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 4,000 |
| Bahamas | 25,000 |
| Barbados | 25,000 |
| Dominica | 4,000 |
| Grenada | 4,000 |
| Jamaica | 170,000 |
| St. Kitts and Nevis | 4,000 |
| St. Lucia | 4,000 |
| St. Vincent and the Grenadines | 4,000 |
| Suriname | 25,000 |
| Trinidad and Tobago | 100,000 |

| Total All Funding Sources: 369,000 | | |
|--|----------------|----------------|
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 369,000 | | |
| Managing Country | Funding Source | Funding Amount |
| Barbados | GHP-State | 369,000 |

| Key Populations: FSW | 100,000 | |
|-----------------------------|--|--|
| Focus Area: | Collection and use of strategic information on SWs and clients | |
| Focus Area: | Monitoring and evaluation of SW programs | |
| Key Populations: MSM and TG | 100,000 | |
| Focus Area: | Collection and use of strategic information | |
| Focus Area: | Monitoring and evaluation of MSM/TG programs | |



Budget Code Information

| Mechanism ID: | 18396 | | | |
|---------------------------|---|---------|---|--|
| Mechanism Name: | CARPHA REPDU FOA GH16-1611 (Follow-on to CoAg GH000688) | | | |
| Prime Partner Name: | Caribbean Regional Public Health Agency | | | |
| Strategic Area | Budget Code Planned Amount On Hold Amount | | | |
| Governance and Systems | HVSI | 369,000 | 0 | |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 18398 | Mechanism Name: GDATA | |
|---|------------------------------|--|
| Funding Agency: HHS/CDC Procurement Type: Contract | | |
| Prime Partner Name: Global Data Analysis and Technical Assistance | | |
| Agreement Start Date: Redacted | Agreement End Date: Redacted | |
| TBD: No New Mechanism: Yes | | |
| G2G: No | Managing Agency: | |

| Benefiting Country | Benefiting Country Planned Amount |
|--------------------|-----------------------------------|
| Guyana | 220,157 |
| Barbados | 325,000 |

| Total All Funding Sources: | | |
|--|--|--|
| 545,157 | | |
| Applied Pipeline Amount: 0 | | |
| Total All Funding Sources and Applied Pipeline Amount: 545,157 | | |

Approved



| Managing Country | Funding Source | Funding Amount |
|------------------|----------------|----------------|
| Guyana | GHP-State | 220,157 |
| Barbados | GHP-State | 325,000 |

Cross-Cutting Budget Attribution(s)

(No data provided.)

Budget Code Information

| Mechanism ID: | 18398 | | | |
|---------------------|---|----------------|----------------|--|
| Mechanism Name: | GDATA | | | |
| Prime Partner Name: | Prime Partner Name: Global Data Analysis and Technical Assistance | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and | | | 0 | |

Implementing Mechanism Indicator Information

(No data provided.)

| Mechanism ID: 18405 | Mechanism Name: HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728) | | | |
|---|--|--|--|--|
| Funding Agency: HHS/CDC | Procurement Type: Cooperative Agreement | | | |
| Prime Partner Name: American Society of Clinical Pathology | | | | |
| Agreement Start Date: Redacted Agreement End Date: Redacted | | | | |
| TBD: No | New Mechanism: Yes | | | |
| G2G: No | Managing Agency: | | | |



| Benefiting Country | Benefiting Country Planned Amount |
|--------------------------------|-----------------------------------|
| Antigua and Barbuda | 5,000 |
| Barbados | 80,000 |
| Dominica | 5,000 |
| Grenada | 5,000 |
| Guyana | 0 |
| Jamaica | 563,000 |
| St. Kitts and Nevis | 5,000 |
| St. Lucia | 5,000 |
| St. Vincent and the Grenadines | 5,000 |
| Suriname | 200,000 |
| Trinidad and Tobago | 389,000 |

| Total All Funding Sources: 1,262,000 | | | | |
|---|-----------|----------------|--|--|
| Applied Pipeline Amount: 200,000 | | | | |
| Total All Funding Sources and A | | | | |
| 1,462,000 | | | | |
| Managing Country Funding Source | | Funding Amount | | |
| Barbados | GHP-State | 1,262,000 | | |

| Gender: Gender Equality | 100,000 | |
|----------------------------|--|--|
| Focus Area: | Increase gender-equitable access to income and | |
| | productive resources, including education | |
| Sub Area: | Capacity building | |
| Human Resources for Health | 100,000 | |

Budget Code Information

-



| | 18405 HQ Lab FOA GH16-1689 (Follow on to AFENET CoAg PS 002728) American Society of Clinical Pathology | | |
|---------------------------|--|----------------|----------------|
| Strategic Area | Budget Code | Planned Amount | On Hold Amount |
| Governance and Systems | HLAB | 1,262,000 | 0 |

Implementing Mechanism Indicator Information

(No data provided.)

Implementing Mechanism Details

| Mechanism ID: 18406 | TBD: Yes | |
|---------------------|----------|--|
| REDACTED | | |

| Mechanism ID: 18427 | Mechanism Name: Global Health Supply Chain Program | | |
|---|---|--|--|
| Funding Agency: USAID | Procurement Type: Contract | | |
| Prime Partner Name: Global Health Supply Chain Program | | | |
| Agreement Start Date: Redacted Agreement End Date: Redacted | | | |
| TBD: No | New Mechanism: Yes | | |
| G2G: No | Managing Agency: | | |

| Benefiting Country | Benefiting Country Planned Amount |
|---------------------|-----------------------------------|
| Jamaica | 0 |
| Bahamas | 0 |
| Barbados | 0 |
| Suriname | 0 |
| Trinidad and Tobago | 0 |



| Total All Funding Sources: 1,233,936 | | |
|---|------------------------------|----------------|
| Applied Pipeline Amount: 2 | 266,064 | |
| Total All Funding Sources a 1,500,000 | and Applied Pipeline Amount: | |
| Managing Country | Funding Source | Funding Amount |
| Jamaica | GHP-State | 100,000 |
| Guyana | GHP-USAID | 226,787 |
| Barbados | GHP-USAID | 226,788 |
| Suriname | GHP-USAID | 226,786 |
| Trinidad and Tobago | GHP-USAID | 226,787 |
| Bahamas | GHP-USAID | 226,788 |

(No data provided.)

Budget Code Information

| Mechanism ID: | 18427 | | | |
|---------------------------|--|----------------|----------------|--|
| Mechanism Name: | Global Health Supply Chain Program | | | |
| Prime Partner Name: | ime Partner Name: Global Health Supply Chain Program | | | |
| Strategic Area | Budget Code | Planned Amount | On Hold Amount | |
| Governance and Systems | OHSS | 1,233,936 | 0 | |

Implementing Mechanism Indicator Information

(No data provided.)



Agency Information - Costs of Doing Business U.S. Agency for International Development

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Applied Pipeline | Total | Total All Cost of Doing Business Categories and Applied Pipeline Amount |
|---|-----|-----------|-----------|---------------------|-----------|--|
| Computers/IT Services | | | 110,119 | 50,408 | 110,119 | 160,527 |
| ICASS | | | 287,157 | 124,268 | 287,157 | 411,425 |
| Management Meetings/Profes sional Development | | | 145,966 | 129,928 | 145,966 | 275,894 |
| Non-ICASS Administrative Costs | | | 35,694 | 16,646 | 35,694 | 52,340 |
| Staff Program Travel | | | 155,344 | 143,192 | 155,344 | 298,536 |
| USG Staff Salaries and Benefits - Internationally Recruited | | | 210,443 | 108,971 | 210,443 | 319,414 |
| USG Staff Salaries and Benefits - Locally Recruited | | | 558,404 | 781,242 | 558,404 | 1,339,646 |
| Total | 0 | 0 | 1,503,127 | 1,354,655 | 1,503,127 | 2,857,782 |



U.S. Department of Defense

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Applied Pipeline | Total | Total All Cost of Doing Business Categories and Applied Pipeline Amount |
|---|-----|-----------|-----------|---------------------|-------|--|
| Computers/IT Services | | 0 | | 5,000 | 0 | 5,000 |
| ICASS | | 0 | | 45,000 | 0 | 45,000 |
| Indirect Costs | | 0 | | 20,000 | 0 | 20,000 |
| Institutional Contractors | | | | 35,000 | 0 | 35,000 |
| Management Meetings/Profes sional Development | | 0 | | 10,000 | 0 | 10,000 |
| Staff Program Travel | | 0 | | 75,000 | 0 | 75,000 |
| USG Staff Salaries and Benefits - Locally Recruited | | 0 | | 175,000 | 0 | 175,000 |
| Total | 0 | 0 | 0 | 365,000 | 0 | 365,000 |

U.S. Department of Health and Human Services/Centers for Disease Control and Prevention

| Agency Cost of Doing GAP GHP-Sta | e GHP-USAID Applied Pipeline | Total | Total All Cost of |
|-------------------------------------|------------------------------|-------|----------------------|
|-------------------------------------|------------------------------|-------|----------------------|



| Business | | | | | | Doing Business Categories and Applied Pipeline Amount |
|---|-----------|-----------|---|---------|-----------|--|
| Capital Security Cost Sharing | 9,900 | 336,231 | | 15,694 | 346,131 | 361,825 |
| Computers/IT Services | 30,000 | 30,000 | | 0 | 60,000 | 60,000 |
| ICASS | 72,175 | 633,400 | | 114,425 | 705,575 | 820,000 |
| Institutional Contractors | | 458,000 | | 0 | 458,000 | 458,000 |
| Management Meetings/Profes sional Development | 4,701 | 79,100 | | 7,453 | 83,801 | 91,254 |
| Non-ICASS Administrative Costs | 7,343 | 29,025 | | 11,641 | 36,368 | 48,009 |
| Staff Program Travel | 27,632 | 246,800 | | 43,808 | 274,432 | 318,240 |
| USG Staff Salaries and Benefits - Internationally Recruited | 1,018,750 | 416,499 | | 0 | 1,435,249 | 1,435,249 |
| USG Staff Salaries and Benefits - Locally Recruited | 83,249 | 746,557 | | 131,979 | 829,806 | 961,785 |
| Total | 1,253,750 | 2,975,612 | 0 | 325,000 | 4,229,362 | 4,554,362 |



U.S. Department of State

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Applied Pipeline | Total | Total All Cost of Doing Business Categories and Applied Pipeline Amount |
|---|-----|-----------|-----------|---------------------|---------|--|
| ICASS | | 0 | | 9,650 | 0 | 9,650 |
| Management Meetings/Profes sional Development | | 0 | | 12,785 | 0 | 12,785 |
| Staff Program Travel | | 0 | | 12,786 | 0 | 12,786 |
| USG Staff Salaries and Benefits - Internationally Recruited | | 399,544 | | 0 | 399,544 | 399,544 |
| USG Staff Salaries and Benefits - Locally Recruited | | 0 | | 59,741 | 0 | 59,741 |
| Total | 0 | 399,544 | 0 | 94,962 | 399,544 | 494,506 |

U.S. Peace Corps

| Agency Cost of Doing Business | GAP | GHP-State | GHP-USAID | Applied Pipeline | Total | Total All Cost of Doing Business |
|-------------------------------------|-----|-----------|-----------|---------------------|-------|---|
|-------------------------------------|-----|-----------|-----------|---------------------|-------|---|

Custom

Page 334 of 335

FACTS Info v3.8.21.10



| | | | | | | Categories and Applied Pipeline Amount |
|--------------------------------------|---|---|---|--------|---|---|
| Non-ICASS Administrative Costs | | 0 | | 2,000 | 0 | 2,000 |
| Peace Corps Volunteer Costs | | 0 | | 68,587 | 0 | 68,587 |
| Staff Program Travel | | 0 | | 10,000 | 0 | 10,000 |
| Total | 0 | 0 | 0 | 80,587 | 0 | 80,587 |